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ABBREVATIONS 
ftICAR ami noi midazole carboxamide ribonucleotide 
ALL acute lymphoblastic leukemia 
ATP adenosine triphosphate 
CTP cytidine triphosphate 
d.. deoxy.. 
DHFR dihydro-folate reductase 
DNA deoxyribonucleic acid 
dTMP (deoxy)thymidine monophosphate (thymidylate) 
dTTP (deoxy)thymidine triphosphate 
FH2 dihydro-f olate 
FH4 tetrahydro-f olate 
GAR glycinamide ribonucleotide 
GTP guanosine triphosphate 
HGPRT hypoxanthine-guanine phosphor i bosyl trans-ferase 
HPLC high-pressure liquid chromatography 
IMP inosine monophosphate 
Me—tIMP methyl—thioinosine monophosphate 
6MP 6-mercaptopurine 
MTX methotrexate 
ODC orotidine monophosphate decarboxylase 
OPRT orotate phosphor i bosyl trans-ferase 
PONS purine de novo synthesis 
PRPP phosphoribosyl pyrophospate 
RNA ribonucleic acid 
t.. thio— (= mercapto—) 
TS thymidylate synthetase 
UMP uridine monophosphate 
DTP uridine triphosphate 
KM-3 human malignant non-B—non—T-lymphoblastic cell line 
MDLT-4 human malignant T-lymphoblastic cell line 
RAJ I human malignant B-lymphoma cell line 
Gl 
S 
G2 
M 
presynthetic cell cycle phase 
DNA synthetic period o-f the cell cycli 
postsynthetic cell cycle phase 
mitosis 
9 

G H f t F - T E R 1 
f 3 E I M E R A L _ X N T R O D U C T I O N 
M E T H O T R E X A - T E A N D Ä» — M E R C A R - T O P - U R I N 1 
E F - F E C T S O N 
R U I R I N E A N D R - Y R Ι M I D I M E M E T A B O I — X S I 
1.1. HISTORICAL BACKGROUND 
The biochemistrv of purine metabolism has drawn the atten­
tion of many pediatricians with the arrival of advanced methods 
for епгуте assays and measurements of purine metabolites. 
Congenital disturbances in purine metabolism were found to be 
associated with severe pediatric diseases with the advent of 
these biochemical techniques. The discovery of the X—linked 
recessive inborn error of the Lesch-Nyhan syndrome by Seeg-
miller et al in 1967 CID. resulting from a severe deficiency of 
hypoxanthine-guanine phosphoribosyltransferase (H6PRT, Fig. 1, 
no. 6 ) , led to a close cooperation 15 years ago between the 
departments of Pediatrics and Human Genetics (University of 
Nijmegen, Faculty of Medicine) on the field of purine metabo­
lism. The investigations of the Lesch-Nyhan syndrome were 
expanded [2,31 and further studies of purine and pynmidine 
metabolism in man C4,5] extended the knowledge of its complex 
mechanism. 
The discoverv of the biochemical disturbances, associated with 
severe combined immunodeficiency syndromes shifted our atten­
tion to the field of hematology and oncology. Congenital 
deficiency of adenosine deaminase (ADA, Fig. 1, no. 16) was 
demonstrated by Giblett [63 in red cell lysates of two patients 
with a severe dysfuntion of T- and B-lymphocytes. Purine 
nucleoside Phosphorylase (PNP, Fig. 1 no. 14) deficiency could 
be detected in patients with defective T—eel1 immunity and 
apparently normal B-lymphocyte function C7]. 5'Nucleotidase 
deficiency (5*NT. Fig. 1. no. 13) was associated with severe 
B—eel 1 dysfunction and X-linked agammaglobulinaemia [8,9]. 
These inborn errors of metabolism demonstrated a close 
relationship between lymphoid cell differentiation and purine 
metabolism С 101. 
The foundation of the Centre of Pediatric Oncology S.E. 
Netherlands in 1977 permitted us to intensify our cooperation 
with the department of Human Genetics on the field of enzymatic 
studies in patients with acute lymphoblastic leukemia (ALL). 
This department focussed its research on enzymatic profiles of 
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PURINE METABOLISM 
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Fiq. 1. SiipHHed schtK of purine letibohii. 
(Il phosphoribosvl pyrophosphate (PRPP) synthetase (EC 2.7.6.1.!: '.21 PRPP aiidotransterase (EC 
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¡.6.6.8.); (12) adenosylate (АИР) deaiinase (EC 3.5.4.6.1; (13) purine 5'-nucleotidase (S'NT; EC 
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2.7.1.20.): (16! adenosine deaiinase (ADA: EC 3.5.4.4.І; UTi ribonucleotide reductase. 
13 
purine and pyrinudine metabolism in lymphoblasts with immunolo­
gical distinctive characterization. Micromethods were developed 
for the measurement of purine enzymes in lymphocytes and malig­
nant lymphoblasts Cll,12], allowing enzymatic assays in less 
than 5,OOn lymphoblasts derived -from patients. The di-f-ferences 
in enzymatic make-up of lymphoblasts from distinctive immuno­
logical lineages contributed ta a diagnostic classification of 
lymphoblastic leukemias C131. These studies suggested tools for 
selective chemotherapy with specific enzyme inhibitors C143 and 
nucleosides C151 in order to selectively destroy malignant 
1vmphoblasts and to rescue normal lymphocytes. 
Investigators from our department developed methods for the 
measurement of purine and pynmidine metabolites in cell 
extracts and body fluids with high-pressure liquid chromatogra­
phy (HPLC) CI6,17 3. The development of a sensitive HPLC-method 
for measurement of the purine antagonist, 6-mercaptopurine 
(6MP), in biological fluids [18,193 permitted further study of 
the pharmacokinetics of 6MP in children with ALL under mainte­
nance therapy with 6MP and in animals with intravenous 
infusions C20-243. Cooperation with the department of Clinical 
Pharmacy, which developed a sensitive method for determination 
of methotre/4ate (MTX) in biological fluids [253, stimulated our 
investigations in the field of the antimetabolites, used in 
ALL. Studies of therapy with MTX in children after repeated 
intrathecal administration and during 24 hr intravenous 
infusions elucidated its pharmacokinetics [26-283. Knowledge of 
purine and руг ι mi dine metabolism and the pharmacokinetics of 
the two agents in the maintenance therapy of ALL in children 
focussed our attention to the biochemical and cell-kinetic 
disturbances of both agents separately and in combination in 
human malignant lymphoblasts. Both agents inhibit purine de 
novo synthesis (PONS), the pathway which was subject of 
investigations of the department of Biochemistry (University of 
Nijmegen, Faculty of Medicine) [29-323. In cooperation with 
this department we could develop an enzymatic microassay of 
phosphonbosyl pyrophosphate (PRPP) in order to measure the 
inhibition of PONS in the present study. 
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1.2. BIOCHEMICAL PHARMACOLOGY OF METHOTREXATE 
Aminopterin and its analogue MTX (amethoptenn) were 
introduced in 1947 as acti\e antineoplastic agents in ALL, 
based on their antagonism to folic acid C33,341. Both agents 
are competitive inhibitors for dihydrofolate reductase (DHFR, 
Fig. 2, no. 1) with noncompetitive kinetics due to the extreme-
ly tight binding to the enzyme C35.36]. The dissociation 
constant of the MTX-DHFR complex was estimated to be less than 
3 :; IO-5 ¿JM; the inhibition was described as "stoichiometric" 
C37D. The dissociation constant for human lymphoblastoid DHFR 
is 7.3 χ ΙΟ"6 μΗ СЗ ]. Detailed kinetics of the enzyme and 
physicochemical properties of MTX (see reviews [27,35,36}) are 
bevond the scope of this thesis. 
MTX-J FH2 « 
» F H , 
Fig. 2. Siiplifnd scheie of folate letabolisi. 
"Ц2 . Obdrofolate. Fn, . tetrahvdra'olate: l i dih/dro'olate reductase (DHFR); (2) serine M r o x v -
«ethi.transfsrase: ' l thvmdvUte svtbetase 'TS): ι4' t r i 'unct io ia! crotein !5,10-шеІЬег\Чеіга-
hydrofülate cicloh^drase I S.lO-iethvlenetetrahvdrcfBlate dehydrogenase / ÜHornYltetrahvdrcfolate 
Sínf'etase': ι5ι GfiR torivlt'ansfe'ase: mi AICSR 'Q'-iyltraisferase: 7) S.lO-eethvienetetrahvdro-
foiate redLctase: IS' «еКію-чпе svitl'etase. 
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It should be emphasized that both MTX and the natural 
metabolites, dihydrof ol ate (FH2) and all tetrahydro-f ol ate (FH4) 
products, are converted in vitro and in vivo from their 
monoqlutdmate forms to polyglutamyl dérivâtes. Polyglutamati on 
of MTX is a time-, dose- and cell type—dependent phenomenon. 
Polyglut amate derivatives form an intracellular depot of the 
drug and Lhey significantly increase intracellular retention of 
MTX, depending on their chain length [37-423. Polyglutamates 
have an increased affinity to folate-dependent enzymes C423. 
Because man/ details of the mode of action of MTX will be 
demonstrated in chapters 2-4, this introduction will describe 
only the basic: principles of the biochemical pharmacology of 
MTX. In order to result in significant inhibition of DNA and 
RNA synthesis and significant cytotoxicity, the intracellular 
concentration of MTX should be in excess of the tightly-bound 
fraction to DHFR, resulting in "free" exchangeable MTX [43-45Í. 
The primary consequences of complete inhibition of DHFR are an 
accumulation of FH2 and a depletion of FH4 and its dérivâtes 
(Fig. 2 ) . The perturbations in folate metabolism result in 
disturbances of both pyrimidine and purine metabolism. 
Figs. 2 and 3 represent a simplified scheme of pyrimidine 
metabolism and its connection with folate metabolism. Depletion 
of FH cofactors inhibits conversion of deoxyundylate (dUMP) 
to thymidylate (dTMP) by thymidylate synthetase (TS, Figs. 2 
and 3, no. 3 ) , subsequently reducing the intracellular levels 
of dTTP, essential for DNA synthesis. Since TS and ribonucleo-
tide reductase (Fig. 1, no.17; Fig. 3, no.6) are S—phase 
spec.fie enzymes, MTX is a S-phase specific antimetabolite 
£46-503. The direct noncompetitive inhibition of TS by MTX 
polvglLitamates will augment the depletion of dTTP [42,51,523-
TS is the only cellular reaction for oxidation of FH to FH2. 
Differences in the activity of TS between malignant and normal 
host cells explain predominant cytotoxicity of MTX in malignant 
cells and the role of leucovonn (Fig. 2) for rescue of normal 
bone marrow and normal host cells [53-553. 
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PYRIMIDINE METABOLISM 
RNA 
Г 
СТР«-
CDP 
CMP 
χ 
•UTP CDP 
6 
5
 У 
DNA 
Λ 
"ì 
dTDP 
Cytidme^—»Uridine 
I I 
Cytosine Uracil 
UDP ^ η dCDP 
j i j d-CWidme Uracil | 
UMPcodUDP d C M P ^ ' ^ s . J dTMP 
OMP 
i V - PRPP 
Orotic acid 
7 d-Uridme/'t L 
Τ
Η Ι I M P
— Γ Thymidin I 
Thymine 
Fiq. 3. Suphf ied schelt of pyrii idine iet abolì s i . 
i l i cotate pho5phonbo5vltrans<e'-ase 'GPRT: EC 1.4.2.10.': '2) OOtidvlate іОЧРІ decarboxylase 'EC 
4.1.!. :3.); '3 thviiidvlate itiTIP) synthetase '73: EC 2.1.¡.45..: '4 thymdne Unase \EC IJA.Z^x 
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Folate metabolism is also involved in amino acid 
metabolism (Fig. 2. nos. 2 and ). So, MTX treatment will lead 
to perturbations in the latter. This was not a subject o-f our 
study. 
Purine metabolism consists o-f two major routes: a) purine 
de novo synthesis (Fig. 1) -from ribose-5-phosphate via PRPP to 
IMP, and b) the purine salvage pathway, from the purine bases 
guanine, hypo>.anthine and adenine (the latter not shown in Fig. 
1) to their corresponding nucleotides, converted by 
phosphor ιbosvl transferases, consuming PRPP. Most cells rely on 
the purine salvage pathway for their production of nucleotides 
and exhibit a low activity of PONS C31,56,57D. However, in 
malignant cells and especially malignant lymphoblasts, subject 
of this Thesis, both pathways are active and these cells, 
exhibiting an active RNfi and DNA synthesis, mainly rely on 
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their FDNS -for the rapid turnover of nucleotides [58,591. Two 
formyltransferase enzymes of PONS are targets for inhibition by 
MTX. Depletion of FH 4 cofactors results in an inhibition of 
ami noi mi daz ol ecarbo,. amide π banucleoside monophosphate (AICAR) 
formyltransferase and glyci amide rιbonucleoside monophosphate 
(GAR) f ormyl transferase (^ ic;. 1, nos. 4 and 5; Fig. 2, nos. 5 
and 6). Moreover, MTX polyqlutamates are more potent and direct 
inhibitors of AICAR formyltransferase than MTX monoglutamate, 
and formation of polyglutamates ixill augment the effects of MTX 
on PDNS Ε42,6Ω]. The inhibition of PONS is accompanied with an 
increase of PRPP levels C61J. The consequences of inhibition of 
PDNS are reflected in a decreased availability of purine 
nucleotides for DNA and RNA synthesis. Thus, the effects of MTX 
on purine metabolism augment the effects of MTX on pynmidine 
metabolism with respect to DNA synthesis, resulting in decrea­
sed levels of the deoxynbonucleotides dTTP, dATP and dGTP [62-
673, and inhibition of cell progression through the cell cycle 
in early Ξ phase or at the Gl/S boundary, associated with a de­
crease of cells in G2 + M phase [67-701. Moreover, depletion of 
purine ribonucleotide pools is associated with a decrease of 
RNA synthesis. 
The role of natural purine and pynmidine bases for rescue 
of the cytotoxic MTX effects especially in non-malignant cells 
has been discussed extensively and will be referred to in this 
Thesis. Differences in MTX cytotoxicity between normal and 
malignant cells can be explained by differences in: 
1) rate of cellular influx and efflux of MTX [71-733; 
2) cell cycle distribution in cells with different growth pat­
terns [46-48,74,753; 
3) enzyme activities involved in folate metabolism, especially 
DHFR activity, Ki of MTX for DHFR and amount of DHFR [38, 
76-783; 
4) rate of dTMP synthesis, as mentioned above [46,48,53,77,793; 
5) polyglutamation of MTX [39-423; 
6) rate of PDNS activity [58,593; and 
7) rate of deoxyundine Phosphorylase activity [803 (Fig. 3: 
uracil -»deoxyundine). 
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1.3. BIOCHEMICAL PHARMACOLOGY OF 6-MERCAPTOPURINE 
ò-liercaptopurine was introduced in 1952 by Elion et al 
C81] as an analogue of hvpoxanthine, having a SH (mercapto)-
group at the oth position o-f the purine ring. Burchenal et al 
demonstrated the e-f-ficacy o-f 6MF in the treatment o-f leukemia 
and allied diseases СВ2Э, which was con-firmed by other clinical 
studies CB3]. 
A-fter its intracellular transport, which is facilitated by a 
hypoxanthine carrier [B4Í, 6MP is rapidly phosphorylated in 
large amounts to its nucleotide, 6-thioIMP (tIMP), by HGPRT 
consuming PRPP as a cofactor (Fig. 1, no. 6) С Э- ВЛ. 6MP is a 
competitive inhibitor of H6PRT for guanine and hypoxanthine, 
and also inhibits cleavage of inosine and guanosine by PNP 
(Fig. 1, no. 14), preventing their utilization by HGPRT [B9D. 
Conversion of tIMP by 5"nucleotidase (Fig. 1, no. 13) to its 
thionucleoside (6-mercaptopurine riboside, 6MPR) was demonstra­
ted to be an important pathway after intravenous infusion 
treatment C23,24,903. Methylation of óMPR to 6-MeMPR occurs by 
a nonenzymatic transfer of the methylgroup of S—adenosylmethio-
nine C913. 6-MeMPR is converted to its nucleotide, Me-tIMP, by 
adenosine kinase (Fig. 1, no. 15) [92,933. Formation of Me-tIMP 
mav also occur by methylation of tIMP [893. 
Catabolism of 6MP to thiouric acid is mediated by xanthine 
oxidase. The other route of catabolism is methylation on the 
sulfur and similar oxidative reactions of the methylated 
dérivâtes. Me—ώΜΡ and its hydroxydenvates give rise to 
inorganic sulphate [94,953. However, xanthine oxidase activity 
is not present in lymphocytes and lymphoblasts [963 and 
selective cytotoxicity of 6MP in malignant cells may be due to 
the fact that xanthine oxidase activity is low in tumor cells 
as compared to normal host cells [B93. 
High levels of tIMP are non-competiti ve inhibitors of adenylo­
succinate synthetase (Fig. 1, no. 9), and competitive inhibi­
tors of adenylosuccinate lyase (Fig. 1, no. IO) [B9,95,97,9B3. 
tIMP also inhibits IMP dehydrogenase (Fig. 1, no. 7) by forma­
tion of di sul phi de bonds between its mercaptogroup and the mer— 
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captogroLip o-f the enzyme C89,95.991. Thus, inhibition of these 
enzymes by high concentrations of 6MP lead to perturbations in 
purine nucleotide levels. 
Like natural nucleotides, especially AMP, IMP and BMP, the 6MP-
nucleotides are feedback inhibitors of the first step in PDNS, 
PRPP amidotransferase (Fig. 1, no. 2) [93,95,100-1063. The 
affinity for the enzyme of Me-tIMP is greater than that of 
tIMP, and both these 6MP—nucleotides have greater affinities 
than natural nucleotides CB9,100.1053. The inhibition of PRPP 
amidotransferase leads to an increased availability of PRPP and 
consequently to self-enhancement of 6MP conversion, as well as 
a decreased formation of purine ribonucleotides C107-111Í, 
causing a delay of cells in the S phase of the cell cycle 
C112,1133. 
However, these biochemical perturbations in PDNS and purine 
salvage pathway do not sufficiently explain the cytotoxic 
capacity of 6MP. Many studies indicated that these events were 
reversible, when cells were grown in drug—free medium 
[109,110,1143. Delayed cytotoxicity of 6MP, and its analogue 
6—thioguanine (6ТБ), was correlated to conversion of tIMP to 
tGMF' and to incorporation as thioguanine deoxynbonucleoside 
triphosphates into DNA [115-1213. Ultimately, this leads to a 
delayed cytotoxic reaction and morphological chromosomal 
changes, due to unilateral chromatid damage in the G2 phase of 
the cell cycle [110,113.121-1233. 
1.4. AIM OF THE PRESENT INVESTIGATION. 
The discovery of potentiating effects on survival in mice 
leukemia with the combination of MTX and B-azaguanine or 6MP by 
Law [124,1253 and with MTX and 6MP by Goldin and Mantel [1263 
evoked its introduction in the treatment of ALL in childhood. 
The enhanced efficacy of the combination of both drugs on 
survival of children with ALL was empirically demonstrated in 
1961 [1273. After the introduction of more potent antileukemic 
agents and the development of an adequate central nervous 
system treatment [1283, the combination of 6MP (50-75 mg per 
20 
square meter once daily) and MTX (20-30 mg per square meter 
once weekly) was introduced as maintenance therapy of ALL. 
Although the survival of children with ALL has dramatically 
improved with the introduction of multidrug induction therapy 
and especially enforced reinduction therapv by Riehm С1293. the 
maintenance treatment of the disease remained unchanged in the 
past 25 years, with the exception of a shortening of its 
duration. In contrast, some studies doubted the efficacy of the 
combination of both agents, based on the bioavailability of MTX 
and 6MP C20,130-1333, although 6MP levels can be determined 
during up to 6 weeks after cessation of chemotherapy [21,1343. 
Based on earlier studies on purine and pynmidine metabolism, 
we decided to study the biochemical pharmacology of separate 
and combination therapy with MTX and 6MP in the three immunolo­
gical subclasses of human malignant lymphoblasts: T—ALL. B-ALL 
and common ALL (MOLT-4, RAJ I and KM-3 cells, respectively), 
especially because studies on the biochemical basis of combina­
tion chemotherapy with both agents were lacking. We used con­
centrations of MTX which could be maintained during several 
hours after oral administration of MTX (0.02-0.2 μΜ) [1135,1363, 
and concentrations of 6MP demonstrating measurable cytotoxi­
city (•= 2 μΜ). 
The hypothesis of our studies was as follows: MTX inhibits 
PONS, resulting in an enhanced availability of intracellular 
PRPP. This event can be used for an increased intracellular 
incorporation and conversion of 6MP by HGPRT. Moreover, 
pretreatment with MTX should lead to increased effects of 
6MP-nucleotides on PONS, enhanced incorporation of 6MP into RNA 
and DNA and a potentiation of cytotoxicity. 
The effects of MTX on FDNS were measured by determination 
of PRPP and AICAR levels, and incorporation of labeled glycine 
into purines. Glycine is a cosubstrate for GAR synthetase (Fig. 
1, no. 2) and incorporation of glycine into purines can be used 
as a parameter of activity of PONS. Determination of PRPP 
levels was performed by a modification of the assay described 
by Tax and Veerkamp C293: labeled orotic acid conversion by 
OPRT and 0DC using PRPP as a cofactor (Fig. 3, nos. 1 and 2) to 
UMP and labeled C0 2. The uptake of the labeled purine bases 
hypoxanthine and its analogue 6MP was measured during 
21 
incubations -for 20 min at certain time-points a-fter addition o-f 
MTX in order to demonstrate increased uptake of these compounds 
after pretreatment with MTX. The uptake of hypoxanthine was 
used as a parameter of the purine salvage pathway. The methods 
and results in MOLT-4 cells are described in chapter 2, and a 
comparison between the three cell lines in chapter 4. 
The effects of MTX on cell-kinetic parameters (cell growth, 
cell viability and colony forming activity), DNA distribution 
(flow-cytometry), and purine and pyrimidine ribonucleotides and 
deoKyribonucleotides in MQLT-4 cells are described in chapter 
3. Comparison of the perturbations of these parameters between 
the three cell lines is shown in chapter 5. 
The consequences of exposure to 6MP on the cell-kinetic 
criteria, mentioned above, DMA distribution and PONS in the 
three cell lines are demonstrated in chapter 6. RNA and DNA 
synthesis was measured after exposure to 6MP, using С PI. The 
incorporation of 6MP into newly synthetized DNA and RNA in 
MOLT-4 cells was calculated from double labeling experiments 
and expressed as С - l 4C] 6MP / С 3 2 P1 incorporation ratio. 
Chapter 7 describes the effects of various sequentially and 
simultaneously administered combinations of MTX and 6MP on the 
cell—kinetic parameters in order to demonstrate potential 
synergistic combinations of both agents. These effects are 
correlated with the effects of simultaneous and sequential 
administration of MTX and labeled óMP on DNA and RNA synthesis 
and DNA flow-cytometry in MOLT-4 cells. Moreover, this chapter 
demonstrates the effects of simultaneous and sequential 
exposure on incorporation of labeled 6MP into newly synthetized 
DNA and RNA. 
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SEQUENCE-, TIME- AND DOSE-DEPENDENT SYNERGISM 
OF METHOTREXATE AND 6-MERCAPTOPURINE IN 
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Abstract—Methotrexate (MTX) and 6-mercaptopurine (6MP) are common drugs in the oral maintenance 
therapy of acute lymphoblastic leukemia (ALL) On the basis of their biochemical effects on cell 
metabolism, a sequence-dependent synergism might be anticipated In order to investigate this hypoth­
esis, MOLT-4 human malignant Τ lymphoblasts were incubated with various concentrations of MTX 
The time at which maximal increase of intracellular 5 phosphoribosyl-1-pyrophosphate (PRPP) levels 
was found correlated with the concentrations of MTX used 
Determination of aminoimidazolecarboxamide nbonucleoside monophosphate (AICAR) levels and 
labeled glvcine incorporation into punne metabolites revealed an incomplete inhibition of purine de 
novo synthesis after incubation with 0 02 μΜ MTX, and a complete inhibition with 0 2μΜ MTX 
After prolonged periods of incubation, glutamine exhaustion of the medium caused inhibition of 
punne de novo synthesis in MTX untreated cells, with a concomitant increase of PRPP levels Addition 
of glutamine to the medium prevented this phenomenon 
The increased availability of PRPP after pretreatment with MTX can be used for enhanced intracellular 
incorporation of hypoxanthine and 6MP in their respective nucleotides The time- and dose-dependent 
effects of MTX on PRPP levels correlated with the enhanced incorporation of hypoxanthine and 6MP 
The data presented in this studv demonstrate that a synergistic action of the combination of MTX and 
6MP can be anticipated in malignant lymphoblasts with an active punne de novo synthesis depending 
on the concentration of MTX and on the time and sequence of administration of both drugs 
During the last decade much attention has been paid 
to drug combinations based on the synergistic and 
sequence-dependent biochemical effects of the drugs 
on cell metabolism The most stnking example of 
synergistic anticancer drug combination is metho­
trexate (MTX) administration preceding 5-fluoro-
uracil (5FU) [1-8] Other examples include MTX 
and 6-thioguanine (6TG) [9], 6-methylmercapto-
punne nbonucleoside (MeMPR) and 5FU [1,10, 
11]. MeMPR and 6TG [12]. and MeMPR and 6-
mercaptopunne (6MP) [13-15] 
The biochemical basis for these synergistic drug 
combinations is the inhibition of punne de novo 
synthesis by MTX or MeMPR with concomitant 
accumulation of 5-phosphoribosyl-l-pyrophosphate 
(PRPP) [1.4,10-12,14,16] The increased avail­
ability of PRPP can be used for enhanced conversion 
of punne and pynmidine bases and analogues, sub-
* This work was funded by the Dutch Queen Wilhelmtna 
Oncer Fund (KWF) grant NUKC 82-3 and presented in 
pari al the XVIth Annual Meeting of the International 
Society of Paediatric Oncology (SIOP) Barcelona Spain 
September 1984 
+ To whom requests for reprints should be addressed 
% Present address JvL Dept of Experimental and 
Chemical Endocrinology St Radboud University Hospi­
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sequently administered, and enhanced incorporation 
into RNA and DNA 
MTX and 6MP have been used for more than 30 
years in the therapy of acute lymphoblastic leukemia 
(ALL) as single drugs [17-20] The combination of 
both drugs is in use for more than 20 years 
[19.21,22] The increased efficacy of the com­
bination in the maintenance therapy of ALL was 
mainly based on empirical data from studies in 
patients To our knowledge no mention has been 
made in literature of the possibly synergistic action of 
both drugs, based on the biochemical considerations 
above Especially for malignant lymphoblasts with 
an active rate of purine de novo synthesis (Fig 1), 
in contrast to normal peripheral blood lymphocytes 
or normal bone marrow cells without an active punne 
de novo synthesis [23], the synergistic effect should 
be more dramatic 
In the present study, we first investigated the time-
and dose-dependent effect of MTX on the punne 
de novo synthesis in MOLT-4 human malignant T-
lymphoblasts especially with reference to the intra­
cellular PRPP and aminoimidazolecarboxamide 
nbonucleoside monophosphate (AICAR) levels and 
the incorporation of labeled glycine We could dem­
onstrate further that the increased availability of 
PRPP. due to pretreatment with MTX, can be used 
for enhanced incorporation of the punne base hypo­
xanthine and its analogue 6MP The time at which 
PRPP levels, and incorporation of hypoxanthine and 
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Fig 1 Simplified scheme of effects of MTX and 6MP 
OD punne metabolism 1, amidophosphonbosyltransfcrase 
(EC 2 4 2 14 ), 2, glycinamide nbonudeotide formyl-
transferase (EC 2 1 2 2 ), 3, aminoimtdazolecarboxamidc 
nbonudeotide formyltransferase (EC 2 12 3), 4, 
hypoxanthine guanine phosphonbosyltransferase (E С 
2 4 2 8 ) 
6MP are maximal, is correlated with the con­
centration of MTX used 
Preliminary data of these studies have been 
reported [24] 
MATERIALS AND METHODS 
Materials MTX (Emtrexate PF) was purchased 
from Pharmachemie (Haarlem, The Netherlands), 
[carboxyl-'4C] orotic acid (51 1 mCi/mmol) from 
New England Nuclear (Boston. MA), [U-14C] gly­
cine (HOmCi/mmol), [8-14C] hypoxanthine 
(55 mCi/mmol) and [8- C] 6-mercaptopurine 
(1 7 mCi/mmol) from Amersham International Ltd 
(Amersham, U K ) , PRPP from Sigma (St Louis, 
MO), a preparation from brewer's yeast containing 
orotate phosphonbosyltransferase (OPRT, E С 
2 4 2 10) and orotidylate decarboxylase (ODC 
E С 4 1 1 23) from Boehnnger Mannheim 
(Mannheim, F R G ), MOLT-4 human T-lympho-
blasts from Flow Laboratories (Irvine, U К ) The 
Ε-rosette forming capacity and the presence of T-
cell antigens on the MOLT-4 cells in culture was 
tested every 3 months The latter by means of mono­
clonal antibodies [25] 
Cell cultures MOLT-4 cells were allowed to grow 
at 37° in a water saturated atmosphere containing 
2 5% C 0 2 in RPMI medium 1640 Dutch Modi­
fication (DM), supplemented with 10% nondial>zed 
fetal calf serum (v/v), penicillin (100,000 U/l) and 
streptomycine (100,000 jug/I) in plastic culture flasks 
In order to avoid peroxide formation by light in the 
presence of HLPES (N-2 hydroxyethyl piperazme-
Ar"-2-ethanesulfonic acid), we supplemented also 
2 mM sodium pyruvate [26] The initial concen­
tration of hypoxanthine in fresh medium, determined 
by high-performance liquid chromatographic 
(HPLC) analysis, was 3-5 μΜ Logarithmically 
growing cells were suspended in fresh medium in a 
concentration of 0 3 χ IO6 cells/ml 24 hr before each 
experiment During the experiments glutamme was 
added every 24 hr to a final concentration of approxi­
mately 2 mM (determined by amino acid analysis) in 
order to prevent glutamme exhaustion of the 
medium, which leads to inhibition of punne de novo 
synthesis and concomitant increase of PRPP 
MTX diluted in medium, was added as a single 
dose in a small volume (1/100 fraction) and 
remained in the culture for the duration of the exper­
iment An appropriate \ olume of medium was added 
to untreated cells 
The number of \iable cells (trypan blue exclusion) 
was counted at each point of time in duplicate in a 
Burker Turk chamber 
PRPP ака We modified and miniaturized the 
assay for determination of PRPP as described by 
Peters and Veerkamp [27] The assay is based on the 
production of "COi from a [carboxyl-'4C] orotic acid 
precursor as described by others [28-30] 
An aliquot of 1 0 ml cell suspension was centn-
fuged (400g 8 min, 4°), suspended in 125 μ\ 50 mM 
Tns-HCl (pH7 4) containing 1 mM EDTA and 
lysed by a micro-ultrasonic cell disrupter (Kontes) 
Inactivation of enzymes was obtained by heating for 
45 sec in boiling water Afterwards correction was 
made for the destruction of PRPP during this pro­
cedure by measuring the recovery of known amounts 
of PRPP simultaneously One hundred microliters 
of the boiled solution were incubated with 10 μ| of 
OPRT/ODC (25 mg/ml) in 100 mM MgCI; solution 
and 5 μ ι (0 8 mM labeled plus 0 8 mM unlabeled) 
orotic acid in a 0 7 ml reaction vessel (Eppendorf, 
Hamburg, F R G ) This reaction vessel was placed 
on another emptv reaction vessel and subsequently 
in a polypropylene scintillation minivial containing 
0 1 ml ethylene glycol/ethanolamme (2 1 v/v) The 
minivial was placed in a glass vial sealed with a 
rubber cap (Fig 2) In this way all "СОг liberated 
was trapped in the ethylene glycol/ethanolamine 
mixture and the reaction vessel could be removed 
afterwards without contamination of "СОг After 
incubation for 90 mm at 37° the reaction was stopped 
by injection of 40 μΐ 5 N HCIO4 through the rubber 
cap into the reaction \ebsel After a second incu­
bation of 90 min at 37° in order to trap all "COi 
liberated from the reaction mixture, the reaction 
vessel was removed and 5 ml scintillation fluid was 
added which consisted of 4 g/1 Ommfluor (New Eng­
land Nuclear Boston MA) in Toluene Scintillator 
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(Packard. Groningen, The Nctherldnds)/methanol 
(2 I \ Λ ) The amount of 'JCO; trapped in ethylene 
glycol/ethanolamine was counted in a liquid scin-
tilUtion analyzer The total recovery of PRPP stan­
dards was 92 8% (SD = 6 1. N = 12) As mentioned 
before, corrections were made for the destruction of 
PRPP during heating The assay is linear between 
OOlSnmol and SOnmol (corr coeff 0 9986, P-
value < 0 001 N = 6) 
Incorporation of [U-14C] glycine The incor­
poration of glycine into purine metabolites can be 
used as a measurement of the activity of purine de 
novo s\mhesis We modified the assay described 
earlier [10] At intervals indicated, 10 ml of the cell 
suspension were incubated for 4 hr at 37° with 100 μ! 
[U-I4C] glycine After centnfugation (1350g, 4 mm) 
the cell pellet was washed once with fresh medium 
in order to remove free glycine The cell pellet was 
incubated for 1 hr at 100° with 400 μΐ 1N H a O d , in 
order to precipitate protein and to hydrolyse nucleic 
acids and nucleotides, which had incorporated 
glycine After centnfugation, the pellet was washed 
with 100 tú 1N HCIO4, and centnfuged again Both 
supernatants were neutralized with 4 Ν KOH, cooled 
immediately afterwards at -20° and centnfuged The 
supernatant was incubated for 1 hr at 37° with Ü 3 mg 
pronase in order to hydrolyse all protein The 
samples were evaporated to dryness and redissolved 
in 25 μΙ of water These samples were counted in a 
liquid scintillation analyzer and further analyzed on 
two-dimensional thm-layer chromatography, util­
izing butanol methanol water ammonia (33%) 
(30 10 10 1) and secondly 0 15 M NaCl. and using 
ninhydnn as a marker This procedure allowed sep­
aration of glycine incorporated into adenine, hypo-
xanthine. guanine and adenosine respectively and 
free glycine 
After correction for the glycine concentration in 
fresh medium (determined by amino acid analysis) 
and correction for losses during the procedure, the 
amount of glycine incorporated into purine metab­
olites was calculated and expressed as pmol/hr/106 
viable cells 
Incorporation of [8-'4C] hypoxanlhme and [8-'''C] 
6-mercaptopurine At sanous intervals, aliquots of 
0 5 ml of the cell culture were sampled and 0 1 ml 
(570 μΜ unlabeled plus 30 μΜ labeled) hypoxan-
thine was added to a final concentration of 100 μΜ 
After mixing the samples were incubated for 20 mm 
at 37° The reaction was stopped by cooling (5 mm, 
0°), cells were centnfuged (8500g, 5 mm) and resus-
pended in 75 μΙ of the supernatant These sus­
pensions were layered in a microtube (0 4 ml, Eppen-
dorf. Hamburg, I R G ) over a discontinuous 
gradient consisting of 50 μΐ 5% saccharose in 0 9% 
NaCl at the bottom and 70 ul silicone oil (AR 20/ 
AR 200 1 1 v/v. Wacker Chemie, München, 
F R G ) on the top of the gradient The microtubes 
were centnfuged (centrifugal force slowly increasing 
to 7500 g and then maintained for 20 sec) in order 
to separate the cell pellet [31] The microtubes were 
cut ]ust above the cell pellet The cell pellets were 
resuspended in 2 ml Soluene (Packard, Groningen, 
The Netherlands) and after 24 hr radioactivity was 
counted in a liquid scintillation analyzer after 
addition of 10 ml scintillation fluid 5% Tnton (v/v) 
in a toluene scintillator 
Analyses with thin layer chromatography after 
centnfugation of the microtubes showed that the 
label in the cell pellet after addition of 100 μΜ 
[8-,4C] hypoxanthine was distributed as follows 75% 
ATP, 12% ADP, 3% AMP, 1 2 % IMP, 3 6% hypo­
xanthine, 0 1% adenosine and 5 1% unknown 8-14C 
label The saccharose-NaCl solution above the cell 
pellet did not contain radioactivity. The medium 
above the oil compartment contained 98% labeled 
hypoxanthine, 1% labeled inosine and 1% labeled 
nucleotides but no cells 
Similar experiments were performed at vanous 
intervals with [8-uC] hypoxanthine m a final con­
centration of 10 μΜ (intracellular label distribution: 
827c ATP, 12 2% ADP, 1 7% AMP, 1 0% IMP, 
0 49c hypoxanthine and 2 7% unknown), and with 
[8-uC] 6-mercaptopurine in final concentrations of 
100 μΜ and 10 μΜ respectively 
After addition of 100 μΜ [8-14C] 6-mercaptopurine 
the intracellular label was distributed as follows: 
6 0% ATP. 1 5% ADP (loss of thiol group), 66 6% 
tIMP. 8 3% thio-inosine, 1 3% 6MP, 11 0% thio-
guanosine and 5 3% unknown label 
MTX 0 ΖμΜ (Ы MTX 0 0 2 μ Μ 
Fig 3 Effects of MTX on intracellular PRPP levels in MOLT 4 cells Cells were exposed at t = 0 to 
MTX, and PRPP levels were determined as desenbed in Materials and Methods (a) 0 2 μΜ M ГХ, (Ь) 
0 02 μΜ MTX Results were expressed as nmol/lO8 viable cells · MTX-treated cells, O. untreated 
cells Each dot represents a determination m duplicate The curve is drawn through the mean of the 
determinations at each point of time 
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Fig 4 Effects of MTX on intracellular AICAR levels in 
MOLT 4 cells Cells »ere exposed aw - 0 to MTX and 
AICAR levels »ere determined as described in Materials 
and Methods Results »ere expressed as pmol/IO* маЫе 
cells Sec further legend for Fig 1 
The amount of incorporated punne bases was 
expressed as nmol/10* viable cells/20 mm 
AICAR assa\ Determinations of AICAR were 
performed by HPLC essentially according to De 
Abreu el al [32] and the levels were expressed as 
pmol/10<' viable cells 
RESI LTS 
Effects of MTX on PRPP levels 
Figure 3 shows the effects on intracellular PRPP 
levels in MOLT-4 cells after incubation with 0 2 fiM 
and 0 02μΜ MTX, respectively These concen­
trations of MTX were used, because thev can be 
maintained m vwo for many hours after oral adminis­
tration in the maintenance therapy of ALL in chil 
dren [33-35] Concentrations of 0 2 uM MTX 
increased intracellular PRPP levels 16-fold after 8 hr 
of incubation, whereas 0 02μΜ MTX increased 
PRPP levels Η fold with a maximum reached at a 
later point of time (i e between 20 and 28 hr) After 
48 hr PRPP levels decreased to those of untreated 
cells 
Effects of MTX on AICAR levels and [U-1 4C| gheme 
incorporation 
After incubation of MOLT-4 cells with 0 Ü2 uM 
MTX a significant (18-fold) increase of AICAR was 
observed with a maximum at 28 hr followed by a 
decrease at 48 hr (Fig 4) suggesting an incomplete 
inhibition of purine de novo synthesis at 2()-28 hr 
which recovered at 48 hr Incubations with 0 2 uM 
MTX (dala nol shown) did no! show any increase of 
AICAR in comparison with untreated cells, sug 
gesting a complete inhibition The results of glvcine 
incorporation into purine metabolites (Table 1) indi-
cate a complete inhibition of purine de novo synthesis 
at 24 and 48 hr after incubation with 0 2 uM MTX 
whereas treatment with 0 02 uM MTX did not result 
in a significant inhibition 
ttfecls of MTX on mlracellular incorporation of 
[8-l4C] Inpoxanlhme and \H-]iC\ b-mercaptopurme 
Figures 5a and 5b represent the incorporation for 
20 mm of 100 μΜ hypoxanthine at various points of 
labiel Incorporation ol [ü "С | duini in MOI I -fulls 
ixpoMd lo Ml \ 
Ml \ Duraiion of ixposun 
(»M) 24 hr 48 hr 
0 214 ± IK (ID) : i l ± П7 (J) 
U02 I M ± 100(8) 219 i 71 ( I) 
0 2 Ü (4) I) (4) 
- In pmol'hr 10* viable cells ± SD 
Numbers in parentheses number of ixpenmints 
time after incubation with 0 2 μΜ and 0 02 /<M MTX, 
respectively 
Figures 5c and 5d represent the same data after 
incorporation of 10 μΜ hypoxanthine 
Similar curves were observed as compared to those 
of intracellular PRPP levels (Fig 3) 
Incorporation (for 20mm) with [в^С] 6-mer-
captopunne in a concentration of 100 μΜ or 10 μ\1 
at various points of time after incubation with MTX 
is demonstrated in Figs 6a-6d Again similar curves 
were observed as compared to bigs 3 and 5 
DISCISSION 
Methotrexate is known to inhibit dihvdrofolate 
reductase (DHFR) The consequences of inhibition 
ot DHFR include accumulation of dihydrofolates 
and corresponding depletion of tetrahvdrofolates 
The results are an inhibition of thymidvlate syn­
thetase in pvrimidine biosynthesis and inhibition of 
tetrahvdrofolate dependent enzvmes in purine de 
novo synthesis with concomitant increase of intra­
cellular PRPP levels [4,16] Figure 3 dtmonstrates 
the correlation between the period of time after 
which PRPP levels are maximal in MOLT-4 T-
Kmphoblasts and the concentrations of MTX used 
We found that 0 002 μίΛ MTX did not result in any 
increase of PRPP in a time period of 48 hr (data not 
shown), 0 02 μΜ MTX resulted in a peak of PRPP 
at 20-28 hr, 0 1 uM MTX in a peak after 18 hr (data 
not shown) and 0 2μΜ MTX in a peak 8hr after 
incubation with MTX Thus higher concentrations 
of MTX resulted in earlier peak levels of intracellular 
PRPP The correlation between the concentration 
of MTX and the moment of maximal PRPP increase 
seems of importance in combination chemotherapy 
consisting of MTX and those antimi tabolites which 
use PRPP as a cofactor for their phosphonlation and 
which are uhimaiely incorporated into RNA and 
DNA 
We could demonstrate the importance of glu-
tamine as an essential nutrient in celis with an active 
purine de novo synthesis as mentioned bv others 
[36 37] When we omitted glutamine addition every 
24 hr glutamine exhaustion of the medium resulted 
in an inhibition of purine de novo synthesis with 
loncomitanl mciease of PRPP espcciallv in 
untreated MOLT 4 cells becausi. glulammt is a 
cosubstrateof amidophosphonbosvltransfirase (Fig 
1) The high capacitv of purine de novo synthesis m 
MOLT 4 cells is reflected in the high PRPP levels in 
untreated cells 0 UH) ± 0 045 nmol/10' viable cells 
(mean ± SD 12 experiments) This is in contrast 
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hypoxanthine. (d) 0 02μΜ I1'.TX, ΙΟμΜ hvpoxanthme See further legend for Fig 3 
VHlh the low PRPP levels in normal, nonstimulated 
peripheral blood lymphocytes 0 008 nmol/10'' cells 
¡18) We could not demonstrate a significant increase 
of PRPP in normal peripheral blood lymphocytes 
after incubation with 0 U2 and 0 2μΜ M T X over a 
time period of 48 hr (data not shownt and we could 
not demonstrate cvtotoxicitv These· data suggest 
that leukemic lymphobUsts are more susceptible to 
the biochemical disturbances of purine de novo svn-
thesis after treatmi m with M T X in comparison with 
( β ) 
-
-
L·/ 
1 
S 
MTX 0 02μΜ 
6 MP 100 f-M 
• 
- - о - - - - 0 - - 0 — - - " 
1 
• 
e 
о 
I 
(с) 
мтх о г м м 
6 MP ΙΟμΜ 
Id) MTX 0 02μΜ 
e MP ю^м 
β 16 24 
^ 
4 
T i m 
ί 
ϊ Ο θ 
e i h r ) 
I 
•б г * «β 
Fip 6 Effects of M T X on intracellular incorporation of [S-^C] 6-mcrcaptopurinc m MOLT-4 cells (a) 
0 2 « M M T X MKl/iMfiMP ( b ) ( l ( 1 2 u M M l X . ИХІнМбМР. (c)0 2/iM M I X ΙΟμΜ OMP. ((J)0 02μΜ 
MTX 10 ιιΜ ήΜΡ Sec further legends for Figs S and 3 
normal peripheral blood Kmphocues and also in 
comparison with normal bone marrow cells which 
did not show an active purine de novo s\nthesis as 
well (21] 
The two enzvmes in\ol\ed in inhibition of purine 
de novo s\nthesis by MTX are ghcinamide ribo­
nucleotide (GAR) formvltransferase and amino-
imidazolecarboxamide ribonucleotide (AICAR) for-
imltransferase (Fig 1) The slow increase of PRPP 
and AICAR (Figs 3 and 4) with maxima at 20-28 hr 
after incubation with 0 02 uM MTX demonstrates 
that at this concentration of MTX GAR-formyl-
transferase is onlv partially inhibited and that the 
inhibition of AICAR-formyltransferase is more pro­
nounced However even the latter enzyme might 
also be partially inhibited After 48 hr AICAR levels 
recovered, suggesting a recovery from the partial 
inhibition of purine de novo synthesis The fact that 
we did not find a significant inhibition of glvcine 
incorporation after 24 hr (Table 1) may be due to 
the excess of glycine under the experimental con­
ditions in the assay 
Incubation with 0 2 μΜ MTX did not increase 
AICAR levels, which suggests a complete inhibition 
of GAR-formyltransferase with higher concen­
trations of MTX This was confirmed by glycine 
incorporation experiments (Table 1) and by the 
changes in intracellular ribonucleotide pools [39] 
The decline of PRPP levels in time is due to reutil-
ization of nucleotide precursors This will be 
explained in more detail in the accompanying paper 
[39] 
The increased availability of PRPP due to MTX 
pretreatment can be used for increased conversion 
and incorporation of natural purine and pynmidine 
bases This was confirmed in our incorporation stud­
ies with [8 U C] hypoxanthine The amounts of incor­
porated hypoxanthine are directly correlated with 
PRPP levels at each point of time after incubation 
with MTX (Figs 5 and 3) The results of incor­
poration with 10 μΜ hypoxanthine are especially 
important because the initial concentration of hypo­
xanthine in the medium was 3-5 μΜ (see below) 
These data support the findings of others that nat­
ural purine and pynmidine bases can be used in order 
to rescue a prolonged purmeless and thymidylateless 
state after treatment with MTX (6,16,40-45] 
Figure 6 demonstrates that the increased avail­
ability of PRPP due to pretreatment of MTX can 
also be used for enhanced incorporation of 6-mer-
captopunne Again, the curves are similar to those 
of intracellular PRPP levels (Fig 3) and those of 
incorporation of hypoxanthine (Fig 5) and emphas­
ize the correlation between the concentration of 
MTX and the moment of maximal 6MP 
incorporation 
The amount of 6MP incorporated in untreated 
cells is approximately 2-3 times lower than the 
amount of hypoxanthine incorporated This can be 
explained by the fact that hypoxanthine can be incor­
porated into nucleic acids in the form of both adenine 
and guanine (deox>)ribonucleotides with a prefer­
ence for adenine [31] 6MP however, can only be 
incorporated as thioguanine (deoxy)ribonucleotides 
The results of incorporation with 10 μΜ 6MP indicate 
that this concentration is also able to show an 
increased incorporation ι e conversion by HGPRT, 
whereas the initial concentration of hypoxanthine in 
the medium is 3-5 μΜ Hvpoxanthine is the physio­
logic substrate for HGPRT and is competitive with 
6MP for this enzyme However, it should be men­
tioned that treatment with MTX causes depletion of 
punne metabolites and that the increase of PRPP 
will be utilized first for conversion of hypoxanthine, 
present in the medium, before 6MP is added We 
could demonstrate a decrease of the initial con­
centration of hypoxanthine in the medium of 3-5 μΜ 
to 0 1-0 2 μΜ after 24 and 48 hr (data not shown) 
Nevertheless, after consumption of PRPP bv hypo­
xanthine in the medium there was still a significant 
increase of PRPP levels (Fig 3), which now became 
available for conversion of 6MP by HGPRT These 
phenomena are of special importance in the in vivo 
situation, where the concentration of hypoxanthine 
is variable [46] These phenomena indicate that the 
concentration of 6MP must exceed the actual con­
centration of hypoxanthine in order to obtain a 
significant intracellular incorporation of 6MP Our 
results indicate that pretreatment with MTX lowers 
the hypoxanthine concentration of the medium So, 
pretreatment of MTX potentiates also the conversion 
of 6MP by lowering its competitive substrate for 
HGPRT Although we found hypoxanthine levels in 
bone marrow samples of 4 8 ± 2 1 μΜ (mean ± SD, 
N = 11), which are similar to those of our experi­
mental conditions, this phenomenon has to be pro­
ven for the in vivo situation 
The data presented in this study demonstrate that 
a synergistic action of the combination of MTX and 
6MP can be anticipated depending on the con­
centration of MTX and on the time and sequence of 
administration of both drugs At present, we inves­
tigate the sequence-, time- and dose-dependent 
effects of various combinations of MTX and 6MP in 
several human malignant lymphoblastic cell lines 
with respect to purine de novo synthesis availability 
of PRPP and cytotoxicity (soft agar colony forming 
activity) 
The synergistic action of MTX and other purine 
and pvnmidme base analogues administered after 
MTX has been demonstrated in many m vitro 
studies MTX and 5FU (1 2 4,6] and MTX and 
6TG [9] Under the experimental conditions used, 
these studies also revealed that the analogues pref­
erentially incorporate into RNA, whereas DNA syn­
thesis is inhibited by MTX However, the differences 
in time of maximal PRPP levels and maximal incor­
poration of the analogues in relation to various con­
centrations of MTX have not been referred Studies 
are in progress in our laboratorv investigating the 
incorporation of 6MP with and without pretreatment 
of MTX into newly formed DNA and RNA by 
means of double-labeling techniques with l4C-6MP 
and 3 2P 
MTX and 6MP are common drugs in the main­
tenance therapy of children with ALL Both drugs 
arc administered orallv The bioavailability of MTX 
after oral administration differs from patient to 
patient [33-35 47] However, the serum concen­
trations of MTX range around levels which have 
been used in our studies The bioavailability of 6MP 
after oral administration is extremely limited and 
35 
variable [4K-511 Moreover because of the complex 
metabolism of 6MP an evaluation of the phar 
macokmetics and bioavailability of 6MP will be very 
difficult 
Nevertheless further pharmacokinetic studies in 
children with ALL and in uiiro experiments in l>m 
phoblastic cell lines on the combination of M l X and 
6MP are necessary in order to elucidate whether the 
present oral administration of MTX and 6MP in the 
maintenance therapy of ALL is sufficient to take an 
optimal advantage of the possible synergism of both 
drugs as presented in this study 
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Abstract—The effects of methotrexate (MTX) on cytotoxicity (trypan blue exclusion and soft agar clonal 
growth), cell cycle perturbation and purine and pynmidinc ribonucleotide and deoxynbonucleotide 
pools have been studied in MOLT-4 malignant T-lymphoblasts Two concentrations of MTX 0 02 μΜ 
and 0 2 uM have been utilized, which can be maintained in υιυο during many hours in the maintenance 
iherap) of acute lymphoblastic leukemia (ALL) The results are correlated with the effects of MTX on 
the inhibition of purine de novo synthesis Treatment with 0 02 μΜ MTX results in an accumulalion of 
cells in early S phase after 20 hr, as measured by DNA flow cytometry and by a significant increase of 
dCTP levels, followed by a slow progression of a cohort of cells through the cell cycle Cytotoxicity also 
becomes evident starting from this point of time The effects on deoxynbonucleotide pools are discussed 
in correlation with the inhibition of DNA synthesis The changes in ribonucleotide pools are associated 
with the partial inhibition of punne de novo synthesis at 20-28 hr and suggest an inhibition of RNA 
synthesis After 48 hr a reutilization of nucleotide precursors due to nucleic acid breakdown and a 
recovery of punne de novo synthesis is shown, associated with a recovery of RNA synthesis whereas 
cytotoxicity increases Treatment of MOLT 4 cells with 0 2μΜ MTX results in a rapid complete 
cessation of cell progression through all parts of the cell cycle after 8 hr, associated with a depletion of 
all deoxynbonucleotide pools, complete inhibition of purine de novo synthesis, inhibition of RNA 
svnthesis and a marked cytotoxicity Ribonucleotide pools demonstrate a reutilization of nucleotide 
precursors after 12 hr of incubation without a recovery of purine de novo synthesis and RNA synthesis 
These data show a close dose- and time-dependent correlation of the effects of MTX on purine de 
novo synthesis, UMP levels and other (deoxy)ribonuclcotide pools, and on RNA and DNA synthesis 
in MOLT-4 cells having an active purine de novo synthesis This correlation is absent in normal bone 
marrow cells and peripheral blood lymphocytes These data can be used in order to elucidate the 
synergistic effects of sequential administration of MTX and 6-mercaptopurine 
Methotrexate (MTX) is a potent drug in the treat­
ment of acute lymphoblastic leukemia (ALL), used 
either as high dose intravenous chemotherapy and 
prophylactic central nervous system treatment [1], 
or as oral maintenance treatment in combination 
with oral 6-mercaptopurine (6MP) [2] 
We demonstrated a sequence-, time- and dose-
dependent synergism of MTX and 6MP in MOLT-4 
malignant human T-lymphoblasts [3] The increased 
availability of 5-phosphonbosyl-l-pyrophosphate 
(PRPP) after pretreatment with MTX could be used 
for an enhanced conversion of 6MP by hypoxanthine-
guanine phosphonbosyltransferase (HGPRT) This 
is a selective phenomenon in malignant lymphohlasts 
with an active purine de novo synthesis and is absent 
in normal bone marrow cells and peripheral blood 
lymphocytes [3,4] 
Determination of ammoimidazolecarboxamide 
ribonucleotide (AICAR) levels and labeled glycine 
incorporation studies indicated a complete inhibition 
of purine de novo synthesis after treatment with 
" This work was funded by the Dutch Oueen Wilhelnuna 
Cancer Fund (KWF), grant MJKC 82-3 
* To whom requests for reprints should be addressed 
0 2μΜ MTX and an incomplete inhibition with 
0 02 μΜ MTX in MOLT-4 lymphoblasts [3] 
Extensive studies [5-19] have been published with 
respect to the effects of various concentrations of 
MTX on cytotoxicity, cell cycle perturbation and 
purine and pynmidme deoxynbonucleotide pools in 
various malignant cell lines However, studies con­
cerning these effects of MTX in correlation with the 
inhibition of purine de novo synthesis and ribo­
nucleotide pools are scarcely available 
To our knowledge, the malignant lymphoblastic 
cell lines currently in study in our laboratory MOLT-
4 T-, Raji B- and KM-3 non-B-non-T-lymphoblasts, 
have not been studied before, utilizing MTX-con-
centrations which can be maintained in vwo during 
many hours in the oral maintenance therapy of ALL 
in children [20-22] 
In the present study we investigated the sequential 
time-dependent effects of 0 02 μΜ and 0 2 μΜ MTX 
on purine and pynmidme nucleotide pools in MOLT-
4 cells These effects were correlated with the effects 
of MTX on cytotoxicity (trypan blue exlcusion and 
soft agar colony forming activity) and cell phase 
distribution, measured by DNA flow cytometry The 
significant role of the inhibition of purine de novo 
за 
s>nthesis with regard to the effects of MTX on 
(deoxy)ribonucleotide levels and DNA and RNA 
synthesis is discussed 
MATERIALS AND METHODS 
Materials MTX (Emtrexate PF) was purchased 
from Pharmachemie, Haarlem, The Netherlands, 
MOLT-4 human malignant T-lymphoblasts from 
Flow Laboratones, Irvine, U К , Bacto-agar from 
Difco Laboratories, Detroit, MI 
Cell culture The conditions for cell culture were 
similar as described earlier [3] 
Soft agar colony forming activity Before cloning, 
cells were washed once in fresh medium, centnfuged 
(5 mm 200 g) and resuspended in medium in order 
to ensure drug removal from the medium Cell count 
and viability were measured Two ml suspensions 
containing cells and Bacto-agar 0 3% (w/v) m fresh 
medium were layered into 6-wells plates (Becton 
Dickinson, Oxnard, CA) Colonies were allowed to 
grow at 37° in a water-saturated atmosphere con­
taining 2 5% CO2 After 10 days colonies of at least 
30 cells were counted, using a Leitz Diavert micro­
scope Cloning results were expressed as plating 
efficiency (in %) number of colonies x 100/number 
of cells before plating In these expenments we 
adjusted the cell concentrations in order to obtain a 
linear correlation between number of cells before 
plating and number of colonies Therefore, we 
diluted the cells after washing to three known con­
centrations in duplicate and chose for each point the 
highest plating efficiency found Plating efficiency of 
untreated MOLT-4 cells was 8% 
Colony forming activity was expressed as per­
centage of plating efficiency of untreated cells All 
experiments were performed in duplicate 
DNA flow cytometry At each point of time 4 ml 
of the cell suspension were centnfuged (8 mm, 400g, 
4°) Cell pellets were resuspended in 0 2 ml NaCl 
0 9% solution and 1 8 ml hypotonic cthidium bro­
mide solution, containing 25 mg/1 ethidiumbromide 
and 1 g/1 sodium citrate Distributions of DNA con­
tent were anilvzed in an impulse cytophotometer 
(ICP 11, Phywe Company, F R G ), and calculated 
utilizing the method described by Baisch et al [23] 
The results were expressed as percentages of cells in 
Gl S, and G2 + M phase In the computerised three-
dimensional graphics the G l peak is placed in chan­
nel 50 on the abscissa and the heights of all G l peaks 
were normalized Exact computer calculations of 
DNA distribution in cells treated with 0 02 μΜ MTX 
were not feasible with this procedure because of the 
indistinct separation of the G l and S peaks 
DNA distribution of untreated cells was (mean ± 
SD N = 6) G l 60 3 ± 3 5, S 32 3 ± 2 4, 
G2 + M 7 7 + 0 8 
Astav of purine and pynmidine nucleotide pools 
After centnfugation 100 μ| 0 4 M HC104 was added 
to the cell pellet containing approximately 44 x 10* 
tells and kept on ice during 15 mm The suspension 
was centnfuged (4 min, 5400g, 4°), the supernatant 
was adjusted to a pH range of 6 0-6 7 with a solution 
containing I M K,HPO 4 + 0 4 M KOH + phenol-
red and centnfuged again 1/11 fraction of the super­
natant was utilized for determination of nbo-
Table 1 Percentages of buffers* used dunng elunon of 
ribonucleotides and deoxynbonucleotides 
Time 
(mm) 
00 
65 
13 0 
16 2 
32 0 
48 0 
510 
57 5 
Buffer A 
(%, v/v) 
10 0 
600 
44 0 
400 
30 0 
20 0 
14 0 
14 0 
Buffer В 
(% v/v) 
900 
40 0 
440 
40 0 
30 0 
20 0 
14 0 
14 0 
Buffer С 
(%,v/v) 
00 
00 
12 0 
20 0 
40 0 
600 
72 0 
72 0 
* See Materials and Methods 
nucleotides For determination of deoxynbo­
nucleotides we had to oxidize the ribonucleotides 
The remaining 10/11 fraction of the supernatant was 
adjusted to 150 ul and we added 6 μΐ 0 5 M sodium 
penodate and 7 5 μΐ 4 0 M diethylaminephosphate 
(pH 7 5) After 30 min of incubation at 37° 2 μΐ 1 M 
rhamnose was added to the mixture in order to 
neutralize the remaining sodium penodate and the 
samples were put on ice and measured immediately 
afterwards Chromatography was performed on an 
HPLC, model SP 8000 (Spectra Physics, Santa Clara, 
CA) with an automated data system and a fixed 
wavelength u ν -detector of 254 nm Separation was 
earned out at 45° on a Partisil-10-SAX column 
(250 x 4 6 mm, Whatman, Maidstone, U К ) with a 
mobile phase consisting of three elution buffers, as 
desenbed in Table 1 (A) 0 05 M potassium 
dihydrogenphosphate + 2% (v/v) CH3CN, pH = 
3 10, (B) 2% (v/v) CH3CN in water, and (C) 0 45 M 
potassium dihydrogenphosphate + 2% (v/v) 
CH3CN, pH = 5 25 Dunng the elution the solutions 
were deaerated by continuous hebum purging A 
constant flow rate of 2 8 ml/min was used 
Recovery sensibility and reproducibility of the 
cell extraction procedure were described earlier [24] 
However the procedure desenbed here resulted in 
lower detection limits Because we found a decrease 
of (deoxy)nbonucleotide levels in untreated cells 
after prolonged penods of incubation, the results 
(pmol/106 viable cells) were expressed as per­
centages of untreated viable cells, harvested at the 
same time of incubation 
Initial levels of (deoxy)nbonucleotides in MOLT-
4 cells (pmol/lO·' viable cells ± SD, N = 6) were 
ATP 1222 ± 92 GTP 282 ± 31 UTP 449 ± 52, 
CTP 141 ± 21 dATP 23 ± 4, dGTP 12 ± 2, dTTP 
17 ± 3, dCTP 7 ± 1 
RESLLTS 
Effects of MTX on cell growth and viability, soft 
agar colony forming activity and cell cycle phase 
distribution 
Figures la and lb show the effects on cell growth 
and cell viability respectively as determined by 
trypan blue exclusion in MOLT-4 cells during incu­
bation with 0 02 uM and 0 2 μΜ MTX respectively 
Cell growth is completely inhibited 20 hr after 
incubation of MOLT-4 cells with 0 02 μΜ MTX (Fig 
3 9 
О 8 16 21 48 
lime ihoufsì 
Ο β 16 24 48 
t ime (hours) 
Fig 1 (a) Effects of MTX on the growth of MOLT-4 cells 
Counts are expressed as number of viable cells only (trypan 
blue exclusion) O, untreated cells, A, 0 02μΜ MTX, · , 
О 2 üM MTX The dots represent the mean of 3 individual 
experiments in duplicate (b) Effects of MTX on viability 
of MOLT-4 cells expressed as percentages of viable plus 
non-viable cells See further legend to Fig la 
la), and cell viability (trypan blue exclusion) is 
gradually decreasing (70% at 48 hr, Fig lb) 
However, colony forming activity is not impaired by 
0 02 μΜ MTX at 24 hr (Table 2) This may be the 
result of washing out the low concentration of MTX 
with fresh medium before the cells were plated on 
agar and were allowed to grow for 10 days [12.17] 
The bias of the procedure of soft agar clonal growth 
due to washing out of MTX has to be taken into 
account, when the results of m vitro and in υιυο 
Table 2 Effects of .MTX on the colony forming activity" 
of MOLT 4 Γ lymphoblasts 
Duration of 
incubation 
(hr) 0 02 μΜ MTX 0 2 μΜ MTX 
0 100 0% 100 0% 
12 — 67 2% 
24 119 9% — 
36 — 2 25% 
48 43 8% — 
60 — 0 05% 
'' Colon) forming activity is defìned as the percentage 
of plating efficiency of treated cells/plating efficiency of 
untreated cells (see Materials and Methods) 
—, not done 
studies with low concentrations of MTX are 
compared This phenomenon was not obvious 48 hr 
after incubation with 0 02 μΜ MTX where colony 
forming activity is reduced to 43 8% (Table 2) Incu­
bation with 0 2/iM MTX produces an inhibition of 
cell growth already after 4hr (Fig la), with an 
increasing loss of cell viability (Fig lb) This is 
reflected in a marked decrease of clonal growth, 
observed already at 12 hr, the shortest time interval 
measured (Table 2) An almost complete inhibition 
of clonal growth is observed at 36 and 60 hr after 
incubation 
The effects of MTX on cell cycle phase distribution 
are presented in Fig 2 After incubation with 
0 02 uM MTX a decrease of the percentage of cells 
in G2 + M phase is noted (Fig 2a) together with an 
accumulation of cells in early S-phase shown by the 
continuing broadening of the descending slope of 
the first histogram peak during the first 28 hr of 
incubation At 48 hr a second peak in the S phase 
appears, indicating a slow progression of a cohort of 
cells through the cell cycle This was also suggested 
by the percentages of viable cells and the colony 
forming activity at 48 hr, which show that a con­
siderable number of cells escape from the cytotoxic 
effects of 0 02 μΜ MTX 
Incuoation with 0 2 uM MTX (Figs 2b and 2c) 
demonstrates a rapid initial increase of cells in Gl 
phase, associated with an almost complete loss of 
cells in G2 + M phase After 8 hr of incubation this 
phenomenon is followed by a complete cessation of 
cell proliferation through all parts of the cell cycle, 
which is associated with a significant decrease of cell 
growth and cell viability (Fig 1) and of clonal growth 
(Table 2) The conspicuous decrease of viability at 
48 hr, shown by the first peak of cell debris in the 
histogram preceding the Gl peak, did not allow us 
to make exact calculations of DNA-distribution at 
that point of time 
Effects of MTX on purine and pynmidme nucleotide 
pools 
MTX inhibits tetrahydrofolate dependent 
enzymes, due to inhibition of dihydrofolate 
reductase [25,26] In pynmidme metabolism, the 
inhibition of thymidylate synthetase in MOLT-4 cells 
after incubation with 0 2 μΜ MTX is shown by a 
rapid decrease of dTTP levels (to 20% of untreated 
cells, Fig 3b) The purine deoxynbonucleotides, 
dATP and dGTP (Fig 4b), and dCTP levels (Fig 
3b) also demonstrate a rapid decrease 
These phenomena explain the complete inhibition 
of progression through all parts of the cell cycle, 
shown in Figs 2b and 2c The complete inhibition of 
purine de novo synthesis due to incubation with 
0 2 uM MTX is shown in an initial decrease of ATP 
and GTP (Fig 5b) A concomitant initial increase 
of pynmidme ribonucleotides is demonstrated (Fig 
6b) which is followed by an increase of all ribo­
nucleotides after prolonged incubation with 0 2 μΜ 
MTX These phenomena and the slow increase of 
UMP levels (Fig 7b) will be discussed later 
The effects of 0 02 μΜ MTX on purine and pynm­
idme pools are less pronounced The partial inhi­
bition of thymidylate synthetase is reflected in a small 
4 0 
Fig 2 Effects of MTX with time of exposure on changes in DNA distribution of MOLT-J cells (a) 
0 02 μΜ MTX, (b) 0 2μΜ MTX The histograms are representative examples of 3 mdiudual experi­
ments (c) Computer calculations of the percentages of cells in various cell cvcle phases O. untredtcd 
cells, # , 0 2^M MTX The dots represent the mean of 3 experiments in duplicate 
• < \ 
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Fig 3 Changes in dCTP (•) and dTTP (•) levels m MOLT-4 cells attor exposure to MTX (d)0 02uM 
MTX, (b) 0 2 μΜ MTX Results were expressed as percentages of umieated cells at each point of lime 
Each dot represents a determination in duplicate The curves are drawn through the mean of the 
determinations at each point of time 
_ 2 0 0 
Fig A Changes in dATP(T) and dGTP (•) levelsin MOLT-4 cells after exposure to MTX See further 
legend to Fig ^ 
16 24 48 
t i m e ( h o u r s ) 
Fig 5 Changes in ATP (•) and GTP (•) levels in MOLT-4 cells after exposure to MTX See further 
legend to Fig 3 
Fig. 6 Changes in CTP (•) and UTP (•) levels in MOLT-4 cells after exposure to MTX See further 
legend to Fig 3 
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Fig 7 Changes in UMP levels in MOLT-4 cells after exposure to MTX (a) 0 02 μΜ MTX, (b) 0 2 μΜ 
MTX, О. untreated controls, # , MTX-treated cells Results are expressed as ртоІ/КУ· viable cells Sec 
further legend to Fig 3 
decrease of dTTP levels (Fig. 3a). During the first 
20 hr of incubation purine deoxynbonculeotides 
show a small decrease, which is followed by an 
increase (Fig. 4a) These effects were associated with 
an accumulation of cells in early S phase and an 
increase of dCTP levels (Fig. 3b) 
Determinations of PRPP and AICAR [3] demon­
strated that a partial inhibition of purine de novo 
synthesis was obtained after 20-28 hr of incubation 
with 0.02 μΜ MTX. At those points of time a con­
comitant increase of UMP (Fig 7a) and all nbo-
nucleoside triphosphate pools (Figs 5a and 6a) is 
noted It should be mentioned that the assay con­
ditions for determination of UMP do not allow a 
distinct separation of UMP and oxidized dUMP. 
However, the course of the levels in Fig 7 is identical 
to that of UDP and CDP levels (data not shown) and 
those of pynmidine triphosphate levels. Although 
treatment with high concentrations of MTX (10 μΜ) 
resulted in an extensive increase of dUMP [8], the 
4 2 
Table 3 Summary oí events as a result of the action of MTX on MOLT 4 cells 
Inhibition of cell growth 
Inhibition of DNA synthesis 
Mriximdl increase of PRPP levels 
Maximal increase of A1CAR levels 
Maximal decrease of purine ribonucleotide levels 
Maximal increase of pynmidme ribonucleotide levels 
Inhibition of RNA synthesis 
Reulilizalion of nucleotide precursors 
Recovery of purine de ηουο synthesis 
Recoven of RNA synthesis 
— not present 
effects of 0 02 μΜ and 0 2 μΜ MTX in our experi­
ments on UDP and UTP levels suggest a pre­
dominant contribution of UMP in our assays 
At 48 hr of incubation with 0 02 μΜ MTX all ribo­
nucleotides decrease to levels of untreated cells, 
whereas at the same time PRPP and AICAR levels 
decreased also, suggesting a recovery of RNA 
synthesis 
Table 3 summarizes the effects of both con­
centrations of MTX on the parameters mentioned 
above 
DISCUSSION 
The effects of MTX on cell growth, cell kinetics 
and purine and pynmidme pools have been studied 
extensively in various cell lines [5-19] Excellent 
reviews of the literature with respect to the various 
effects of MTX were presented by Jackson [25,26] 
Important differences were demonstrated between 
different cell lines and. within one cell line, between 
different investigators Some investigators used rela­
tively high concentrations of MTX in their cell 
cultures, up to 10 or 100 μΜ, which can be obtained 
with high dose MTX infusions in patients [1] 
However, the purpose of our investigations was to 
study the effects of MTX in concentrations, which 
can be maintained m vwo during many hours in the 
oral maintenance therapy of ALL in children [20-
22], and, moreover, to study the effects of various 
combinations of MTX and 6MP 
We demonstrated the inhibitory effects of 0 02 μΜ 
and 0 2 uM MTX on purine de novo synthesis of 
MOLT 4 cells [3] These effects were time- and dose-
dependent This prompted us to study extensively 
the sequential time-related effects of MTX on cyto­
toxicity and on purine and pynmidme metabolism. 
whereas most studies in the literature only address 
the effects of MTX at limited points of time In the 
present studv we are measuring all parameters at 
those points of time, which proved to be important 
with regard to the time-related inhibitorv effects of 
MTX on purine de novo synthesis [3] Our study 
indicates that these time- and dose-related effects 
of MTX are important for further elucidating the 
complex mode of action of MTX 
As shown in big la. 0 02 μΜ MTX inhibits cell 
growth after 20 hr of incubation At the same time 
an increase of the fraction of cells in early S phase is 
Time (hr) at which the events become evident 
0 02μΜΜΤΧ 
20 
20 
20-28 
28 
_ 28 
28 
48 
48 
48 
0 2 μΜ MTX 
4-8 
8 
8 
— 8-12 
8 
12 
12 
— 
— 
noted (Fig 2a) Although cell viability decreased, 
clonal growth (Table 2) was not inhibited at 24 hr, 
indicating that accumulation of cells in early S phase 
was reversible when the low concentration of MTX 
was washed out before the cells were plated on soft 
agar 
Our studies of the effects of 0 02 μΜ MTX on 
intracellular incorporation of radiolabeled hypo-
xanthine in a concentration of 10 μΜ [3]. showed a 
marked increase of incorporation at 24 hr of incu­
bation Thus, addition of fresh medium containing 
3-5 μΜ MTX hypoxanthine could contribute to the 
recovery of clonal growth due to a recovery from the 
effects of the partial inhibition of purine de novo 
synthesis [12,19] At 48 hr, colony forming activity 
was reduced to 43 8%, indicating that MTX-cyto-
toxicity was obvious at that point of time and that 
the accumulation of cells in the S phase did not 
recover by addition of fresh medium 
The effect of 0 02 μΜ MTX on the inhibition of 
thymidylate synthetase is shown in an initial small 
decrease of dTTP levels (Fig 3a) The initial 
decrease of dGTP and dATP levels between 0 and 
20 hr may be caused by consumption, because DNA 
synthesis is inhibited incompletely, and also by an 
increasing inhibition of purine de novo synthesis 
The significant rise of dCTP levels (Fig 3a) between 
0 and 20 hr confirmed our flow cytometry results 
(Fig 2a) and earlier findings [5 13,14 18,28-31] of 
increased dCTP levels as a phenomenon of accumu­
lation of cells in early S phase The increased levels 
mav be the result of a diminished inhibition of CDP-
reductase by decreased dTTP and dATP levels [27-
31] The further rise of dCTP levels with a maximum 
at 28 hr is accompanied by a small increase of dTTP, 
dGTP and dATP between 20 and 28 hr, and may be 
the result of a decreased consumption for DNA 
synthesis Figure 2a demonstrated that most cells 
were arrested in early S phase between 20 and 28 hr 
This arrest is incomplete, because the histogram of 
DNA distribution at 48 hr indicates a slow pro­
gression of a cohort of cells through the S phase 
This was accompanied by a decrease of dTTP dGTP 
and dCTP levels as occurs in late S phase, indicating 
an inhibition of all ribonucleotide reductases due to 
a recovery of dATP levels (Fig 4a) [27-3Ü] 
We noticed significant differences between 
MOLT-4 cells in our study and CCRF-CLM cells 
in the studies of others [7.17-19] Treatment with 
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О 02 uM MTX in both T-cell lines resulted in less 
progression through the S phase of the cell cycle and 
more pronounced decreases of deoxynbonucleotide 
levels in CCRF-CEM cells, compared to MOLT-4 
cells This may be due to more pronounced effects 
of MTX on ribonucleotide pools and RNA synthesis 
in MOLT-4 cells 
Between 0 and 20 hr of incubation, purine ribo­
nucleotide levels (Fig 5a) are not significantly im­
paired. whereas pynmidme ribonucleotide pools 
(Fig 6a) increase This phenomenon may be due to 
the partial inhibition of purine de novo synthesis 
with increasing availability of PRPP and concomitant 
increase of pvnmidine de novo synthesis. We did not 
perform two parameter flow cytometry as described 
by Taylor and Tattersall [17] However, our data 
suggest that RNA synthesis is still ongoing between 
0 and 20hr [9-11]. ι e unbalanced growth Between 
20 and 28 hr a significant increase of all ribo­
nucleotides is noted (Figs 5a and 6a), which coincides 
with the maximal increase of PRPP levels [3] and 
which also indicates a decreased utilization of all 
ribonucleotides These data suggest an inhibition of 
RNA synthesis between 20 and 28 hr. The increase 
of pyrimidine ribonucleotides (Fig 6a) is more pro­
nounced compared to that of purine ribonucleotides 
(Fig 5a) This can be explained by the maximally 
increased availability of PRPP between 20 and 28 hr, 
due to partial inhibition of punne de novo synthesis, 
which can be utilized for an increased pyrimidine de 
novo synthesis. The tremendous increase of UMP 
levels (Fig 7a) between 20 and 28 hr also indicates 
an increased pyrimidine de novo synthesis and a 
decreased utilization due to inhibition of RNA syn­
thesis. Thus, the maximal inhibition of purine de 
novo synthesis coincides with the inhibition of RNA 
synthesis [9-11], ι e balanced growth (inhibition of 
both DNA and RNA synthesis) This may explain 
the differences between MOLT-4 cells and CCRF-
CEM cells, because CCRF-CEM cells did not dem­
onstrate balanced growth at 24 and 48 hr [7,17,18] 
Figures 3a-7a demonstrate that the effects of 
0 02 μΜ MTX almost disappear at 48 hr However, 
a further increase of cells in early S phase is noted, 
associated with a slow progression of a cohort of cells 
through the S phase Moreover, dCTP levels remain 
elevated at 48 hr These data may seem contra­
dictory However, an increasing loss of viability (Fig 
lb) is demonstrated at 48 hr and an inhibition of 
clonal growth (Table 2) The increased cell loss at 
48 hr leads to increased nucleic acid breakdown and 
provides the viable cells with punne and pyrimidine 
nucleotide precursors These precursors can be 
reutilized to produce punne and pyrimidine nucleo­
tides [9-11], consuming PRPP as a cofactor We 
demonstrated that PRPP le\els at 48 hr decreased 
to those of untreated cells [3], suggesting PRPP 
consumption Moreover, we noted a decrease of 
AICAK levels at 48 hr, indicating a concomitant 
recovery of the inhibition of purine de novo 
synthesis 
The decrease of all ribonucleotides at 48 hr (Figs 
5a and 6a), which coincides with the recovery of 
purine de novo synthesis, suggests a consumption of 
ribonucleotides and a recovery of RNA synthesis in 
the surviving viable cells, ι e unbalanced growth 
However, the recovery of RNA synthesis did not 
result in a recovery from cytotoxicity [9-11] 
Thus, in MOLf-4 cells, treated with 0 02μΜ 
MTX. the inhibition of purine de novo synthesis is 
accompanied by an inhibition of RNA synthesis and 
DNA synthesis, ι e balanced growth, after a period 
of classical unbalanced growth between 0 and 20 hr. 
whereas recovery of purine de novo synthesis at 48 hr 
is associated with a recovery of RNA synthesis 
The effects of incubation with 0 2 μΜ MTX differ 
in many aspects from those with 0 02 μΜ MTX, 
described above The effect on cytotoxicity and cell 
cycle distribution (Figs 1 and 2 and Table 2) were 
described in Results 
The inhibition of thjmidylate synthetase is almost 
complete, leading to a rapid decrease of dTTP levels 
(Fig 3b) The complete inhibition of purine de novo 
synthesis [3] is reflected in a rapid decrease of ATP 
and GTP levels (Fig 5b) ADP and GDP reductions 
are impaired due to decreased levels of their acti­
vators, GTP, dTTP and ATP [27,29], leading to 
decreased levels of dATP and dGTP (Fig 4b) 
Because of the initial arrest of cells in Gl phase and 
a decrease of their activators, the activation of all 
ribonucleotides is nullified, leading also to decreased 
levels of dCTP (Fig 3b) Moreover, the decreased 
dTTP levels may result in a "de-inhibition" of dCMP-
deaminase [7,28,29], leading to increased avail­
ability of dUMP and a decrease of dCTP The rapid 
decrease of all deoxynbonucleotides at 8 hr ulti­
mately prevents cell cycle progression through all 
parts of the cell cycle (Figs 2b and 2c) 
As mentioned before, the initial decrease of purine 
ribonucleotides between 0 and 8 hr after incubation 
with 0 2 μΜ MTX is a consequence of the complete 
inhibition of purine de novo synthesis Nevertheless, 
these effects also suggest a decreasing, but still ongo­
ing RNA synthesis [10,11] between 0 and 8 hr with 
consumption of ATP and GTP, ι e classical unbal­
anced growth The initial increases of UMP (Fig 7b) 
and UTP and CTP (Fig 6b) may be the result of 
an increased pyrimidine de novo synthesis due to 
increased availability of PRPP They also reflect an 
increasing inhibition of RNA synthesis [11] 
Between 8 and 12 hr after incubation with 0.2 μΜ 
ΜΓΧ, the decrease of ATP and GTP levels ceases, 
suggesting a complete inhibition of RNA synthesis 
This phenomenon also occurred at that point of time, 
where the inhibition of purine de novo synthesis is 
maximal, as was shown before m cells treated with 
0 02 μΜ MTX at 28 hr The initial increase of UTP 
and CTP levels ceases between 8 and 12 hr, and 
UMP levels do not increase to such an extent as 
shown in cells treated with 0 02 μΜ MTX, which 
indicates that pyrimidine de novo synthesis will be 
diminished 
After 12 hr of incubation with 0 2 μΜ MTX a 
significant rise of all ribonucleotides is shown (Figs 
5b and 6b) and the increase of UMP levels continues 
These effects are л consequence of nucleic acid 
breakdown together with a reutilization of nucleotide 
precursors [10,11] Our data from labeled glycine 
incorporation [3] indicated that the inhibition of 
purine de novo synthesis continues over a penod of 
at least 48 hr after treatment with 0 2 μΜ MTX 
Thus, the consumption of PRPP, due to reutilization 
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of nucleotide precursors will ultimately result in a 
decrease of PRPP levels, as was shown earlier [3] 
These events occur at an earlier point of time as 
compared with MOLT-4 cells treated with 0 02 μΜ 
MTX Moreover, these data suggest a complete inhi­
bition of R N A synthesis and balanced growth after 
12 hr of incubation with 0 2 μΜ M T X We could not 
demonstrate a (partial) recovery or stabilization of 
R N A synthesis, as was shown in our M O L T - 4 cells 
treated with 0 02 μΜ M T X and was demonstrated 
also by others [10, 11], using concentrations of M T X 
up to 1 and 2 μΜ in other cell l ines 
Our data suggest a prominent role of the inhibition 
of purine de novo synthesis with regard to cyto­
toxicity in M O L T - 4 cells having an active purine de 
novo synthesis Borsa and Whitmore [6] stated that 
the punneless state tended to prevent efficient cell 
killing Our study and those of others [ 9 - 1 1 ] , 
however, demonstrated a close correlation between 
the onset of cytotoxicity and maximal inhibition of 
purine de novo synthesis, associated with an inhi­
bition of R N A synthesis (balanced growth) 
The role of the inhibition of punne de novo syn­
thesis is also demonstrated in the effects of M T X 
on growth-arrested cells [11] and on normal bone 
marrow cells and peripheral, non-stimulated blood 
lymphocytes, which do not have an active purine de 
novo synthesis [4] Incubation of peripheral blood 
lymphocytes with 0 02 μΜ and 0 2μΜ M T X did not 
result in a rise of P R P P levels over a t ime period of 
48 hr (Bokkermk, unpublished data), nor could we 
demonstrate cytotoxicity In addition, normal bone 
marrow cells, treated with M T X [16] did not dem­
onstrate significant changes in deoxynbonucleot ide 
pools Thus, both the antithymidylate and the anti-
purme effects of M I X probably contribute to an 
efficient cytotoxicity in MOLT-4 cells T h e s e pheno­
mena are dose- and time-dependent 
The effects of various concentrations of M T X on 
purine and pyrimidine nucleotides and on R N A and 
D N A svnthesis are of great importance in order 
to elucidate the potential synergistic effects of a 
sequential combination chemotherapy with M T X 
and 6 M P W e demonstrated a close correlation 
between the maximal inhibition of purine de novo 
synthesis and the maximal intracellular uptake of 
e x o g e n o u s labeled hypoxanthine and 6 M P [3] In 
order to explain the potential synergistic effects after 
sequential administration of M T X and 6MP, an 
increased uptake of 6 M P into R N A [12] is necessary 
after pretreatment with MTX, which requires an 
ongoing R N A synthesis However, the phenomena 
presented in this study demonstrated that the inhi­
bition of purine de novo synthesis and the increased 
intracellular uptake of hypoxanthine and 6 M P was 
associated with a decreased R N A synthesis These 
phenomena might be explained by a partial rescue 
of R N A synthesis due to the administration of 
exogenous hypoxanthine or 6 M P 
Therefore, studies are in progress in our laboratory 
with respect to the incorporation of 6 M P , after pre-
treatment with M T X into newly formed D N A and 
R N A . by means of double-labeling techniques with 
N C - 6 M P and , : P 
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4.1. ABSTRACT 
Methotrexate (MTX) causes an inhibition of purine de novo 
synthesis (PONS), resulting in increased intracellular availa­
bility o-f 5-phosphoribosyl-l-pyrophosphate (PRPP) in human 
malignant lymphoblasts with an active PONS. Normal bone marrow 
cells and peripheral blood lymphocytes lack this capacity. The 
increased levels o-f PRPP can be used for an enhanced incorpora­
tion of 6-mercaptopurine (6MP), indicating a potential time-, 
sequence- and dose—dependent synergism of both drugs. The 
effects of 0.02 μ» and 0.2 μΜ MTX on the PONS of MOLT-4 (T-), 
RAJ I (B-) and KM-3 (non-B-non-T-) human malignant lymphoblasts 
were studied with respect to PRPP levels,' aminoimidazolecai— 
boxami de ribonucleoside monophosphate (AICAR) levels and the 
incorporation of labeled glycine into purine metabolites. These 
results were correlated with the activity of the PONS (labeled 
glycine incorporation) and the purine salvage pathway (labeled 
hypoxanthine incorporation) in untreated cells. Inhibition of 
PONS by 0.02 μΜ MTX was complete in KM-3 cells with a 
moderately active PONS and salvage pathway. RAJ I cells, with a 
relatively low PONS and high salvage pathway, demonstrated an 
incomplete, but increasing inhibition of PONS, whereas 
inhibition of PONS in MOLT-4 cells with both pathways active 
was minimal and recovered in time. Treatment with 0.2 μΜ MTX 
resulted in a complete inhibition of PONS in all cell lines. 
After treatment with MTX an enhanced incorporation of labeled 
hypoxanthine and 6MP was noticed, confirming the potential 
rescue from MTX cytotoxicity by hypoxanthine and a potential 
synergism of MTX and 6MP on cytotoxicity. The enhanced incorpo­
ration of 6MP was more obvious in RAJ I and KM—3 cells in compa­
rison with MOLT-4 cells. These data demonstrate the important 
role of both the activities of the PONS and the purine salvage 
pathway in malignant lymphoblasts with respect to the synergism 
of MTX and 6MP and indicate that B— and поп—В—non-T-lympho— 
blasts are more vulnerable for combination treatment with MTX 
and 6MP than T-lymphoblasts. 
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4.2. INTRODUCTION 
During the last years much attention has been paid to key 
enzymes in the purine salvage pathway and interconversion in B-
and T-lymphocytes and leukemic lymphoblasts. Congenital defi-
ciencies of adenosine deaminase (ADA, E.C. 3.5.4.6.), purine 
nucleoside Phosphorylase (PNP, E.C. 2.4.2.1.) and 5'nucleoti— 
dase (5*NT, E.C. 3.1.3.5.) are associated with severe distur-
bances in lymphocyte—mediated immune function. These and other 
key enzymes play an important role in lymphoid cell differen-
tiation CI,23. The differences in purine enzyme activities in 
malignant lymphoblasts can be used as diagnostic biochemical 
markers in immunologically different subclasses of acute lym-
phoblastic leukemia (ALL) C3-7]. Moreover, they may serve as 
specific targets for chemotherapy with specific inhibitors: for 
example, high activities of ADA m T—ALL can be inhibited by 2' 
deoxycoformycin, leading to cell kill C8,9i. Otherwise, altera-
tions in enzyme activities may result in resistance to certain 
chemotherapeutic agents: for example hypoxanthine—guanine 
phosphonbosyl transferase (HGPRT, E.C. 2.4.2.8.) deficiency due 
to somatic mutations is associated with resistance to 6-mercap-
topunne (6MP) , 6-thioguanine (6TG) and azathioprine [10,113. 
Methotrexate (MTX) and ¿MP have been utilized for many 
years in the oral maintenance therapy of ALL [121. The increa-
sed therapeutic efficacy of the combination of these drugs was 
based on empirical data from studies in mice [13] and in pa-
tients [143. However, on the basis of their interactions with 
the purine de novo synthesis (PONS) and the purine salvage 
pathway, a synergism of both drugs could be expected. 
Me demonstrated a sequence-, time-, and dose-dependent 
synergism of MTX and 6MP in MOLT-4 human malignant T-lympho-
blasts [153. We studied the effects of MTX on the PDNS of 
MOLT-4 cells, with special reference to intracellular 5-phos-
phoribosyl-1-pyrophosphate (PRPP) and aminoimidazolecarboxamide 
nbonucleoside monophosphate (AICAR) levels and the incorpora-
tion of labeled glycine. The increased availability of PRPP 
after pretreatment with MTX could be used for an enhanced 
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intracellular conversion of 6MP. The time at which the 
inhibition of PONS and the incorporation of 6MP were maximal, 
depended on the concentration of MTX. The concentrations of 
MTX, used in these studies (0.02 μ» and 0.2 μΜ), can be 
maintained in vivo for many hours in the oral maintenance 
therapy of ALL in children [16-1Θ1. 
Although the role of the purine salvage pathway in various 
subclasses of ALL has been well established as mentioned above, 
scarce data have been published with respect to the role of the 
PONS in these cells and in normal lymphocytes and bone marrow 
cells С191. In the present study, we compare the time— and 
dose-dependent e-ffects o-f MTX on the PONS and on the intracel­
lular incorporation of labeled hypoxanthine (Hx) and its 
analogue 6MP in the three human malignant lymphoblastic cell 
lines: MOLT-4 (T-cells), RAJI (B-cells), and KM-3 (common ALL, 
поп—В—non—Τ—celIs). 
4.3. MATERIALS AND METHODS 
Materials: 
MTX (Emtrexate PF) was purchased from Pharmachemie (Haarlem, 
The Netherlands); Ccarboxyl-14C] orotic acid (51.1 mCl/mmol) 
from New England Nuclear (Boston, MA); CD- 1 4CD glycine (110 
mCl/mmol), CB- I 4C1 hypoxanthine (55 mCi/mmol) and C8- 1 4C1 
6—mercaptopurine (1.7 mCl/mmol) from Amersham International LtD 
(Amersham, U.K.); PRPP from Sigma (St. Louis, MO); a pre­
paration from brewer's yeast containing orotate phosphoribosyl— 
transferase (OPRT, E.C. 2.4.2.10) and orotidyl ate decarboxylase 
(0DC, E.C. 4.1.1.23) from Boehringer Mannheim (Mannheim, 
F.R.G.). The cell lines MOLT-4 and RAJI have been maintained in 
continuous culture in our laboratory for several years. KM-3 
cells were supplied by the Department of Hematology, St.Radboud 
Hospital, University of Nijmegen (head prof. Dr. C. Haanen). 
The absence of mycoplasma contamination, the Ε-rosette forming 
capacity and the presence of antigens on the cells in culture 
were tested regularly. The latter by means of monoclonal anti­
bodies [203. 
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Cell culturem. 
All cell cultures were allowed to grow at 37° in a water-
saturated atmosphere containing 2.57. C 0 2 in RPMI medium 1640 
Dutch Modi-f ι cation (DM), supplemented with 1071 nondialyzed 
•fetal cal-f serum (v/v) , penicillin (100,000 U/l ) , streptomycine 
(100,000 pq/l), and sodium pyruvate (2 mM) in plastic culture 
-flasks. Logarithmically growing cells were resuspended in -fresh 
medium in a concentration o-f 0.3 χ IO 6 cells/ml 24 hr before 
each experiment. During the experiments glutami ne was added 
every 24 hr to a final concentration of approximately 2 mM in 
order to avoid glutamine exhaustion of the medium С153. 
MTX, diluted in medium, was added as a single dose in a small 
volume (1/100 fraction) in a final concentration of 0.02 μη and 
0.2 μΜ, respectively, and remained in the culture for the 
duration of the experiment. An appropriate volume of medium was 
added to untreated cells. 
The number of viable cells (trypan blue exclusion) was counted 
at each point of time in duplicate in a Bürker-Türk chamber. 
PRPP assay and incorporation of CU-14C3 glycine. 
The PRPP assay was based on the production of C0 2 from a 
Ccarboxyl— C3 orotic acid precursor, as described previously 
by us [153. The incorporation of CU— 14C3 glycine into purine 
metabolites can be used as a parameter of the activity of PONS. 
The assay, described earlier [213. was modified by us [153. 
Incorporation of CB-14C3 hypoxanthine and [8-14C3 6-mercapto-
purlns. 
At various intervals, cells were incubated with labeled Hx 
in a final concentration of 100 μΜ during 20 m m at 37°. The 
amount of intracellular incorporated Hx was assayed as 
described previously by us [153. The incorporation of labeled 
Hx in untreated cells can be used as a parameter of the 
activity of the purine salvage pathway. 
Similar experiments were performed at various intervals with 
[8-14C3 Hx in a final concentration of 10 pM and with [8- 1 4C3 
6MP in final concentrations of 100 μΜ and 10 μΜ, respectively. 
The amount of incorporated purine bases was expressed as nmol/ 
10 6 viable cells/20 m m . 
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AICAR assay 
Determinations of AICAR Mere performed by HPLC essentially 
according to De Abreu et al. [223 and the levels were expressed 
as pmol/106 viable cells. 
4.4. RESULTS 
Effects of MTX on PRPP levels. 
Before performing the extensive experiments in the three 
cell lines, to be described below, we measured PRPP levels in 
each cell line separately at relatively short periods of time 
after addition of 0.02 μΜ and 0.2 μη MTX, respectively. In our 
further experiments, we measured at 0, 24, and 48 hr after 
addition of MTX and at some points close to the peak level of 
PRPP. 
PRPP 
II10LT-4 ΜηΚΙΙ 
ки-з 
Ϊ 
2\ 
MTX 0 . 0 2 μΠ 
В 
MTX 0 . 2 /ld J 
T 
16 48 hr 
Fig. 1. Effect« of (ITI on ìntracellulir PRPP levil i in HDLT-4, RAJ I, md КИ-3 « H i . 
(Al 0.02 /iti НТК, (В) 0.2 μ* NT». Mean of 3 expenients in duplicate. Expressed as 
niol/10' viable cells. PRPP levels in untreated cells: nQLT-4: 0.100; Raji: 0.150; 
and КИ-3: 0.0Θ0. 
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Figure IA shows the effects on intracellular PRPP levels in the 
three cell lines after incubation with 0.02 pH MTX. PRPP levels 
increased to a maximum after 20-28 hr of incubation in MOLT-4 
cells (15-fold increase). The maximum in RAJI cells was reached 
after 12 hr (6-fold increase). In KM-3 cells a maximum increase 
of 10-fold was noticed after 16 hr. After 48 hr PRPP levels re­
turned to those of untreated cells in the case of MOLT-4 cells, 
whereas both in RAJI and KM-3 cells a 5-fold increase 
persisted. Incubation with 0.2 μΜ MTX (Fig. IB) resulted in a 
16-fold maximum increase of PRPP levels after 8 hr in MOLT-4 
cells, in a 17-fold increase after 6 hr in RAJI cells and in a 
14-fold rise after 6 hr in KM-3 cells. At 48 hr PRPP levels in 
RAJI and KM-3 cells remained increased, whereas those in MOLT-4 
cells returned to the levels of untreated cells. 
Effects of MTX on AICAR levels end CU-l4Ci glycine 
i ncorporati on. 
After incubation of MOLT-4 cells with 0.02 /iM MTX a 
relatively rapid increase of AICAR was observed with a maximum 
at 28 hr; after that time levels decreased (Fig. 2). AICAR 
levels in RAJI and KM-3 cells slowly increased until 24 hr of 
incubation and then remained constant. 
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Fig. 2. Effects of 0.02 μ* H U on intracellulir AICAR level* 
in nOLT-4, RAJI, and КП-З cells. Expressed as 
piol/10' viable cells. See further legend to Fiq. 1. 
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-•-MOLT-4 
+ RAJI 
-¡f-KH-3 
1 — 
HTX 0 . 0 2 μΠ A 
— ι 1 
Tibiι 1. Activity of purine de novo tynthtiii in lyiphoblists 
of different lineages eiposed to ПТІ. 
HOLT-4 RAJI КП-3 
HT! ΙμΜ 
At 24 hr: 
0 214 */- 38 (100! 13» •/- 58 (!00) 183 +/- 28 (100! 
0.02 189 *l- 100 168Ì 4( •/- 21 (29) 2.1 +/- 2.1 II) 
0.2 0 (0) l.B •/- 2.« (1) 0 10) 
At 48 hr: 
0 231 +/- 137 (100) 52 •'- 29 (100) 
0.02 219 +/- 71 (94) 10 -.'- 8 (19) 
0.2 0 (0) -
(expressed as piol incorporated [U-I4C] qlvcine/hr.'lO' viable cells; 
•ean */- SD of at least 4 expernents. - : not done. Nuibers betNeen 
parentheses: percentages of treated/untreated cells) 
The data on glycine incorporation into purine metabolites 
(Table 1) after 24 hr of incubation with 0.02 /JM MTX indicated 
a slight, but not significant inhibition of PONS in MOLT-4 
cells, which recovered after 4Θ hr. Glycine incorporation into 
purine metabolites in RAJI cells after treatment with 0.02 μΜ 
MTX revealed an incomplete, but in time increasing inhibition 
of PONS, whereas KM-3 cells demonstrated a complete inhibition 
of PONS. It should be noticed that the incorporation of glycine 
in untreated RAJI cells after 4B hr is lower than after 24 hr. 
This may be caused by a depletion of an essential cofactor for 
PONS in these cells С23J. 
Incubations with 0.2 μΜ MTX did not show any increase of 
AICAR in comparison with untreated cells in all cell lines. 
With this concentration of MTX almost no glycine incorporation 
into purine metabolites occurred (Table 1). Both findings 
indicated a complete inhibition of PDN5 by 0.2 μΜ MTX. 
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Hypoxanthine incorporation 
• HOLT-4 Q R A J I ^ К Н - З 
O Β 16 24 48 Ο θ 16 24 48 hr 
Fig. 3. EHicti ai ПТІ on Intricillulir Incorpontien of t8-"C] hypoxtnthini 
in I10LT-4, RAJI, and КН-З cells. Expressed as neol/lO' viable cells / 20 u n . 
'ft) 0.02 μΝ НТК, 100 jiH hvpoíanthine; (В) 0.2 рИ ИТХ, 100 /iN hypoxanthine; 
(CI 0.02рИПТХ, 10 |ΐΝ hypoxanthine; (D) 0.2 μη Ψϊ, 10 jiH hypoxanthine. 
Incorporation of 100 /id hypoxanthine in untreated cells (A): NOLT-4 1.600, 
RAJ! 1.500, КИ-З 0.620. Incorporation of 10 ^ N hypoxanthine in untreated cells 
(Cl: H0LT-4 0.900, RAJI 0.900, М-* 0.3B0. See further legend to Fig. 1. 
Effects of MTX on intracellular incorporation of С - > 4C3 hypo­
xanthine and C8- t 4C] 6-marcaptopurin·. 
Figures ЗА and 3B represent the incorporation for 20 min 
of 100 μΜ Hx after various periods of incubation with 0.02 μΜ 
and 0.2 μΜ MTX, respectively. Figures 3C and 3D represent the 
same data of incorporation with ΙΟ μΜ Hx. The time- and 
dose-dependent effects were parallel to the intracellular PRPP 
levels (Fig. 1). 
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6-Mercaptopurine incorporation 
HOLT-4 ^ R A J I 
Fig. 4. Effects of ΝΠ on intracellulir incorporation of [8- CI 6-urcaptopurine 
in nOLT-4, mi and КС-З cells. Expressed as ι\·ο1/Ι0' viable cells/20 «in 
'ЙІ 0.02 μη НТК. 10' jiN oNF; IB) 0.2 μΛ ИП. 100 ^Г ¿HP; 'О 0.02 μη HU, 
10 рГ 6flP; (D) 0 . : / J N NTX, 10 μΆ Ml?. Incorporation of 100 jiH ¿HP in 
untreated cells (A): I10LT-4 0.600, RAJI О.І00, к.И-3 0.400. Incorporation 
of 10 μη 6ПР in untreated ceils iCi: KOLT-I 0.260, RAJI 0.160. kH-3 0.110. 
See further legend to FIQ. 1. 
The results of incorporation for 20 min with CB- C3 6MP 
in a concentration of lOO μη or 10 μΜ after various periods of 
incubation with MTX are depicted in Figs. 4A-4D. Again, the 
time- and dose-dependent effects were comparable to Figs. 1 and 
3. Thus, the time— and dose— dependent increased availability 
of PRPP a-fter incubation with MTX can be used for enhanced 
intracellular anabolism by HGPRT into nucleotides С153 of Hx 
and its analogue, 6MP. 
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4.S. DISCUSSION 
MTX and feMP are the most applied drugs in the maintenance 
treatment o-f non-B-non-T- and T-^LL in children 123. Both 
antimetabolites inhibit purine de novo synthesis: 6M* inhibits 
a rate limiting step in PONS: PRPP amidotrans-ferase (E.C. 
2.4.2.14.), and MTX inhibits both formy1 transferases in PONS: 
glycinamide ribonucleotide (GAR) formyltransferase (E.C. 2.1.2. 
2.) and AICAR formyltransferase (E.C. 2.1.2.3.). The role of 
PONS in the mitogenic response of lymphocytes and in thymocyte 
differentiation has been mentioned in the literature C24-2B1, 
and both MTX and 6MP suppress mitogenic responses. Variations 
in PRPP synthetase (E.C. 2.7.6.11.), in PRPP amidotransferase 
activity and in overall PONS activity and availability of PRPP 
have been reported between normal and stimulated lymphocytes, 
bone marrow cells, and leukemic cells C25,26,29-341. However, 
few data concerning the activity of PONS in different 
subclasses of lymphocytes and malignant lymphoblasts have been 
reported. We previously demonstrated the importance of an 
inhibited PONS with regard to the cytotoxicity of MTX in MOLT-4 
malignant T-lymphoblasts C35]. Moreover, we found an enhanced 
intracellular uptake of 6MP, when 6MP was added to MOLT-4 cells 
at the moment of maximal inhibition of PONS by MTX, indicating 
a potential synergism of the combination of both agents CIS]. 
Differences between three subclasses of malignant lymphoblasts 
(T-, B- and common ALL-cells) concerning these phenomena are 
presented in this paper. 
The different activities of PONS in untreated lympho-
blasts, measured by the incorporation of radiolabeled glycine 
into purine metabolites (Table 1), did not correlate with the 
actual PRPP levels in untreated cells (Fig. 1). The basal 
levels of PRPP depend on the activity of PRPP synthetase, the 
activity of the PONS and the purine salvage pathway. The 
incorporation of labeled Hx in untreated cells (see legend to 
Fig. 3) can be used as a measure of the activity of the purine 
salvage pathway [361. Our data suggest differences in the 
activity of the purine salvage pathway of the three cell lines. 
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Tibie 2. Suuiry o< relativ« ictnit\es of PONS and purine salvage pathiiay 
in lyiphoblastt of different lineages 
nOLT-4 
RAJI 
MI-: 
PONS 
++ 
•/-
* 
'a' •age pathxav 
t+ 
++ 
+ 
++ : high, t : iiLd»rate, -/ . rather Ion act itv. 
A summary of the activities o-f the PONS and the purine salvage 
pathway is presented in Table 2. The characteristics o-f RAJI 
cells are in concordance with those of B-lymphocytes t373, 
expressing a relatively high activity of PRPP synthetase, a low 
activity of PONS and a high activity of the purine salvage 
pathway in comparison to T-lymphocytes. The characteristics of 
the three cell lines lead to their differences with respect to 
the incorporation of 6MP (see further) and the levels of 
ribonucleotides C36D after treatment with MTX. 
Figs. 1A and 2 and Table 1 demonstrate the events in PONS 
due to treatment with 0.02 μΜ MTX. MOLT-4 cells with an active 
PONS and salvage pathway show the highest increase (15-fold) of 
PRPP levels at 20-28 hr after incubation with 0.02 μη MTX. The 
increase of AICAR levels and the small decrease of glycine 
incorporation indicate an incomplete inhibition of PONS in 
MOLT-4 cells. 
Although we did not measure the activities of dihydro-
folate reductase (DHFR, E.G. 1.5.1.3.) and the formation of MTX 
polyglutamates, our data suggest that 0.02 μη MTX is a critical 
concentration with regard to its inhibition of DHFR in MOLT-4 
cells. The results in MOLT-4 cells are comparable with those 
found in the T-cell line, CCRF-CEM С393, which demonstrated an 
inhibition of DHFR after 16 hr. Inhibition of DHFR is known to 
occur when intracellular MTX levels are in excess of the tight­
ly bound fraction to DHFR, resulting in intracellular "free" 
exchangeable MTX C40,413. However, our data suggest that 0.02 
μΜ MTX in MOLT-4 cells did not result in a complete saturation 
of the enzyme. The decreased tetrahydrofolate cofactors in 
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MOLT-4 cells, as a consequence of incomplete inhibition of 
DHFR, are unable to cause sufficient inhibition of PONS. The 
significant increase of AICAR levels in MOLT-4 cells suggests 
differences in the Km values of 10—formyltetrahydrofolate for 
the two formyltransferases in PONS, resulting in a partial 
inhibition of GAR formyltransferase and a more pronounced 
inhibition of AICAR formyltransferase. The decrease of AICAR 
levels in MOLT-4 cells at 48 hr suggests a recovery of 
10-formyltetrahydrofolate pools, which may be the result of 
overproduction of DHFR (see below). This decrease was 
associated with a partial recovery of PONS (Table 1) and a slow 
progression of cells through the cell cycle at 48 hr and a 
complete recovery of clonal growth at 72 hr [351. These data 
also suggest that the intracellular "free" concentration of MTX 
in MOLT-4 cells treated with 0.02 pM MTX was unable to produce 
a significant amount of MTX polyglutamates C42,433. This was 
supported by the small decrease and subsequent recovery of dTTP 
levels [351. 
These phenomena differ from those in RAJ I cells with a 
relatively low PONS and an active salvage pathway and from KM—3 
cells with a moderately active PONS and salvage pathway (Table 
2). Incubation with 0.02 μΜ MTX resulted in a significant 
inhibition of PONS in RAJ I cells (Table 1), associated with a 
6-fold increase in PRPP levels at an earlier point of time (12 
hr) compared to MOLT-4 cells (Fig. 1A). These effects remained 
for 48 hr. In KM-3 cells the inhibition of PONS was complete. 
This was associated with a 10-fold increase of PRPP levels at 
16 hr, followed by a slow decrease at 48 hr (Fig. 1A). 
Figure 2 demonstrates a slow initial increase of AICAR levels 
after incubation with 0.02 μΜ MTX in RAJI and KM-3 cells until 
24 hr, which then remained constant. This seems in contrast 
with the inhibition of PONS in these cells, shown in Table 1. 
However, these findings suggest that this critical concen­
tration of MTX results in an excess of intracellular "free" MTX 
levels, far above the Ki value of MTX for DHFR in order to 
produce polyglutamates. MTX polyglutamates are more potent and 
direct inhibitors of AICAR formyltransferase, demonstrated by 
their 2,500 fold greater affinity for the enzyme as compared to 
the weak inhibitory effects of MTX [44,451. The inhibitory 
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e-f-fects o-f MTX pol yg 1 ut amates on SAR -f ormyl transferase, while 
greater than those o-f MTX, are less impressive [453. Thus, the 
net result will be a partial inhibition of GAR formyltransfe­
rase by reduced levels of lO-formyltetrahydrofolate and a much 
more pronounced and direct inhibition o-f AICAR f ormyl transfe­
rase by MTX polyglutamates. The formation of polyglutamates in 
RAJI and KM-3 cells treated with 0.02 uM MTX, in contrast to 
MOLT-4 cells, is also re-flect-ed in the severe depletion of dTTP 
levels t3B]. 
These phenomena suggest differences in the Ki's of MTX for DHFR 
or in the cellular amount of the enzyme between MOLT-4, RAJI, 
and KM-3 cells. Differences in Ki"s and in cellular content of 
DHFR between various cells have been reported C46-4BD. An 
increase in DHFR activity after treatment with MTX due to gene 
amplification or an alteration in the structure of the enzyme 
may even result in resistance C49-593 
The results of incubation with 0.2 jiM MTX with respect to 
the PONS of MOLT-4, RAJI and KM-3 cells were almost identical: 
glycine incorporation was completely inhibited in all cell 
lines and AICAR levels were not detectable, indicating a 
complete inhibition of PNDS. PRPP levels (Fig. IB) raised to 
the same extent (14-17 fold) after similar periods of time. 
However, the maximal increase of PRPP levels in all cell lines 
occurred earlier than in cells treated with 0.02 μη MTX. These 
data suggest a complete inhibition of DHFR, a total depletion 
of 10-formyltetrahydrofolate, and an important formation of 
polyglutamates in our cell lines with 0.2 μΜ MTX, comparable to 
that in CCRF-CEM cells C60D and superior to that reported in 
other cells C40-42,61,623. 
After 48 hr of incubation with 0.2 ¿iM MTX, PRPP levels in 
MOLT-4 cells returned to those of untreated cells, whereas PRPP 
levels in RAJI and KM-3 cells decreased less and remained 
elevated 5-fold and 4-fold, respectively. Table 1 indicates 
that this cannot be attributed to a relief of the inhibition of 
PDNS, as was the case in MOLT-4 cells treated with 0.02 JJM MTX. 
The decrease of PRPP levels in our cell lines after 48 hr of 
treatment with 0.2 μΜ MTX is in agreement with the decrease 
found in L1210 cells which have a shorter cell-doubling time 
C633. In L1210 cells no increase of PRPP synthetase activity 
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was demonstrated during this period in contrast to human fibro­
blasts [641. The decrease of PRPP synthesis in L1210 cells was 
attributed to a decreased aval labili tv of the co-substrates ATP 
and ribose-5-phosphate C23,27,65-673. However, we could 
demonstrate unchanged or even increased levels of ATP 48 hr 
after treatment with MTX [35,3811. Therefore, the lowering or 
PRPP levels after 48 hr have to be attributed to differences in 
cytotoxic sensitivity between MOL Γ-4 cells and RAJI and KM-3 
cells, associated with nucleic acid breakdown and reuti1ization 
of purine and pynmidine precursors, consuming PRPP as a 
cofactor [68-72D. 
The increased availability of PRPP due to inhibition of 
PONS after treatment with MTX can be used for an enhanced in­
corporation of hypoxanthine (Fig. 3). The amount of incorpora­
ted hypoxanthine at each point of time and within each cell 
line is directly correlated with the PRPP levels. These time-
and dose-dependent effects indicate that administration of 
natural purine and pynmidine bases are able to rescue a 
prolonged puri nel ess and thymidylatei ess state after treatment 
with MTX [3·?, 63, 65, 69-VOJ. 
It should be emphasized, that the in vitro situation in 
our investigations may be different from the in vivo situation. 
We could demonstrate a decrease of the initial concentration of 
Hx in the culture medium from 3-5 μΜ to O.1-0.2 μΜ after 24 and 
48 hr due to consumption by growing cells via the salvage 
pathway, irrespective of the presence of MTX. Although the 
presence of 5 μΜ Hx in the medium was insufficient to modulate 
MTX toxicity of CCRF-CEM cells [883, concentrations of 3-5 μΜ 
Hx were able to inhibit PONS in other cells [36,67,91]. However 
concentrations of 0.1-0.2 μΜ were unable to do so. These data 
could imply that the activities of PONS in our untreated cells 
(Table 1) would be even higher in a purine-free medium. The 
influence of decreased or normal Hx levels on the activity of 
PONS and the synergistic effect of MTX and purine or pynmi­
dine analogues was subject of many studies [63,64,86,91-94]. 
Most cells rely on HBPRT for synthesis of nucleotides in the 
presence of Hx [64,68,95] because of a much lower Km of PRPP 
for HGPRT than for PRPP amidotransferase [95]. Hx exhaustion of 
the medium in our experiments could therefore attribute to an 
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increased inhibition o-f PDNS, a more pronounced puri nel ess 
state and increased cell kill. However, MTX treatment of nor-
mal peripheral lymphocytes with a low PNDS activity [25-27,31, 
331 did not result in elevated PRPP levels or cytotoxicity -for 
a time period of 48 hr (Bökkerink, unpublished data). Moreover, 
the Hx exhaustion of the medium did not prevent MOLT-4 cells, 
treated with 0.02 μΜ MTX, from recovery of PDNS activity at 4Θ 
hr, followed by recovery of cell growth. Thus, the Hx exhaus­
tion in our studies is of minor importance with respect to the 
effects of MTX. Our data indicate, that in malignant lympho-
blasts both the salvage pathway as well as the PDNS are 
important for cell growth and that both activities are 
determinants for MTX cytotoxicity. 
The higher peak levels of Hx incorporation in MOLT-4 cells 
in comparison to KM—3 cells are in agreement with earlier 
studies of Hx protection for MTX cytotoxicity in comparable 
cell lines CB6]. However, the total amount of incorporated Hx 
should not be considered to reflect the punneless state of 
these cells, because the activity of PDNS and purine salvage 
pathway and its inhibition by MTX differ between these cell 
lines. This is stressed by the fact that the decrease of PRPP 
levels in MOLT-4 cells after 48 hr of incubation with 0.2 μΜ 
MTX, due to reuti1ization of nucleotide precursors and leading 
to increased levels of ATP and 6TP [35,383, prevent 
incorporation of exogenous Hx. The absence of Hx incorporation 
is therefore not a consequence of decreased PRPP synthesis, as 
mentioned by others [633. 
Figure 4 demonstrates that the increased availability of 
PRPP can also be used for an enhanced incorporation of the Hx 
analogue, 6MP. Similar time- and dose-dependent effects were 
obtained as in the case of PRPP and Hx (Figs. 1 and 3 ) . The 
absolute amount of 6MP incorporated in untreated cells is 
approximately 2-5 times lower than the amount of Hx 
incorporated. This can be explained by the fact that 6MP can 
only be incorporated into nucleic acids as thioguanine (deoxy)-
ribonucleotides, whereas Hx is incorporated into nucleic acids 
in the form of both adenine and guanine (deoxy)ribonucleotides 
[25,963. The absolute amount of incorporation of Hx and ¿MP in 
untreated MOLT-4 and RAJI cells with an active purine salvage 
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Tibie 3. Cotparison of incorporation increase ratio for 10 /iH 6-iercaptopurine 
ifld 10/iH hypounthini i f t i r t r i i tun t «ith 0.02 ¡Л ИТІ. 
Tue (hr) i a 12 l i 20 24 2B К 
hOLT-4 cells 
6-aercaptopurine 1.3 2.9 2.9 3.2 2.9 1.0 
tiypoxanthine 1.3 2.1 2.7 2.7 3.1 1.0 
RAJ1 cells 
¿-lercaptopurine 2.В 4.0 4.0 3.3 
Iwpoxanthine 2.2 2.2 2.2 2.0 
KH-3 c e l l s 
i-iercaptopunne 10.9 12.9 10.9 3.3 
hypoxanthine 3.5 4.2 3.4 2.1 
(expressed as incorporation of 6NP or Hx in liTK-treated / untreated cells. 
As an exaiple the incorporation increase for 10 pN 6ПР and Hx is shtun after 
treatient nith 0.02 /id І Ш (on the basis of data in Fiqs. 3C and 4CI. 
pathway is higher as compared to KM-3 cells. However, the time 
period of increased incorporation in MOLT-4 cells with an 
active PONS is shorter: after 48 hr of incubation with MTX the 
incorporation of Hx and 6MP in MOLT-4 cells almost returned to 
levels of untreated cells, whereas it was still increased in 
RAJI and KM-3 cells. 
It is a conspicuous phenomenon that the factor of increa­
sed incorporation (ratio of incorporation in treated cells / 
untreated cells) for 6MP in RAJI and KM-3 cells at each point 
of time is higher than the factor of increased incorporation 
for Hx. This is not the case in MOLT-4 cells. MOLT-4 cells also 
demonstrate a shorter time period of increased 6MP and Hx 
incorporation. An example of such calculated ratios for Hx and 
6MP incorporation is shown in Table 3. These data indicate that 
¿»MP is more actively incorporated than Hx in RAJI and KM-3 
cells in the presence of increased PRPP levels. Both RAJI and 
KM-3 cells showed a lower activity of PONS and a more complete 
inhibition of PONS by MTX in comparison to MOLT-4 cells. This 
may suggest that the inhibition of PRPP amidotransferase by 
methylthio—IMP, a metabolite of 6MP, is more effective in RAJI 
and KM-3 cells. The increased inhibition of PONS by the combi-
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nation of MTX and 6MP results in a further increase of PRPP 
levels, which can be used for an increase of 6MP incorporation 
(self-enhancement). With respect to Hx this self—enhancement is 
absent, which explains the lower factors for Hx in Table 3. 
Our data suggest that RAJI and KM-3 cells are more vulnerable 
for combination treatment of MTX and 6MP than MOLT-4 cells, 
notwithstanding the commonly higher peak levels of PRPP in 
MOLT-4 cells after treatment with MTX. Our cytotoxicity studies 
(soft agar colony forming activity), using various combinations 
of MTX and 6MP in MOLT-4 and RAJI cells (manuscript in 
preparation), are in agreement with these metabolic findings. 
The results of these in vitro investigations have to be 
translated to the in vivo situation. Because both Hx and 6MP 
are competitive substrates for HGPRT, the plasma concentrations 
of 6MP in vivo should be equivalent or higher than the plasma 
concentrations of Hx, especially in bone marrow. We found high 
Hx values in bone marrow in patients after cessation of mainte-
nance therapy for leukemia: 6.7 +/- 5.0 JJM (N = 92), whereas 
the ratio bone marrow Hx/piasma Hx was 9.2 (N = IB, range 2.4 -
46). These are in concordance with bone marrow Hx concentra-
tions found by others C83,97,98]. In order to obtain equivalent 
6MP concentrations in bone marrow in vivo, intravenous or high 
dose oral 6MP administration will be necessary C99]. Therefore, 
further studies in children with T-ALL, B-ALL and CALL are 
necessary in order to define the optimal sequence, dose, and 
route of administration of MTX and 6MP for a maximum benefit 
from the synergism of both drugs. 
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5.1. ABSTRACT 
MOLT-4 (T-), RAJI (B-), and KM-3 (non-B-non-T-, common 
ALL) malignant lymphoblasts demonstrated significant differen­
ces in their activities of purine de novo synthesis (PDNS) and 
purine salvage pathway and in their cell-kinetic parameters. 
Incubations with concentrations of methotrexate (0.02 and 0.2 
μΜ), which can be maintained during many hours in the oral 
maintenance therapy of acute lymphoblastic leukemia, indicated 
large differences between the three cell lines with respect to 
the inhibition of PDNS, depending on the concentration of 
methotrexate (MTX) and on the activities of the two pathways. 
These dose- and cell line—dependent differences corresponded to 
the perturbations of eel 1—kinetics and purine and pyrimidine 
(deoxy)ribonucleotide pools in the three cell lines. 
Exposure of MOLT-4 cells to 0.02 μΜ MTX resulted in an 
incomplete inhibition of DNA synthesis in early S phase, as 
shown by DNA-flow cytometry and increase of dCTP levels, which 
recovered spontaneously after 48 hr. Almost no impairment of 
RNA synthesis occurred (unbalanced growth). In RAJI cells, 
exposed to 0.02 μΜ MTX, DNA synthesis was delayed in the S 
phase, not arrested, and RNA synthesis was not impaired, also 
indicating an unbalanced growth pattern, which, however, did 
not recover in time. KM—3 cells were arrested in Gl phase and 
subsequently in early S phase after incubation with O.02 μΜ 
MTX, and perturbations of ribonucleotides indicated a complete 
inhibition of RNA synthesis, resulting in a balanced growth 
pattern. Cytotoxicity was more pronounced in KM-3 cells. 
The reliability of the soft agar colony forming assay after low 
dose MTX treatment is discussed. Differences in polyglutamation 
of MTX between the cell lines could be attributed to differen­
ces in the inhibition of thymidylate synthetase and PDNS. 
Exposure of MOLT-4 and KM-3 cells to 0.2 μΜ MTX resulted 
in a complete inhibition of DNA synthesis, with cessation of 
cell progression through all parts of the cell cycle and arrest 
in Gl phase. RAJI cells showed an increasing accumulation of 
cells in Gl phase without complete cessation of cell cycle 
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progression. Perturbations af ribonucleotide pools suggested an 
inhibition of RNA synthesis in all cell lines, indicating a 
balanced growth pattern in KM-3 cells and MOLT-4 cells. 
Increased levels of ribonucleotides after prolonged exposure to 
0.2 μη MTX were due to reut 11ization of purine and pyrimidine 
precursors from nucleic acid breakdown consuming PRPP, whereas 
consumption of ribonucleotides for RNA synthesis was absent. 
The perturbations of deoxynbonucleotide pools after exposure 
to 0.02 and 0.2 μΜ MTX were in agreement with the changes in 
DNA-flow cytometry. Increased levels of dCTP after exposure to 
0.02 μΜ MTX correlated with accumulation of cells in early S 
phase. A conspicuous phenomenon was the absence of decrease in 
dGTP pools in RAJI cells, in which cytotoxicity was low. 
Cytotoxicity was correlated with the degree of PONS inhibition 
and the decrease in both dGTP and dTTP pools. 
The differences between the T-, B-, and non-B-non-T-, 
common ALL cell lines with respect to the parameters studied 
may explain the different réponses to treatment of patients 
with corresponding lymphoid leukemias and lymphomas and suggest 
possibilities for different treatment strategies. 
S.2. INTRODUCTION 
Methotrexate (MTX) is a well established chemotherapeutic 
agent in the treatment of all immunological subclasses of acute 
lymphoblastic leukemia (ALL) and non-Hodgkin's malignant lym-
phoma in childhood Cl-33. It is used in high dose intravenous 
chemotherapy and prophylactic central nervous system treatment 
C43- The combination of MTX and 6-mercaptopurine (6MP) is 
widely used in the oral maintenance therapy of non-B ALL and 
non-Hodgkin's lymphoma [1—31. 
In a previous study [53, we demonstrated a synergistic action 
of the combination of MTX and 6MP in the three human malignant 
lymphoblastic cell lines MOLT-4 (T-lineage), RAJI (B-lineage), 
and KM-3 (non-B—поп-T-, common ALL cells). The sequence—, 
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dose-, time-dependent synergism was based on the inhibition of 
purine de novo synthesis (PONS) after treatment with MTX, 
resulting in increased availability of 5-phosphoribosyl—1-pyro-
phosphate (PRPP). The increased availability of PRPP could be 
used for an enhanced conversion of 6MP by hypoxanthine—guanine 
phosphoribosyltransferase (H6PRT). We demonstrated differences 
with respect to this synergism between MOLT—4 cells and RAJI 
and KM-3 cells, due to differences in the activities of the 
PONS and the purine salvage pathway in these cells. In 
addition, this selective synergism in malignant lymphoblasts 
will not be observed in normal bone marrow cells and peripheral 
blood lymphocytes with a low activity of PONS C6-103. 
Many studies til—26] described the effects of MTX on cyto-
toxicity, cell-kinetic parameters and purine and pyrimidine 
deoxyribonucleotide pools in bone marrow, stimulated peripheral 
blood lymphocytes and various malignant cell lines. However, 
according to our knowledge, correlations between these effects 
of MTX and differences in inhibition of purine de novo 
synthesis and ribonucleotide pools between various malignant 
lymphoblasts are scarcely available. This especially holds for 
concentrations of MTX which can be maintained in vivo for many 
hours during oral maintenance therapy of ALL in children Z271. 
In the present study we have compared the sequential time-
dependent effects of 0.02 uM and ^.'Z JJM MTX on purine and pyri-
midine nucleotide pools in MGLT-4, RAJI and KM-3 cells. These 
effects were correlated with the effects of MTX on cytotoxicity 
(trypan blue exclusion and soft agar colony forming activity) 
and cell cycle phase distribution, as determined by DNA-flow 
cytometry. The differences found in these three cell types and 
the significance of an inhibited PDN5 with respect to the 
effects of MTX on (deoxy)ribonucleotide levels are discussed. 
5.3. MATERIALS AND METHODS 
MTX (Emtrexate PF) was purchased from Pharmachemie (Haarlem, 
The Netherlands); the cell lines MOLT-4 and RAJI have been 
maintained in continuous culture in our laboratory for several 
72 
years. KM-3 cells were supplied by the Department of Hemato-
logy, St. Radboud Hospital, University o-f Nijmegen (head prof. 
Dr. C. Haanen). The corresponding cell doubling times are 20 hr 
for MOLT-4 cells, 20 hr for RAJ I cells and 16 hr for KM-3 
cells. 
The conditions for cell culture, soft agar colony forming acti-
vity and DNA-flow cytometry were identical to those described 
by us earlier C28,29i. Colony forming activity was expressed as 
percentage of the plating efficiency of untreated cells. 
Plating efficiency of untreated cells was (mean +/- SD, in %): 
MOLT-4: 7.0 +/- 3.8 (N=16); RAJIs 35.8 +/- 8.9 (N=15); KM-3: 
19.6 +/- 6.6 (N=10). 
The assay of purine and pyrimidine nucleotide pools was 
described earlier by us C29]. The results are expressed as 
percentages of untreated cells, harvested at the same time of 
incubation. Initial levels (pmol/lO* viable cells) of (deoxy)-
ribonucleotides in untreated cells are shown in table 1. 
Tibli 1. Initial I »vel s o< puni» ind pyrin dint nucleoside triphosphttti 
in huun iilignjnt lyiphobluts of different hmgei. 
ATP GIF UTP CTP 
!<0LT-4 tN=ti) 1222 •/- 92 282 +/- 31 449 +/- 51 141 "- 2! 
FAJI IM=7i 1175 +.'- 225 2è4 •/- 48 359 +/- 9? 129 •/- 2B 
КП-3 (N=71 968 tí- 72 27b +/- 73 :03 +/- 24 115 t/- 13 
dATP íBTt· dTTP dCTP 
H O L M iN=(i) 23 t/- 4 12 t/- 2 17 t/- 3 7 •/- 1 
RAJI (N=7i В +/- 1 3 t/- j.5 9 t/- 1 7 t/- 1 
КП-З 'N=7) 18 t/- 5 24 •/- 12 24 +/- 7 10 •/- 3 
Mean f - 5D, erpressed JS peol/lO* viable cells. N = nuiber of expernents. 
»OLΤ 4: T-cells; PAJ¡: B-cells: КИ-З: non-B-non-T, coieon ALL cells. 
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5.4. RESULTS 
E-f-fectB o-f MTX on cell growth and viability, soft agar colony 
-forming activity and cell cycle phase distribution. 
The assays described bel ом were performed at 0, 24, and 4B 
hr after addition of MTX and at some points which proved to be 
important with regard to the time— and dose—dependent 
inhibitory effects of MTX on PONS C5D. Therefore, these time 
intervals are not identical in the three cell lines and differ 
between the concentrations of MTX used (0.02 μΜ and 0.2 μΜ). 
The effects of treatment with MTX on cell growth, cell 
viability (determined by trypan blue exclusion) and on colony 
forming activity are presented in Figures In and IB and in 
Table 2, respectively. After incubation with 0.02 μη MTX cell 
growth is retarded and even levels off after 20 hr in MOLT—4 
cells. Arrest of growth is seen earlier in RAJ I and KM-3 cells, 
but RAJI cells continue to grow, albeit very slowly. The KM—3 
cells show a decline in their growth curve. As far as cell 
viability is concerned (Fig. IB), a more significant loss of 
viability is observed in MOLT-4 cells after 4B hr than in RAJI 
and KM-3 cells. 
In MOLT-4 cells clonal growth capacity is impaired in the 
presence of 0.02 JJM MTX (Table 2). However, a significantly 
increased clonal growth is observed after 72 hr. The explana­
tion for this phenomenon is found in the data from the DNA-flow 
cytometric studies (Fig. 1С). After incubation with 0.02 μΜ MTX 
MOLT-4 cells accumulate in Gl phase and subsequently in early S 
phase, which can be demonstrated by the continuing broadening 
of the descending slope of the first histogram peak during the 
first 2Θ hr. After 48 hr a second peak in the S phase of MOLT-4 
cells is obvious, indicating a progression of a synchronized 
cohort of cells through the cell cycle. 
RAJI cells show a delayed progression from Gl phase into 
subsequently early, mid and late S phase (Fig. 1С), demonstra­
ted by the straithening of the descending slope of the Gl-S 
peak. These data suggest that a considerable number of RAJI 
cells continue to progress through the cell cycle. This may ex— 
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C e l I g r o w t h 
Fig. 1. Efficti of П П on cill kinetic pirueten in mLT-4, KAJI tnd KIH celli. 
iA Effects on cell oroxth. Counts are expressed as nuibers of v.able eel s onh 
(t'vpar blue eiclusion). The dots represent the sean of at least 3 nlividual 
experiments in duplicate. O t untreated cells; •, 0.'2^11 NTH; % , 0.2 /iN 
ITU. 
(B) Ef-ects of T X on cell viabilitv. expressed as oercertaqes of viab e glus 
поп-чаЫе cells. See further lenend to Fig. IA. 
•С
1
- С Effects of ,^ Τϊ on chafes i» DNA distribution. 'C' 0.02 μη m-, D 0.2 μη 
f1"!. The histocrais are representative e!a«ples of 3 indi.idual esperiiients. 
Г
к
е ^eights of tie Gl peals «ere norîali:ed ir th» graphs. (El Oosputer 
calculations of the percentages of cells in '31, S and 62 f H phas» after 
eïoosj'e to C.2 ^П ИТІ dean с* Г ечремаеп^ in dupl cate!. 
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Tabic 2. Effects of NT I on the colony foning ictivity of huían « h grunt 
lyiptiobUsts of different hneiges. 
Dirahoi of 0.02 jJI »T« 0.2 μη НТК 
ncjbat'on ^ ' — ^ ~ ^ ~ " ' " * " — - ^ ^ " ^ " ^ " ^ 
ihr1 HILT-I RAJ] Л-З NOLM RftJl И-3 
0 
& 
12 
16 
24 
Ч 
34 
4J 
45 
54 
(.0 
64 
7? 
1J0Ï 
-
-
-
i:oi 
-
-
-
44ϊ 
-
-
-
13ΒΪ 
ιΟΟΙ 
-
123Ϊ 
-
-
-
105Z 
-
-
-
571 
-
-
1J0Ï 
-
-
9ог 
-
-
-
4.37. 
-
-
-
l.U 
-
MOI 
-
&7Z 
-
-
-
2.3Ï 
-
-
-
0.05Z 
-
-
lOvï 
901 
-
-
-
231 
-
-
-
4.71! 
-
-
-
мог 
951 
-
-
-
12! 
-
-
-
0.4'. 
-
-
-
Colonv foriinq activity is defined as the percentage of plating efficiency 
of treated cells / platina efficiency of untreated cells. -. not done. 
p l a i n t h e s m a l l d e c r e a s e of c l o n a l growth i n RAJI c e l l s t r e a t e d 
w i t h 0 . 0 2 pM MTX ( T a b l e 2 ) . 
KM-3 c e l l s a r e a r r e s t e d and s y n c h r o n i z e d i n Gl p h a s e and 
s u b s e q u e n t l y i n e a r l y S p h a s e w i t h o u t f u r t h e r p r o g r e s s i o n 
t h r o u g h t h e c e l l c y c l e , c o n f i r m i n g t h e most pronounced i n h i b i ­
t i o n of c l o n a l growth w i t h 0 . 0 2 μΜ MTX. I t s h o u l d be n o t e d t h a t 
e x a c t computer c a l c u l a t i o n s of DNA d i s t r i b u t i o n i n c e l l s t r e a ­
t e d w i t h 0 . 0 2 jiM MTX were n o t f e a s i b l e b e c a u s e of t h e i n d i s ­
t i n c t s e p a r a t i o n of t h e Gl and S p e a k s and t h e marked e f f e c t s 
on t h e s e c e l l c y c l e p h a s e s . 
I n c u b a t i o n w i t h 0 . 2 JJM MTX p r o d u c e s a c o m p l e t e and imme­
d i a t e i n h i b i t i o n of c e l l growth in a l l c e l l l i n e s ( F i g . I n ) , 
a s s o c i a t e d w i t h an i n c r e a s i n g c y t o t o x i c i t y and l o s s of c e l l 
v i a b i l i t y , which i s most pronounced i n MOLT-4 c e l l s ( F i g . I B ) . 
T h i s i s c o n f i r m e d by t h e s h a r p d e c r e a s e of c l o n a l growth ( T a b l e 
2 ) of MOLT-4 c e l l s t r e a t e d w i t h 0 . 2 μΜ MTX (2 .3X of c o n t r o l 
a f t e r 36 h r ) . Aga in, RAJI c e l l s a r e i n h i b i t e d l e s s . T h i s i s 
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also demonstrated by the DNft-flow cytometry results (Figs. ID 
and IE), which show an increasing and continuing accumulation 
of RAJI cells in Gl phase and a continuing decrease of cells in 
S and G2 + M phase. These data suggest that a small number of 
RAJI cells is still able to progress through the cell cycle 
after 4B hr. 
In MOLT-4 and KM-3 cells a rapid initial accumulation and 
arrest in Gl phase is observed, associated with a rapid 
decrease in S phase in KM-3 cells and in G2 + M phase in both 
<Figs. ID and E ) . These events are followed within 8 hr by a 
complete cessation of cell progression through all parts of the 
cell cycle in both cell lines, because the percentages of cells 
in Gl and S phases remain unchanged and cells in G2 -·- M phase 
are undetectable. These phenomena are more pronounced in KM-3 
cells. DNA distribution data in KM-3 cells at 24 hr show that 
B2.4·/. of the cells are in 61, 17.67. in S, and 07. in 62 + M. 
Corresponding values for MDLT-4 cells are Gl: 67.77.; S: 32. ЗХ; 
G2 + M: 0'/.. The cytotoxic sensitivity, shown by the extensive 
decrease of cell viability and clonal growth, is more obvious 
in MOLT—4 cells than in KM-3 cells. This may be explained by 
the differences in the histograms. The decrease of viability in 
MOLT-4 cells at 48 hr, shown by the first peak of cell debris 
in the histogram, preceding the Gl peak, did not allow us to 
make exact calculations of DNA distribution at that point of 
time (Fig. IE). 
Effects of MTX on purine and pyrimidine nucleotide pools. 
Deoxyr1bonuc1eo»id· tri phosphate*. 
Effects of incubation with MTX on the inhibition of 
thymidylate synthetase (TS) is shown in Fig. 2. After incuba­
tion during up to 16 hr with 0.02 μΜ MTX a decrease of dTTP 
levels is apparent in all cell types (Fig. 2A). dTTP levels in 
MOLT-4 cells recover after that period of time, whereas the 
levels in RAJI and KM-3 cells remain depressed, most pronounced 
in RAJI cells. Incubation with 0.2 jiM MTX (Fig. 2B) causes 
depletion of dTTP levels in all cell lines, again the· most pro­
nounced decline is seen in RAJI cells. 
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The initial decrease of dATP (Fig. 3ft) and dGTP (Fig. 4A) 
levels between О and 16 hr in MOLT-4 cells treated with 0.02 μΜ 
MTX, due to an incomplete inhibition of DNA synthesis and ai— 
rest in Gl phase [251, is followed by an increase of dATP, dGTP 
and dTTP and, especially, a more significant increase of dCTP 
levels at 28 hr (Fig. 5A). This finding is in agreement with an 
accumulation and synchronization of cells in early S phase as 
shown in Fig. 1С, and with results described by others 
C12,14,17,22,24,25,30-323. Between 2Θ and 48 hr dATP, dGTP and 
dTTP levels return to the values of untreated cells and dCTP 
levels decrease, which is associated with a recovery of DNA 
synthesis and a progression of a cohort of cells through the 
cell cycle (Fig. 1С) and recovery of clonal growth afterwards 
(Table 2). 
The decrease of dTTP levels in KM—3 cells treated with 
0.02 μΜ MTX (Fig. 2A) is associated with an initial decrease of 
dATP and dGTP, whereas dCTP levels are unchanged (Figs. 3A-5A). 
These events are in agreement with the initial arrest of KM—3 
cells in Gl phase (Fig. 1С). However, after 16-24 hr deoxynbo— 
nucleotide pools, except for dTTP, show an increase. The pro-
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nounced increase o-F dCTP levels con-firms a more obvious arrest 
and synchronization in early S phase (Fig. 1С), shown by the 
broadening o-f the descending slope o-f the Gl-S peak o-f the his­
togram. The increase o-f dCTP levels in KM-3 cells occurs at a 
later point o-f time than in MOLT-4 cells, indicating a more 
delayed progression o-f KM-3 cells through SI and early S phase. 
This is in line with the significant and increasing inhibition 
oí clonal growth in KM-3 cells by 0.02 μΜ MTX in Table 2. 
The changes in deoxynbonucleotide pools in RAJI cells 
treated with 0.02 μΜ MTX di-ffer in many aspects -from those in 
MOLT-4 and KM-3 cells. dTTP levels <Fig. 2A) are severely 
depleted, however dCTP levels (Fig. 5A) are almost unchanged. 
dATP levels (Fig. ЗА) decrease to a minimum o-f 67% at 12 hr, 
-fallowed by increasing values. However, dGTP levels show a 
continuous increase (Fig. 4A). These events are associated with 
a delayed, but substantial progression through the cell cycle 
shown in Fig. 1С and confirm the minor inhibition of cell 
growth and clonal growth in RAJI cells treated with 0.02 μΜ 
MTX. 
80 
The e-f-fects o-f incubation with 0.2 μη MTX on deoxvribonu-
cleotide pools are presented in Figs. 2B-5B. The decrease o-f 
dTTP, dATP and dGTP levels is almost similar in MGLT-4 cells 
and KM-3 cells, although KM-3 cells are more a-ffected. These 
events are associated with an initial increase and synchroniza­
tion o-f cells in Gl phase -followed by a complete cessation of 
cell progression through the cell cycle (Figs. ID and IE), 
which is again more pronounced in KM-3 cells. The increasing 
severe inhibitions of clonal growth in MOLT-4 and KM-3 cells 
treated with 0.2 μΜ MTX (Table 2) are in agreement with these 
phenomena. At 4Θ hr an increase of deoxyribonucleotide pools, 
except for dTTP, is noticed which may be due to reuti1ization 
of purine and pynmide nucleotide precursors, without restora­
tion of DNA synthesis. 
The relatively small initial decrease of dATP (Fig. 3B), 
dSTP (Fig. 4B), and dCTP (Fig. 5B) in RAJI cells after treat­
ment with 0.2 μ» MTX is in accordance with the increasing accu­
mulation of cells in 61 phase and a decrease of cells in S and 
G2 + M phase. However, a small proportion of cells is still 
able to progress slowly through the cell cycle, as demonstrated 
by the data of DNA distribution (Fig. ID) at 48 hr (Gl: 74.9'/.; 
S: 24.7V.; G2 + M: 0.47.) and the incomplete inhibition of clonal 
growth (Table 2 ) . The relatively unchanged dGTP pools in RAJI 
cells after treatment with 0.2 μη MTX are a conspicuous pheno­
menon, especially because dGTP pools in untreated RAJI cells 
are very low with regard to MOLT-4 and KM-3 cells (Table 1). 
Ribonucleoside triphospates. 
The changes in ribonucleoside triphosphate pools and UMP 
after treatment with MTX are demonstrated in Figs. 6—IO. Levels 
of ribonucleoside mono— and diphosphate pools were assayed 
simultaneously, but the data are not shown here because of the 
less significant differences, except for UMP. ATP and GTP 
levels in all cell lines treated with 0.02 μη MTX (Figs. 6A and 
7A) show an initial decrease during the first 16 hr, indicating 
a partial inhibition of purine de novo synthesis together with 
consumption of ribonucleotides for RNA synthesis [5,16,23]. 
This is associated with an increase of UTP, CTP and UMP levels 
(Figs. BA-10A) due to increasing availability of PRPP resulting 
in increased pyrimidine de novo synthesis and due to a 
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decreased consumption for RNA synthesis C5,16,233. After 16 hr 
a significant increase of all ribonucleotide levels is 
observed, especially in MOLT-4 and KM-3 cells. This suggests a 
cessation of consumption for RNA synthesis due to maximal 
inhibition of RNA synthesis. 
At 4Θ hr pyrimidine ribonucleotide pools in MOLT-4 cells 
treated with 0.02 μΜ MTX decrease (Figs. BA-lOA). This may be 
due to a decrease of PRPP levels by restoration o-f PONS C53 or 
recovery of RNA synthesis with consumption of ribonucleotides. 
However, the decrease of purine ribonucleotides (Figs. 6A and 
7A) indicate that the latter is the case in MOLT-4 cells, as 
was also shown in the T-cell line CCRF-CEM treated with O.02 μΜ 
MTX C2U. 
In KM-3 cells all ribonucleotide pools increase further at 48 
hr, indicating an ongoing inhibition of RNA synthesis. The 
effects of 0.02 μΜ MTX on ribonucleotide synthesis and RNA 
synthesis are most pronounced in KM-3 cells. These cells also 
displayed the most pronounced inhibition of purine de novo 
synthesis C53. In RAJI cells the changes in ribonucleotide 
B4 
pools are less and UMP levels (Fig. 10A) only increase 
moderately, suggesting almost no impairment o-f RNA synthesis. 
Treatment with 0.2 μη MTX induces a initial depletion of 
purine ribonucleotides (Figs. 6B and 7B) in all cell lines due 
to complete inhibition o-f purine de novo synthesis t53 and 
ronsumption for a still ongoing, but decreasing RNA synthesis 
£23]. The initial increase in pyrimidine nbonucleoside 
triphosphate pools (Figs. 8B and 9B) with maxima at 6 hr for 
RAJI and ИМ-З cells and at θ hr for MOLT-4 cells is' exactly 
correlated with the maximal levels of PRPP L5]. Thereafter, all 
nbonucleoside triphosphate pools decrease, leading to a com­
plete inhibition of RNA synthesis at 12 hr in MOLT—4 cells, and 
at 24 hr in RAJI and KM-3 cells. The increase of nbonucleoside 
triphosphates at 48 hr is a consequence of reuti11zation of 
purine and pyrimidine precursors С16,23,33-35] from increased 
cell lili and nucleic acid breakdown. This is most obvious in 
MOLT-4 cells, in which cytotoxicity is most pronounced (Figs. 
1A and lb and Table 2). However, the increased levels of 
nbonucleoside triphosphates are not consumed for RNA synthesis 
and do not result in a restoration of RNA synthesis as was 
shown in MaLT-4 cells treated with 0.02 /iM MTX. 
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5.5. DISCUSSION 
Untreated MOLT-4 (T-), RAJ I (B-) and KM-3 (non-B-non-T, 
common ALL) cells demonstrate important differences with regard 
to their purine and pyrimidine metabolism and cell—Iinetic 
parameters. Our time—dependent measurements after exposure to 
MTX also clearly demonstrate differences between the cell lines 
with respect to the effects of MTX on this metabolism and the 
cell-kinetic parameters. These differences were most obvious in 
incubation experiments with the critical concentration 0.02 jiM 
MTX. They can be attributed to the characteristics of the cell 
lines and their connection with the biochemical basis for MTX 
toxicity C36-41]. The following aspects will be discussed with 
respect to the effects of MTX investigated in our studies: a) 
cell growth and cell cycle kinetics, b) polyglutamation of MTX, 
с) activities of purine de novo synthesis and purine salvage 
pathway in the cell lines and the role of a purineless state, 
and d) relevant perturbations in deoxyribonucleotide pools. 
Although the cell doubling times of the three cell lines 
were almost similar, our DNA-flow cytometric studies demonstra­
ted that the percentages of cells in S phase and Б2 + M phase 
were high in untreated RAJI cells, indicating a longer duration 
of these cell cycle phases in RAJI cells than in MOLT-4 and 
KM-3 cells (Table 3). The long duration of these cell cycle 
phases in RAJI cells is reflected in the relatively low pools 
of deoxyribonucleotides in comparison to the pools of MOLT-4 
and KM-3 cells (Table 1). The levels of dGTP pools in RAJI 
cells are especially low, as was also the case in other B-cel1 
lines C42]. These data may suggest that the rate of deoxyribo­
nucleotide consumption in DNA synthesis in RAJI cells is rela­
tively high compared with the rate of deoxyribonucleotide sup­
ply by the S phase-specific enzymes thymidylate synthetase (TS) 
and ribonucleotide reductase СЗО-32,39,40,43,44]. However, the 
significant perturbations in deoxyribonucleotide pools do not 
indicate that the activities of both enzymes are low in RAJI 
cells. Thus,the low cytotoxicity in RAJI lymphoblasts (Table 2) 
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Table 3. Distribution of cells in various cell cycle phases, 
as detenmed bv DNA-Нои cytoietry. 
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might be correlated with an increased length o-f the actively 
DNft-synthetizing cell cycle phases. 
This seems to be in contrast to the observations that the S 
phase o-f the cell cycle is the target o-f MTX [45-52]. However, 
Hill C53] demonstrated that treatment with the anti folate 
metoprine did not delay the progression o-f synchronized late S 
phase cells through the cell cycle, indicating that only early 
and mid S phase cells are sensitive to MTX. 
The cell doubling time o-f MOLT-4 cells was twice as long 
as those oí L5178Y cells and L1210 cells, which will account 
for less MTX toxicity in MOLT-4 cells than in L1210 and in 
L517BY cells, as discussed above. However, comparison of 
cytotoxic effects of MTX in L1210 and L5178Y cells [14,26,34, 
543 and the cytotoxic effects of 0.02 μΜ MTX in MOLT-4 cells 
suggests that the differences in cytotoxic effects of MTX are 
also due to differences in polyglutamation of MTX after prolon­
ged incubation with MTX. 
The role of polyglutamation of MTX with respect to the 
inhibition of PONS was discussed in a previous study by us [53. 
The increase in clonal growth activity after 72 hr in MOLT-4 
cells exposed to 0.02 μΜ MTX (Table 2), the reversal of the 
partial inhibition of PONS [53 and the recovery of dTTP levels 
in MOLT-4 cells in the presence of 0.02 μΜ MTX (Fig. 2A), 
suggest that this concentration of MTX is unable to result in a 
complete saturation of the dihydrofolate reductase (DHFR) 
Θ7 
binding sites and in "free" intracellular MTX in order to -form 
MTX polyglutamates C553. Although MOLT-4 cells had identical 
amounts of DHFR in comparison to L1210 and L5178Y cells [56], 
the differences in polyglutamati on in these cell lines may also 
be dependent on other factors, as was reviewed by Goldman C36]. 
The levels of dTTP pools after exposure to 0.02 uM MTX 
(Fig. 2A) also suggest differences in polyglutamation between 
MOLT-4 cells, RAJI cells and KM-3 cells. The increasing 
depletion of dTTP levels in RAJI and KM-3 cells indicate an in 
time increasing inhibition of TS by increasing levels of MTX 
polyglutamates, which are more potent and direct inhibitors of 
TS С41,57,58]. Our data in Table 2 confirm the contribution of 
increasing amounts of MTX polyglutamates, especially in KM-3 
cells. However, these data also demonstrate the limitations of 
the soft agar colony assay in predicting MTX—toxicity. As shown 
in Table 2, colony forming activity of MOLT-4 and RAJI cells, 
incubated with 0.02 μΗ MTX, was higher than Í007. at a conside-
rable number of time-points, whereas other assays indicate an 
inhibition. This has to be attributed to efflux of "free", non-
polyglutamated MTX during the wash-procedure, before the cells 
are allowed to grow in fresh agar medium C41,59-643. Moreover, 
the addition of fresh agar medium may also supply the cells 
with purine and pyrimidine precursors, which are able to rescue 
the toxic effects of MTX (see below) and which may influence 
the results of the assay. These phenomena are absent when MTX 
is converted to polyglutamates because polyglutamates are 
preferentially retained by cells and will not be washed out 
during the soft agar procedure C41,62-64]. The latter is the 
case in KM-3 cells at all time-points and in RAJI cells after 
60 hr of incubation and partially explains the differences in 
cytotoxicity, measured by clonal growth activity, between KM-3 
cells and MOLT-4 and RAJI cells after treatment with 0.02 μΜ 
MTX. However, the results of the colony forming assay with 
respect to cells treated with 0.2 μΜ MTX can be regarded as 
"real", since at this concentration of MTX polyglutamates are 
produced in all cell lines, demonstrated by a significant 
decrease of dTTP levels (Fig. 2B), and a complete inhibition of 
PONS, as measured by labeled glycine incorporation [5]. 
The "false-positive" results of the clonal growth assay in 
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MOLT-4 cells are also disclosed in our DNA-flow cytometric 
results a-fter treatment with 0.02^iM MTX (Fig. 1С). In these 
studies almost similar perturbations in DNA distribution in 
MOLT-4 and KM-3 cells are shown, which is in contrast to the 
data in Table 2. The differences between MOLT-4 and KM-3 cells 
in Fig. 1С become obvious a-fter 48 hr of exposure to 0.02 μΜ 
MTX, where the absence of polyglutamates in MOLT-4 cells allows 
the cells to progress through the cell cycle, whereas the 
inhibition of DNA synthesis in early S phase is progressive in 
KM-3 cells. 
We demonstrated the prominent role of the activity of the 
PDNS and the purine salvage pathway, especially with respect to 
cytotoxicity of 0.02 μΜ MTX. Cytotoxicity (Table 2) was rather 
limited in RAJ I cells with a relatively low PDNS and a high 
salvage activity. This could be attributed to a partial inhibi­
tion of PDNS, whereas the purine salvage pathway was also able 
to supply the cells with essential purine and pyrimidine pre­
cursors, for example from RNA turnover. The partial inhibition 
of PDNS in RAJI cells in the presence of 0.02 μη MTX did not 
impair ATP and GTP pools (Figs. 6A and 7A). In MOLT-4 cells, 
with both pathways active, cytotoxicity was the least, since 
the inhibition of PDNS was almost absent, and the cells also 
could rely on the activity of the purine salvage pathway for 
their supply. However, KM-3 cells with both pathways moderately 
active, demonstrated the highest cytotoxicity of 0.02 uM MTX. 
The punneless state of KM—3 cells was a consequence of the 
severe inhibition of PDNS and the inability of the rather low 
purine salvage pathway to supply the cells with purines. The 
pools of ATP and GTP in Figs. 6A and 7A confirmed the punne­
less state in KM-3 cells. These data indicate, that low concen­
trations of MTX can introduce a punneless state in cells which 
rely partially on the salvage pathway for their purine supply, 
but also on their moderately active PDNS. However, when the 
activity of the salvage pathway is high (RAJI cells), a punne­
less state is prevented. 
The low activity of PDNS in bone marrow cells and 
lymphocytes, which escape from MTX toxicity by their active 
salvage pathway, again elucidates the selective toxicity of MTX 
for malignant cells. This escape is also favoured by the fact 
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that normal cells, like bone marrow and small intestinal cells, 
have a low capacity -for glutamation o-f MTX C41,64-661. When MTX 
exposure is prolonged, or when MTX doses are extremely high, 
non-polyglutamated MTX can be toxic -for rapidly growing normal 
cells due to a prolonged thymidyl^teless state. However, this 
of-fers selective protective capacities for normal cells, when 
thymidine and a purine are administered early after MTX [67D. 
The role of a purineless state with regard to the toxic 
effects of MTX has been the object of intensive study in the 
literature. Many authors based their conclusions on studies 
showing the reversal of MTX cytotoxicity by addition of purine 
bases alone, thymidine alone or a combination of a purine plus 
thymidine C33,35,51,54,68-761. Controversial results were 
obtained with these "reversal" studies between different cell 
lines, different investigators and even within one study. For 
example. Borsa demonstrated that addition of adenosine and 
deoxyadenosine enhanced the cytotoxicity of MTX, measured after 
72 hr exposure [511, but partially reversed the cytotoxicity of 
MTX, when measured after 48 hr exposure [683. The controversial 
conclusions with regard to the role of the purineless state 
have to be attributed to the fact that MTX toxicity, in the 
presence of a purine precursor in the medium, cannot be equali­
zed with the measurement of the thymidylatei ess state, or 
inversely that MTX toxicity in the presence of thymidine in the 
medium cannot be equalized with the measurement of the purine­
less state. Moreover, measurement of MTX toxicity by incorpora­
tion studies with labeled purine and pyrimidine precursors 
(thymidine, uridine, deoxyundine, deoxycytidine) into DNA or 
RNA are also inappropriate, because the addition of these pre­
cursors may change the biochemical disturbances of MTX on both 
the purine and the pyrimidine pathways or because incubation of 
MTX may alter the activity of enzymes involved in the conver— 
Sion of these precursors С36,37,73,771. 
Our data indicate that direct measurements of all 
nucleotide pools, the activity of PONS and cell—kinetic 
studies, especially DNA-flow cytometry, are necessary in order 
to understand the cytotoxic effects of MTX. This is stressed by 
the perturbations of the dTTP pools in our cell lines. Although 
MTX caused a severe depletion of dTTP levels in RAJI cells 
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(Fig. 2A-B), our cell-kinetic studies showed a partial inhibi­
tion o-f cell growth with both concentrations o-f MTX (Table 2). 
Moreover, progression through the cell cycle (Fig. IC-Ε) was 
not arrested, but only delayed. Thus, these results -failed to 
demonstrate the main role o-f the inhibition o-f TS with respect 
to MTX toxicity, as has been proposed by others C33,513. The 
failure to inhibit DNA synthesis completely in RAJI cells has 
to be correlated with the increased levels o-f dGTP (Fig. 4). 
The depletion o-f dTTP levels and the antipunne e-f-fects o-f MTX 
would suggest a decrease of dGTP levels, because both are 
activators o-f ribonucleotide reductase for GDP C30,31D. Most 
studies demonstrated decreased levels of dGTP after incubation 
with MTX C12-15,17,18,20,22,24-263 except for three cell lines 
with long cell doubling times and low TS activity [14,223. Our 
data do not suggest a low TS activity in untreated RAJI cells. 
Thus, the levels of dGTP under these conditions suggest an 
increased GDP reductase activity after treatment with MTX 
[43,443, or that GDP reduction exceeds dGTP consumption for DNA 
synthesis. 
In contrast, both dTTP and dGTP pools are severely depleted in 
KM-3 cells with both concentrations of MTX, and in MOLT-4 cells 
after 0.2 μΜ MTX. These incubations also showed the most severe 
impairment of cell growth and DNA—distribution. These phenomena 
confirm the findings of Taylor et al [25,263, that MTX toxicity 
is correlated with low levels of both dGTP and dTTP. These 
authors also demonstrated that the failure of reversal of high 
dose MTX toxicity by hypoxanthine alone or the combination of 
hypoxanthine plus thymidine was associated with toxicity due to 
extremely high levels of dATP in conjunction with low levels of 
dGTP and dTTP. The authors stressed the importance of a balan­
ced growth pattern (inhibition of both DNA synthesis and RNA 
synthesis) for MTX cytotoxicity. Our data indicate that a 
balanced growth pattern is obtained when both DNA synthesis as 
well PONS are completely inhibited. This is observed in KM-3 
cells exposed to 0.02 jiM MTX and in MOLT-4 and KM-3 cells, 
exposed to 0.2 μΜ MTX. MOLT-4 cells, incubated with 0.02 μΜ MTX 
demonstrated an "classical" unbalanced growth pattern [783: 
partial inhibition of DNA synthesis in early Ξ phase and less 
inhibition of PONS and RNA synthesis, which recovered sponta— 
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neously. Treatment o-f RAJI cells with 0.02 jjM MTX also resulted 
in "classical" unbalanced growth: delayed progression o-f cells 
through the cell cycle, a partial inhibition o-f PONS and almost 
no impairment o-f RNA synthesis, whereas treatment with 0.2 jiM 
MTX in RAJI cells completely inhibited PONS and RNA synthesis, 
but allowed some progression o-f cells through the cell cycle. 
The differences between M0LT-4, RAJI and KM-3 cells may 
have consequences for further studies in patients with T-, B-
and non-B-non-T-, common—ALL. Our data suggest that maintenance 
therapy with low dose MTX (0.02 jjM) can be effective in KM-3 
cells, since these cells are able to form polyglutamates, which 
was denied by others C3BD. However, low dose MTX therapy does 
not result in sufficient cytotoxicity in MOLT-4 and RAJI cells. 
High dose MTX therapy, is able to result in severe cytotoxicity 
in all cell lines; however, RAJI cells may recover. These data 
can be transferred to the in vivo situation: Treatment of 
common ALL with maintenance therapy, including low dose MTX and 
6-mercaptopurine, has proved to result in superior survival as 
compared to T-cel1 ALL. The current therapy of B-cel1 lymphoma 
and B-cell ALL [31 with short intensive courses including 
high-dose MTX at short intervals without maintenance therapy 
has dramatically improved survival in these patients. 
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6.1. ABSTRACT 
6—Mercaptopurine (6MP) is an important antimetabolite in 
the maintenance treatment of acute lymphoblastic leukemia. How­
ever, data on the biochemical pharmacology and cytotoxicity of 
this drug in human malignant lymphobiasts are scanty available. 
We studied the effects of prolonged exposure to 2 μΜ and ΙΟ μΜ 
6MP in human lymphoblastic cell lines with respect to the fol­
lowing parameters: cell growth, cell viability, clonal growth, 
flow-cytometry, phosphoribosyl pyrophosphate (PRPP) levels, DNA 
and RNA synthesis ([ 3 2P] incorporation), C8- MCÍ 6MP incorpora-
tion into newly synthetized DNA and RNA, and formation of 6MP 
nucleotides. Our study provides new insights in the complex 
mechanism of action of 6MP in human malignant lymphoblasts. 
Exposure to 2 μΜ 6MP resulted in a rapid inhibition of 
purine de novo synthesis (PDNS), affecting early cell growth 
and clonal growth in MOLT-4 (T-) and RAJI (B-> lymphoblasts, 
but not in KM-3 (nan B, nan T) cells. Inhibition of PDNS did 
not result in significant early loss of viable cells. Prolonged 
exposure to 2 μΜ 6MP affected MOLT-4 with respect to cytotoxi­
city, but not RAJI and KM-3 cells. Late inhibition of clonal 
growth was comparable in all cell lines. These data suggest 
differences in incorporation of 6MP into DNA between the cell 
lines, resulting in differences in late cell death. 
DNA synthesis in MOLT-4 cells was equally lowered to 40-50% of 
untreated cells within the first and the second 24 hr after 
exposure to 2 μΜ 6MP. This was associated with an increasing 
delay of cells in S phase, and an increasing arrest of cells in 
62 phase (already after 1 doubling time). RNA synthesis was 
lowered to 40% of control within the first 24 hr, but showed 
some recovery in the second 24 hr, due to increased availabili­
ty of natural nucleotides. f»MP-nucleotide formation could not 
be detected in this period and 6MP levels in the culture medium 
were already undetectable after 6 hr of exposure to 2 μΜ 6MP, 
indicating a high rate of incorporation within this period. 
Incorporation of âMP-nucleotides into DNA was 4.6 and 5.9 times 
as high as into RNA in these subsequent periods. 
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Exposure to ΙΟ μΜ 6MP resulted in early cytotoxicity after 
12 hr in MOLT-4 cells. This was associated with a complete 
inhibition o-f PONS by the large pool o-f 6MP-nucleotides, and 
accumulation and arrest o-f cells in 5 phase. Early cell kill 
did not occur in RAJ I and KM-3 cells, suggesting that these 
cells were delayed, but not arrested in 5 phase. Arrest o-f 
MOLT-4 cells in G2 phase after 4B hr was less as compared to 24 
hr, due to the arrest of cells in S phase. DNA and RNA synthe­
sis were lowered to 154 of control within the first 24 hr and 
the incorporation of 6MP into DNA was 3.7 times as high as into 
RNA. These data suggest that inhibition of PONS due to 6MP-
nucleotides is responsible for decreased RNA synthesis and 
decreased availability of natural deoxynbonucleotides, causing 
a delay of DNA synthesis in S phase. This favours incorporation 
of 6MP into DNA in S phase and subsequent cell kill in G2 
phase. However, with high concentrations of 6MP, the large pool 
of 6MP-nucleotides causes severe reduction of natural deoxyn­
bonucleotides in cells with an active PDNS and purine salvage 
pathway. This is responsible for additional kill in 5 phase. 
The differences in early and late cytotoxicity and clonal 
growth inhibition after exposure to 6MP between the cell lines 
(MaLT-4 > RAJ I > KM-3) can be explained by the differences in 
PDNS and purine salvage enzyme activities and may be also due 
to differences in IMP dehydrogenase activity and methyl ation of 
¿>MP. 
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6.2. INTRODUCTION 
6-Mercaptopurine (6MP) has been used as an important agent 
in the maintenance treatment o-f childhood non-B acute lympho­
blastic leukemia (ALL) and non-Hogdkin's malignant lymphoma 
since its introduction in 1952 [ID and the -first clinical 
studies in 1953 C2D. Although many studies concentrated on the 
anabolism and catabolism o-f 6MP and the biochemical effects o-f 
6MP-metabolites on purine metabolism C3-7D, many questions 
regarding the exact mechanism o-f 6MP cytotoxicity remained 
obscure or have been subject o-f debate in the literature. The 
role of the 6MP-metabolites, 6-thioIHP (tIMP) and 6-methylthio-
IMP (Me-tIMP), with regard to the allosteric inhibition of the 
first enzyme in purine de novo synthesis (PDNS), PRPP amido-
transferase, has been studied extensively CB—123, and Me-tIMP 
proved to be the more effective inhibitor of PDNS Cll-193. The 
non—competi ti ve inhibition of adenylosuccinate synthetase, the 
competitive inhibition of adenylosuccinate lyase, and the 
inhibition of IMP dehydrogenase in the purine interconversion 
pathway C3,4,9,14,20,213 requires relatively high concentra­
tions of 6MP(-metabolites) and might not have clinical impor— 
tance. Moreover, increase of IMP dehydrogenase activity has 
been described after exposure of 6MP to human fibroblasts C223. 
The contribution of the inhibition of PDNS to early cell growth 
inhibition or early cytotoxicity of 6MP has extensively been 
discussed in the literature C16,23-283. The most important 
mechanism of cytotoxicity of 6MP was shown to be incorporation 
as 6-thioguanine (6ТБ) nucleotides into DNA 126,27,293. 
Although human malignant lymphoblasts were the most susceptible 
cells to exposure of 6MP among human malignancies [2,30-333, 
studies with respect to the mechanism of action of 6MP in human 
lymphoblastic cells are scarcely available. With the exception 
of the study of Zimm et al [343, this especially holds for the 
various subclasses of lymphoblastic leukemia. 
In previous studies, we demonstrated the biochemical and 
cell-kinetic disturbances caused by methotrexate (MTX) in three 
different human malignant lymphoblastic cell lines [35,363. 
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Moreover, a potential synergism o-f the combination treatment o-f 
MTX and brie-f exposure to 6MP was demonstrated, when lympho-
blasts were pretreated with MTX C3S3. These studies showed an 
increased intracellular uptake and conversion o-f 6MP to its 
nucleotides С373 with maxima at those points oi time, which 
correlated with the maximal inhibition o-f purine de novo 
synthesis by MTX. 
In the framework o-f the effects of prolonged exposure to 
combinations of MTX and 6MP on cytotoxicity and synthesis of 
DNA and RNA in human malignant lymphoblasts, this study pre­
sents the effects of prolonged exposure to 2 and 10 μΜ 6MP on 
cell-kinetic parameters (cell growth, cell viability, clonal 
growth, flow-cytometry), on purine de novo synthesis (PRPP 
levels) and double labeling experiments, concerning the incor— 
poration of C8- 1 4C3 6MP into newly synthetized DNA and RNA, 
measured by incorporation of C 3 2?] phosphate. 
6.3. MATERIALS AND METHODS 
CB- l 4C3 6-mercaptopurine (1.7 mCi/mmol) and С 3 2 Ρ Ί 
phosphoric acid (200 mCi/mmol) were purchased from Amersham 
International LtD (Amersham, U.K.); PRPP and calf-thymus DNA 
from Sigma (St. Louis, MO); a preparation from brewer's yeast 
containing orotate phosphoribosyltransferase (OPRT, E.G. 2.4.2. 
10) and orotidylate decarboxylase (ODC, E.G. 4.1.1.23), Pro-
nase, 4',6-diamidino-2-phenylindole (DAPI), and dithiothreitol 
(DDT) from Boehnnger Mannheim (Mannheim, F.R.G.); Aqua Luma 
scintillation fluid from Lumac 3M (Schaesberg,The Netherlands). 
The cell lines MOLT-4 (T-lymphoblasts), RAJI (B-lympho-
blasts), and KM-3 (non-B-non-T-, common ALL lymphoblasts) have 
been maintained in continuous culture in our laboratory. The 
absence of mycoplasma contamination, and the presence of anti­
gens on the cells in culture were tested regularly. The latter 
by means of monoclonal antibodies СЗ З. 
Logarithmically growing cells were suspended in fresh RPMI 
1Ó40 Dutch Modification medium in a concentration of 0.3 χ IO 6 
cells/ml 24 hr before each experiment. The conditions for cell 
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culture, soft agar colony forming activity, DNA-flow cytometry 
and PRPP assay were identical to those described earlier by us 
C37,393. Cell doubling times were 20 hr for MOLT-4 cells, 20 hr 
for RAJ I cells, and 16 hr for KM-3 cells. Glutamine was added 
every 24 hr to a final concentration of 2 mM in order to pre­
vent glutamine exhaustion of the medium, resulting in a small 
inhibition of PONS [373. Glutamine addition was not performed 
in the double labeling experiments (see below). Cell number and 
viability (trypan blue exclusion) was counted in duplicate in a 
Btirker—Turk chamber. Cell growth was expressed as percentage of 
viable untreated cells. The number of non-viable cells was 
corrected for non—viable untreated cells. Colony forming 
activity was expressed as percentage of plating efficiency of 
untreated cells, and the results were plotted on a 
semi logarithm!cal scale. 
C8-l4C3 6-mercaptopurine, from a stock solution containing 
60 mg/1 DDT in order to prevent desulfuration of 6MP [403, and 
[32P3 phosphoric acid were diluted in a small volume of RPMI 
1640 DM medium (0.002-0.01 fraction), and were added as a 
single dose at time points indicated below. 
Incorporation of CB- 1 4C3 6-mercaptopurine and/or [32P3 phosphate 
into newly synthetized DNA and RNA. 
These investigations were performed in MOLT-4 cells in the 
framework of more extensive studies on the effects of simulta­
neous or sequential MTX and 6MP administration on DNA and RNA 
synthesis. In the context of this paper, we will focus on the 
exposure of 2 pM [8- l 4C3 6MP during 48 hr and 10 fiM [8- MC3 6MP 
during 24 hr. 
Final concentrations of 2 μΜ and 10 μΜ [8- 1 4C3 6MP, respecti­
vely, were added to 11 ml of the cell suspension after 24 hr of 
preincubation. All experiments were performed in duplicate. In 
order to measure the amount of newly synthetized DNA and RNA 
during the first or the second 24 hr after addition of 6MP or 
in untreated cells, the cell suspension was exposed to [^РЗ 
phosphate (further indicated as [32P3) in a final concentration 
of 1 μα /ml at 0 hr or 24 hr. After 24 hr incubation with [32P3 
in the presence or absence of [8-14C3 6MP, the cell suspension 
was divided into 5 Eppendorf vials, each containing 2 ml of the 
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cell suspension: -four -for quadruplicate determinations o-f 
t8-14CJ and/or С 3 2Р] incorporation. In the fifth sample the DNA 
content o-f the cell suspension was measured a-fter the indicated 
incubation period, using a fluorometric DNA assay with DAPI 
C41Í. Furthernore, 100 μΐ of the cell suspension was in liquid 
scintillation fluid was counted in duplicate in a liquid 
scintillation analyzer for determination of the specific 
activity of C 3 2P] at the time of measurement of all samples. 
The 5 Eppendorf vials were centrifuged (5,500 g; 3 m m ) and the 
cell pellets were washed three times with 0.9 '/. NaCl solution 
and stored at -20°. In order to remove all protein, to destroy 
the cell membranes, and to precipitate DNA and RNA, we used the 
method described by Kufe et al C423. The cell pellet was re-
suspended in 0.5 ml of 0.01 M Tris buffer (pH 7.4), containing 
0.1 M EDTA, 0.5% sodium dodecyl sulfate and freshly dissolved 
nuclease-free Pronase (2 mg/ml). After careful sonification 
during 3υ s, incubations were performed during 3 hr at 37°. In 
order to precipitate both DNA and RNA, the samples were frozen 
after mixing with 100 \x\ 4 M NaCl and 1.2 ml ethanol 1007. 
during 24 hr at -20°. After centrifugati on <B,500 g; 5 min) the 
supernatants, containing 6MP-nucleotides, were evaporated at 
60°, resuspended in 1 ml water and 15 ml scintillation fluid, 
and radioactivity was determined. The pellets, containing DNA 
and RNA, were washed twice at 0° with 1007Í ethanol and 
evaporated at 60°. In order to measure the incorporation of 
C8-14C] 6MP and/or С 3 2P] into RNA, the RNA was hydrolysed 
during incubation for 1 hr at 37° with 0.4 M K0H solution, 
containing also 0.5 mg/ml calf-thymus DNA. Calf-thymus DNA was 
used as a carrier during precipitation of DNA. After cooling on 
ice DNA was precipitated during 1 hr by addition of lOO μΐ 4 M 
HC10 4. After brief centrifugation the supernatant, containing 
RNA, was neutralized to pH 7.0 with 0.5 ml of a solution, 
containing 0.4 M КОН and 0.1 M K 2HP0 4, and radioactivity was 
determined after addition of scintillation fluid. The pellet 
containing DNA was resuspended in 1 ml of a solution, 
containing 0.04 M K0H and 0.01 M K 2HP0 4, and radioactivity was 
counted after addition of 15 ml scintillation fluid. 
The final results of incorporation of CB- 1 4CD 6MP and/or C 3 2P] 
into DNA and RNA and the formation of [ - 1 4СЗ 6MP-nucleotides 
Ю З 
were expressed as nmol/mg DNA aftpr correction for the specific 
activity of C 3 2P] and the overlap of С^РЗ counts in the C 1 4C3 
channel. 
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6.4. RESULTS 
Effect* of 6MP on cell growth and colony forming activity in 
three cell lines. 
The effects of 2 μΜ and ΙΟ μΜ 6MP, respectively, on cell 
growth and colony forming activity of the three cell lines are 
shown in Fig. 1 ft-D. Growth inhibition of MOLT-4 cells exposed 
to 2 μΜ 6MP already occurs after 6 hr (Fig. ΙΑ), whereas growth 
inhibition of RAJI and KM-3 cells occurs after 12 and between 6 
and 24 hr, respectively. Also after prolonged exposure to 2 μΜ 
6MP, cell growth inhibition is more pronounced in MOLT-4 cells 
than in RAJ I and KM-3 cells. This has to be attributed to 
greater cytotoxicity in MOLT-4 cells, demonstrated by the 
percentages of non-viable cells after prolonged incubation 
(Table 1): The number of non-viable cells rapidly increased in 
MOLT-4 cells to 4Θ7. after 72 hr; RAJI and KM-3 cells did not 
show significant cell death. Fig. 1С demonstrates comparable 
effects of 2 μΜ 6MP on the clonal growth potential of MOLT-4 
and RAJI cells, whereas the initial inhibition of clonal growth 
in KM—3 cells is much lower. However, after prolonged exposure 
to 2 μΜ 6MP, clonal growth of MOLT-4 and RAJI cells seems to 
recover and is comparable to that of KM-3 cells. 
Exposure of 10 μΜ 6MP to the three cell lines results in 
an earlier growth inhibition of MOLT-4 cells as compared to 
RAJI cells and much more initial growth inhibition, when 
compared to KM-3 cells (Fig. IB). However, after prolonged 
exposure to 10 μΜ 6MP a steep cell growth inhibition for all 
cell lines is apparent. Cell viability (Table 1) is already 
affected after 12 hr in MOLT-4 cells and shows rapidly 
increasing number of non-viable cells to B43C after 72 hr of 
incubation. In RAJI cells cytotoxicity is apparent after 36 hr 
exposure with a maximum of Ò4X non-viable cells at 72 hr. 
Again, in KM—3 cells cytotoxicity is less with a maximum of 42X 
after 60 hr. The effects of 10 μΜ 6MP on clonal growth capacity 
(Fig. ID) demonstrate a rapid initial inhibition of clonal 
growth in MOLT-4 and RAJI cells and a more delayed inhibition 
in KM-3 cells. However, after prolonged exposure to 10 μη 6MP, 
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Table 1. Percentages ot non-vuble celle ifter eiposure 
to 2 μΛ and 10 μη 6-iercaptopurine. 
Duration of exposure: 
2 jiH iNP: 
COLT-' 
PflJ! 
tn-z 
10 |iN 6I1P: 
I1DLI-4 
PA J I 
КИ-3 
i 
3 
: 
3 
3 
3 
1 
non-vi 
12 
5 
3 
2 
26 
4 
2 
24 
.5 
τ 
1 
53 
5 
1 
able 
36 
26 
2 
3 
'0 
30 
9 
cells 
48 
2 J 
3 
2 
74 
44 
23 
II) 
60 
¿3 
a 
0 
Θ4 
60 
42 
72 hr 
4G 
0 
-
B4 
64 
-
(nedsured bv trypan blue erdusior expressed as percentaoes. 
c!irrected for untreated non-viable ^ells at each point of ti»e¡ 
lean of 4 experuents in duplicate) 
inhibition of clonal growth is approximately 2.5 log in RAJ I 
and KM-3 cells after 60 and 64 hr, respectively, whereas MOLT-4 
cells did not show any clonal growth after 72 hr. 
Effects of 6MP on PRPP lavéis 
The effects of 6MP on intracellular PRPP levels were 
studied in MOLT-4 and RAJI cells. Exposure to 2 μΜ 6MP resulted 
in a rapid initial increase of PRPP levels in MOLT-4 cells with 
a maximum after 6 hr (Fig. 2A; 8—fold increase), indicating a 
rapid formation of tIMP and Me-tIMP and inhibition of PONS in 
these cells. After prolonged exposure PRPP levels remained 
elevated to the same extent, confirming the long half—life time 
of Me-tIMP C15,433. The increase of PRPP levels in RAJI cells 
was somewhat delayed in comparison to MOLT-4 cells (Fig. 2B), 
with a 10-fold maximum increase after 24 hr, followed by a 
small decrease. Exposure to 10 μΜ 6MP resulted in a similar 
rapid increase of PRPP levels in both cell lines and 7—fold 
maxima after 6 and 9 hr, respectively. After prolonged exposure 
to 10 μΜ 6MP, PRPP levels rapidly declined to levels below 
those of untreated MOLT-4 and RAJI cells. 
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Flg. 2. I n t r i c i l l u U r PRPP l i v i l i In I40LT-4 (A) ind RAJl (B) c e l l i 
after exposure to 2 /ιΝ and !0 рП бПР. 
letpreEsed as naol/ io ' viable ce l l s ; 
lean cf 2 expencents in duplicate) 
D N A d i s t r i b u t i o n 
Flg. 3. Effects of MP on DNA diitribution of HOLM celli, 
•easured by DNA-flou cytoietry. 
A. 2 (id 5ІР B. 10 /ill i№ 
Gl ВІ+И 
0 hr 54.32 37.0'. 8.7X 
24 hr 51.61 3 8 . : : 9.91 
48 hr 42.21 47.2л 10.Ы 
Gl S2tH 
54.3Î 37.OX B.7X 
4B.41 41.41 10.2: 
38.71 54.2X 7.0Z 
!«ean nf 3 experieents) 
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E-f-fects o-f 6MP on changes in DNA distribution 
Flow—cytometric studies were performed in MOLT—4 cells in 
relation with the double labeling studies, described below. The 
ef-fects of 2 μΜ 6MP on DNA distribution, measured by DMA-flow 
cytometry, in MOLT-4 cells (Fig. ЗА) demonstrate a decrease of 
cells in Б1 phase, associateJ with an increase of cells in S 
and Б2 + M phase. Exposure to 10 μΜ 6Γ1Ρ results in similar, but 
more pronounced effects (Fig. 3B). Exact computer calculations 
of DNA distribution in cells treated with 2 μΜ 6MP after 72 hr 
were not possible, due to the indistinct separation of the Gl 
and S peaks and the marked effects on these cell cycle phases. 
DNA-flow cytometry studies in cells treated with 10 μΜ 6MP 
after 72 hr were not feasible due to extreme cytotoxicity. 
Incorporation o-f C8- 1 4C3 6MP and/or С 3 2P] phosphate into newly 
•ynthetized DNA and RNA. 
The extensive double labeling experiments in MOLT-4 cells 
were performed to gain more insight into the effects of 6MP on 
DNA and RNA synthesis and the formation of 6MP-nucleotides. 
The effects of exposure to 2 μΜ and 10 μΜ 6MP on DNA and RNA 
synthesis in MOLT—4 cells are demonstrated in Fig. 4. The 
observation, that the incorporation of phosphate into both DNA 
and RNA of untreated cells (black bars) is more pronounced in 
the second 24 hr than in the first 24 hr, is probably due to 
environmental conditions, such as longer culture duration. 
Exposure to 2 μΜ 6MP lowers the phosphate incorporation 
into DNA within the first 24 hr to 497. of control cells, 
whereas 10 μΜ 6MP lowers DNA synthesis to 12.'/. of control cells 
(Fig. 4 ) . In the second 24 hr after exposure to 2 μΜ 6MP DNA 
synthesis decreases to 43yC of control. Incorporation studies 
during the second 24 hr with 10 μΜ 6MP were not performed due 
to its excessive effects in this time period. 
Phosphate incorporation into RNA lowers to 40% of control with­
in the first 24 hr and to 537. in the second 24 hr after 2 μΜ 
6MP, indicating a small recovery of RNA synthesis. Exposure to 
10 μΜ 6MP results in 1Ь7. residual incorporation. 
Measurement of purine and pyrimidine nucleotide synthesis with 
C 3 2P3 phosphate incorporation in the soluble fraction after 
ethanol precipitation of DNA and RNA could not be performed, 
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Fig. 4. [ 5 г Р! incorporitiofl durinq 24 hr into DNA ind RNA 
D{ NOLT-4 cells after exposure to 2 fill and 10 μη 
¿NP. lespressed as moi 'ц DNA; lean +/- SD sf 
quadruplicate deterimatians in 3 experuents m 
duplicate) 
Fiq. 3. Ratio [ β - " θ 4 Ν Ρ / СИР1 incorporation 
into DNA and RNA of !*OLT-4 cells after 
exposure to 2 μη and lu jifl [8-uC]-tNF 
durino 24 tir exposure to [ n P ] . (x 10"2; 
•ean +/- SD of quadruplicate detenina-
tions in 3 expenients in duplicate) 
because this -fraction also contained other soluble compounds 
which incorporate phosphate (e.g. sugar phosphates and PRPP). 
The incorporation o-f [8-14C3 6MP into DNA, RNA and 
6MP-nucleotides is shown in Table 2. The ratio o-f incorporation 
o-f 2 uM 6MP into DNA, RNA and nucleotides in the first 24 hr is 
4.6 : 1 : 9.3, and in the second 24 hr 5.9 : 1 : O, indicating 
that 6MP is -far more incorporated into DNA in comparison to 
RNA. We could not demonstrate formation of бІІР-nucleotides in 
the second 24 hr after exposure to 2 μη 6MP. These data do not 
exclude synthesis of 6MP—nucleotides in this period, but merely 
indicate that the consumption of 6MP-nucleotides for DNA and 
RNA synthesis exceeds their synthesis. These data are in 
agreement with the HPLC-measurements of 6MP levels C443 in the 
culture medium after exposure to 2 uM 6MP, shown in Table 3. 
After 6 hr of incubation with 2 μΜ 6MP we could not detect 
measurable amounts of 6MP in the culture medium, indicating a 
very rapid uptake and complete conversion of 2 pM 6MP from the 
culture medium. 
In cells treated with Id μΜ 6MP, the ratio of incorporation 
into DNA, RNA and nucleotides in the first 24 hr is 3.7:1:13.3 
109 
Tibi« 2. IB-" CI 6-itrcaptopurine incorporation into DNA, RNA ind nue 1ioti des o< I40LT-4 cells. 
DNA RNA 6HP-nucleotldej 
0-2Í lir 24-4B hr 3-24 h- 24-48 hr 0-24 hr 24-48 h' 
2 μ* 6ПР Ь.Ч •/- 0.2 7.7 •/- О.' 1.5 •/- С 1 1.3 +/- O.Í 14.0 */- 2.3 О 
Ю р Ч Ы І Р 10.0 +/- 2.6 2.7+/- η.5 36.0 tt- 14Л 
(expressed as niol/ic DNA; tean •/- SD of quadruplicate aeasureients in 2 or 3 experinents in duühcate) 
(Table 1), also indicating more incorporation o-f òMP into DNA 
as compared to RNA. However, the majority o-f 6MP is incorpora-
ted into nucleotides and Table 3 indicates that approximately 
70-757. of the total available amount of ΙΟ μΜ 6MP is 
incorporated into the cells. These findings are not in 
agreement with those of Breter and Zahn [45], who demonstrated 
only 0.48% incorporation using 10.2 μΜ С 3 5SD 6MP in L5178Y 
cells. However, the enormous amount of thiouric acid, 
thioxanthine and sulphate after short incorporation periods 
suggests that these cells may have been infected, because 
lymphocytes lack xanthine oxidase activity C43. 
In order to account for the inhibition of DNA and RNA 
synthesis by 6MP and its cytotoxic effects, the incorporation 
of CB-I4C3 into RNA and DNA, shown in Fig. 5, was expressed as 
percentage of C 3 2?] incorporation into these compounds. In this 
way we could measure to what extent 6MP is incorporated with 
respect to newly synthetized DNA and RNA, which is the main 
goal of treatment with 6MP. The data in Fig. 5 demonstrate that 
the amount of 61*^ incorporation into DNA after exposure to 2 uM 
6MP is 3.5% of total nucleotide incorporation into DNA in both 
time periods. The incorporation of 6MP into RNA is more 
pronounced in the first 24 hr, as compared to the second 24 hr. 
Moreover, the amount of 6MP incorporation expressed as ratio of 
the total amount of nucleotide incorporation into RNA is lower 
as compared to DNA. Thus, 6MP preferentially incorporates into 
DNA. These findings are even more clear in our experiments with 
10 μΜ 6MP (Fig. 5): 6MP-nucleotides form approximately 15% of 
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Tibi ι 3. Conctntritioni o( 6ЯР m thi cul turi itdlui i H t r iipoiuri 
ai H0LT-4 cills ta 2 jiN ind 10 рП MP. 
Duriti on af opoiure (hr) 0.S 2. S 4 6 В 24 46 
СЫІРІ in culture l t d l u · : 
2 μΒ ЬП? O.B 0.5 0.3 О О О О 
lOjilUHP 4.4 3.0 2.4 3.0 2.4 2.2 2.9 
(expressed is /ifl; іеап эі 2 experuentsl 
nucleotide incorporation into DNA, whereas DNA synthesis is 127. 
of control in the -first 24 hr (Fig. 4 ) , cell growth (Fig. IB) 
and clonal growth (Fig. ID) are rapidly inhibited in the first 
24 hr, and cytotoxicity (Table 1) and flow-cytometry (Fig. 3) 
demonstrate important changes in this time period. In contrast, 
the amount of 6MP incorporated into RNA is only 3.27. of total 
nucleotide incorporation, whereas RNA synthesis is inhibited to 
the same extent as DNA synthesis. 
DISCUSSION 
The effects of 6-mercaptopurine have extensively been 
studied in various malignant cell lines. After its introduction 
by Elion et al in 1952 CID. the first clinical study 
demonstrated the efficacy of this hypoxanthine analogue in the 
treatment of leukemia and allied diseases C23. Its efficacy was 
also proven in many non-lymphoid or non—human experimental in 
vitro and in vivo models, especially L1210 leukemia C9,46-53], 
L5178Y lymphoma C25,26,2B, 45. 54 J , Sarcoma-IBO C«?, 17, IB, 55D , 
Ehrlich ascites tumor cells C9,12,13D, chinese hamster ovary 
cells [56-581 and human epidermoid cancer cells С 11,23,27,591. 
Nevertheless, the agent did not arouse interest in the 
treatment of various human cancers [30-32]. Until now, 6MP is 
predominantly used in the maintenance treatment of ALL and 
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non-Hodgkin's lymphoma in children Сбои. Before the 
introduction of cyclosporin, 6ІІР and its prodrug, azathioprine, 
were used in order to reduce cellular immunity and natural 
liller function in renal transplant recipients and in systemic 
diseases C61—653. 
Pharmacokinetic studies of oral ¿»MP administration in a 
dosage of 50—100 mg per square meter in patients witl· ALL 
demonstrated a very low bioavailability [66,673, which could be 
improved by coadministration of the xanthine oxidase inhibitor, 
allopunnol [683. In contrast, the combination of oral 6MP and 
MTX proved to be superior as compared to each agent separately 
in the early treatment of ALL [693. The maintenance treatment 
of ALL has not been changed since, except for a tendency to 
shorten the period of treatment with the advent of aggressive 
multi agent induction and intensified reinduction therapy [603. 
In previous studies of human malignant lymphoblastic cell lines 
of all immunological subclasses, we demonstrated the potential 
synergism of pretreatment with MTX followed by administration 
of 6MP at the moment of maximal inhibition of PDNS by MTX [353. 
The increased availability of PRPP could be used for an 
enhancement of the facilitated transport of 6MP [703 and an 
enhanced conversion to its important metabolites, tIMP and 
Me—tIMP [373. In the present study, we used concentrations of 
6MP, which gave rise to cytotoxicity in these cell lines, and 
which could easilv be maintained for several hours after short 
time intravenous infusion in vivo [71-733. 
The inhibition of the first enzyme in PDNS, PRPP 
amidotransferase, due to the first metabolites of 6MP, tIMP and 
Me-tIMP, was demonstrated in MOLT-4 and RAJ I cells by the rapid 
rise of intracellular PRPP levels after exposure to 6MP (Fig. 
2). These data closely correlated with the rapid increase of 
tIMP levels in MOLT-4 cells after exposure to IO pM 6MP in the 
study of Zimm et al [343, and in human bone marrow cells [743. 
The persistence of increased PRPP levels in cells exposed to 2 
uM 6MP is in agreement with the long half-life time of Me—tIMP, 
shown in other cell lines [153 and in human red blood cells 
[433. Steady state PRPP levels in MOLT-4 were reached earlier 
and were lower than in RAJI cells. This can be explained by a 
higher activity of PRPP synthetase in B-lymphocytes [753 and a 
IÍ2 
lower PRPP amidotransferase activity in RftJl cells as compared 
to MOLT-4 cells C353. Differences in the activity of PRPP 
amidotransferase were also shown in other human leukemic cells 
1119,49,503. 
Although we did not perform PRPP measurements in KM-3 cells, 
earlier studies by us [353 demonstrated a moderate activity of 
both PDNS and purine salvage pathway, suggesting that 6MP will 
not be converted to metabolic active metabolites as fast as in 
MOLT-4 and RAJ I cells, and that PDNS will be inhibited less. 
These data may explain the relatively small initial effects of 
2 μη 6MP in KM-3 cells on cell growth, clonal growth and cell 
viabi1ity. 
Inhibition of PDNS in other cell Ііпеь was accompanied by a 
decrease of ATP and GTP levels and an increase of pyrimidine 
nucleotide levels С17,18,24,25,273. We found a decrease of ATP 
levels to 907., 457. and 50/C at 6, 24 and 48 hr, respectively, 
after incubation with 2 JJM 6MP in MOLT-4 cells (data not 
shown). 6TP levels decreased to 507., 55X and 607., respectively; 
UTP levels increased initially to 2007., and CTP levels to 1607. 
of control. The data in Table 1 indicate that the perturbations 
of ribonucleotide levels after exposure to 2 uM 6MP do not 
result in a significant early cytotoxicity (i.e. loss of viable 
cells within 1 doubling time), but only in a decrease of cell 
growth and clonal growth (Fig. 1), which is in agreement with 
the studies in other cell lines, mentioned before. The effects 
of inhibition of PDNS in these cell lines were reversible, when 
cells were resuspended in fresh medium [24,25,273, associated 
with a decrease of thiopunne nucleotides C23,25,343. These and 
other studies demonstrated that cytotoxicity of 6MP and its 
analogue 6TG was due to incorporation as thioguanine deoxynbo— 
nucleotides into DNA [26,29,51,52.58,763. 
It should be stressed, however, that many studies in the 
literature misused the term cytotoxicity, and in fact meant 
loss of clonal growth or cell growth. We could not detect late 
cell death in RAJI and KM-3 cells after exposure to 2 JJM 6MP 
(Table 1), whereas late cell growth and clonal growth were 
reduced to a similar extent (Fig. 1). These data suggest, that 
the significant inhibition of PDNS in RAJI cells (Fig. 2) is 
responsible for early growth inhibition, and that the probably 
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small inhibition of PDNS in KM-3 cells does not result in early 
growth inhibition. Moreover, the formation of 6TG-nucleotides 
and their incorporation into DNA is probably insufficient in 
both cell lines in order to produce late cytotoxicity. This may 
be due to differences in formation of Me-tIMP and/or in IMP 
dehydrogenase activity, which is responsible for conversion of 
6MP-nucleotides to ¿>TG-nuclee tides. 
The flow-cytometric studies in MOLT-4 cells after exposure 
to 2 μΙΛ 6MP demonstrate an increasing accumulation of cells in 
S phase. The increase of cells in 32 -t M phase suggests that 
cells are blocked already after 24 hr (1 doubling time) and 
even more in the second G2 + M phase. Moreover, the 
accumulation of cells in S phase does not prevent progression 
through the S phase, but merely delays progression. This was 
also demonstrated by the decrease of cells in Gl phase. These 
data suggest the following sequence of events in MOLT-4 cells: 
6MP is incorporated in cells in all phases of the cell cycle. 
Incorporation as thioguanine nucleotides into DNA occurs in the 
subsequent S phase, indicating that cells in early S phase are 
most sensitive to 6MP exposure C52,56,77]. Progression through 
the S phase is delayed [53,59,79] (increase in S phase at 24 
hr, Fig. ЗА), but not arrested by the consequences of PDNS 
inhibition: decreased levels of natural ribonucleotides for RNA 
synthesis and deoxynbonucleotides for DNA synthesis С2 Л. 
These events cause early cell growth and clonal growth 
inhibition, but do not affect early cell viability (Table 1). 
After progression through the S phase, cells which incorporated 
thioguanine nucleotides into DNA, are arrested in the G2 phase 
C53,55,57,78,793 (increase in G2 + M phase at 24 hr. Fig. ЗА). 
Cells which were in mid or late S phase and 62 + M phase at the 
time of exposure to 6MP, do not incorporate 6MP into DNA and 
continue to divide normally. Progression through the S phase is 
delayed, resulting in a further accumulation of cells in S 
phase, shown at 48 hr (Fig. ЗА). These cells incorporate 6MP as 
thioguanine nucleotides into DNA (between 1 and 2 cell doubling 
times after exposure to 6MP), resulting in an increase of cells 
in the second G2 phase (Fig. ЗА, 48 hr). Moreover, cells which 
already incorporated thioguanine nucleotides into DNA in the 
first S phase after exposure to ЫЛР contribute to these events. 
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Cytotoxicity becomes obvious between 24 and 48 hr (Table 1); 
this is associated with morphological changes in the 
chromosomes in G2 phase: chromosomal curling and unilateral DNA 
strand breaks [57,581. 
Comparison o-f these events in the cell cycle with data from the 
literature is not altogether possible, because most authors 
studied ¿TS induced phenomena C52.57,58,7Ь,791, some authors 
used shcrt time incubations followed by resuspension [52,573, 
and some authors only measured the e-f-fects after two or more 
doubling times [53,58,793. Our data cannot be compared to flow 
cytometric studies in 9L rat brain tumor monolayer cultures 
[803 due to large variations in cell cycle distribution in 
untreated cells at different points of time in this study, 
associated with a large decrease of these cells in S phase in 
time. The most striking difference between the effects of 2 uM 
6MP in our study and the effects of IO pM 6TB in L1210 cells in 
the study of Wotring and Roti Roti [783 is an increase of 
I40LT-4 cells in the first 62 phase, whereas L1210 cells demon­
strated an increase in the second Б2 phase. However, chinese 
hamster ovary cells also demonstrated an increase in the first 
G2 phase after exposure to 4 μη 6TG [573. These differences may 
be due to differences in 6MF or 6ΤΘ sensitivity. 
The effects of exposure to 10 uM 6MP demonstrate important 
differences with those of 2 діМ 6MP. The increase of PRPP levels 
in MOLT-4 and RAJ I cells is almost similar (Fig. 2 ) . The subse­
quent decline of PRPP levels does not represent a cessation of 
the inhibition of PONS. It merely points to an increased con­
sumption of PRPP for the conversion of 6MP (table 2), which 
exceeds its synthesis. The decline may also be due to the 
induction of salvage enzymes [223. Moreover, increased consump­
tion of PRPP may be caused by reuti1ization of purine and pyri— 
mi dine precursors from nucleic acid breakdown due to increased 
loss of viable cells (Table 1), similar to our previous studies 
with MTX [35,363. 
Fig. 3B demonstrates more pronounced effects on cell cycle 
distribution of MOLT-4 cells measured after 24 hr, compared to 
2 uM 6MP: more decline of cells in Gl phase, and increase of 
cells in S and G2 + M phase. However, the results of 
f 1ow-cytometrv after 4B hr of exposure show a decrease of cells 
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in Б2 *• M phase. These data suggest that the complete 
inhibition o-f PONS due to very high amounts o-f 6MP-nucleotides 
(Table 2) results in severe perturbations o-f normal 
ribonucleotide and deoxvnbcnucleotide levels С2 1. We found a 
decrease of ATP levels to 60V.. 207. and 557. at 6, 24 and 4B hr, 
respectively, after incubation with 10 uM óMP (data not shown). 
GTP levels decreased to 457., 25/1 and 90У. of control, 
respectively at those points of time; and UTP and CTP levels 
increased initially, followed by =» significant decrease at 24 
hr below levels of untreated cells and a small increase at 48 
hr. These data are in agreement with decreased PRPP levels, due 
to reuti1ization of purine and pvrimidine precursors from 
nucleic acid breakdown. mentioned before. The severe 
perturbations of natural nucleotide levels are associated with 
both a delay and an arrest of cells in 5 phase, leading to 
early cytotoxicity in MDLT-4 cells after 12 hr (Table 1). The 
differences between the occurrence of cytotoxicity in MOLT—4 
cells after 12 hr and in RAJI and KM-3 cells after 36 hr may be 
due to differences in the formation of Me-tIMP C23,28]. 
Fig. 1 and Table 1 further show some important differences with 
regard to cell-kinetic criteria: Although cell growth (Fig. IB 
and non—viability (Table 1) are more impaired in MOLT-4 cells 
compared to RAJI cells between О and 36 hr, early clonal growth 
is more impaired in RAJI cells. These data indicate that all 
cell-kinetic parameters should be taken into account in order 
to understand the cytotoxic mechanism of cytostatic therapy. 
After prolonged exposure to IO uM 6MP MOLT-4 cells are most 
vulnerable with respect to all parameters, in accordance with 
Dalke et al, comparing MOLT—4 cells and other B-lymphoblasts 
C81]. 
The extensive double labeling experiments in MOLT-4 cells 
with C8- 1 4C1 6MP and C 3 2P3 were used as a model system to study 
the effects of various combinations of MTX and 6MP on newly 
synthetized DNA and RNA and the formation of 6MP-nucleotidee. 
As shown in Fig. 4, the synthasis of DNA after exposure to 2 uM 
6MP is almost equally blocked in bath time periods, confirming 
that the accumulation of cells in S phase (Fig. 3) is not 
associated with an arrest of cells in S phase and cell death. 
If arrest of cells in S phase would be the case in the first 24 
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hr, this should be accompanied with a further decrease of 
phosphate incorporation in the second 24 hr. Our data also 
indicate that both DNA and RrJA synthesis are inhibited almost 
to the same extent (40-50X с f control). However, RNA synthesis 
seems to recover somewhat in the second 24 hr: phosphate 
incorporation into RNA was 53X of control in the second 24 hr 
compared 40% of control in the first 24 hr (Fig. 4). This mav 
be explained by the fact that we could not measure 
òMP-nucleotide formation in the second 24 hr of incubation 
(Table 2), because all 6MP was al-eady incorporated after CJ hr 
(Table 3). Nevertheless, PRPP le\^ls remain elevated and are 
now available for conversion of natural purine and pyrimidine 
bases to nucleotides, leading to recovery of RNA synthesis. 
This is confirmed by the data in Fig. 5, which demonstrate that 
the ratio thiopurine—nucleotides / newly formed nucleotides 
incorporated into DNA is identical in both time periods, 
whereas this ratio is less for RNA in the second 24 hr, 
indicating more incorporation of natural nucleotides into RNA. 
Table 2 and Fig. 5 also demonstrate that the incorporation of 
6MP into (newly synthetized) DNA significantly exceeds the 
incorporation of 6MP into (newly synthetized) RNA, which is in 
agreement with previous studies C26,27,29,5Θ,763. 
Nevertheless, RNA synthesis is inhibited to almost the same 
extent as DNA synthesis (Fiij. 4). Comparison with the results, 
discussed above, indicates that the inhibition of RNA synthesis 
by 2 μη 6MP is predominanti/ caused by the inhibition of PONS 
by tIMP and Me—tIMP, and not by incorporation of thiopurine-
nucleotides into RNA. The incorporation of thiopurine—nucleoti­
des into DNA is favoured by the ithibition of DNA synthesis in 
the S phase of the cell cycle, due to the biochemical effects 
of PONS inhibition (decrease of natural purine deoxyribonucleo— 
tides), leading to arrest of cells in Б2 phase and increasing 
cell kill in G2 phase. 
These phenomena are even more apparent in the experiments with 
10 ^ дМ 6MP: DNA synthesis and RNA synthesis are almost equally 
inhibited to approximately 157. (Fig. 4). The complete inhibi­
tion of PONS, associated with even more decreased levels of 
natural deoxyribonucleotides [283, results in more significant 
delay of the S phase as compared to 2 uM óMP. Fig. 5 shows a 
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predominance o-f incorporation o-f thiopur ine—nucleotides into 
newlv synthetized DNA, which is almost 5 times as high as RNA 
incorporation, leading to an increased arrest and cytotoxicity 
ι η G2 phase as compared to 2 yjM óMP. However, because 6MP is 
still available in the «nediun after 24 and 48 hr of exposure to 
10 utl 6MP (Table 3), further conversion and persistence of 
abundant 6MP-nucleotide levels (Table 2) will ultimately result 
ι η an arrest of the cell cycle in S phase and will contribute 
to cytotoxicity by cell kill in S phase, associated with a 
decrease of cells in 62 + M phase (Fiç. 3). 
These data suggest that 6MP should classified as a class II 
chemotherapeut ic agent in thj» originai studies of Bruce et al 
[02,831, as was later done bv Hill С771 and demonstrated by 
lidd and Paterson С25Л: further increase of 6MP concentration 
will not further increase cytotoKicity after a certain maximum, 
due to a shift from maximal arrest and cell kill in 62 phase to 
maximal arrest and cell kill in S phase. 
Our studies on the cytotoxicity and biochemical pharmaco­
logy of óMP in all immunological subclasses of human malignant 
lymphoblasts, using a large number of parameters, provide new 
insights regarding its mechanism of action, which were unknown 
until now in non-1ymphoid, поп—human studies. 
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7.1. ABSTRACT 
Combination chemotherapy witi methotrexate (MTX) and 
6-mercaptopurine (6MP) in the maintenance treatment of acute 
lymphoblastic leukemia (ALL) has been proven to be more 
efficacious as compared to treatment with each drug separately 
in clinical studies. Me could demonstrate a biochemical basis 
for this synergism, consisting in an enhanced intracellular 
uptake and conversion of 6MP (in short-time incubations) due to 
perturbations by pretreatment with MTX in purine de novo 
synthesis (PONS). In this study we present further evidence for 
this synergism, using prolonged simultaneous and sequential 
combination treatment with MTX and ¿»MP in three human lympho-
blastic cell lines: MOLT-4 (T-), RAJI <B-> and KM-3 (non-B, 
non-T, common ALL) lymphoblasts. We studied the following para-
meters: cell viability, clonal growth, f low—cytometry, DNA and 
RNA synthesis (C32P] incorporation), and incorporation of 
CB-14C3 6MP into DNA and RNA. The concentrations of Í.MP used (2 
and 10 /JM) gave rise to cytotoxicity in vitro; the concentra-
tions of MTX used (0.02 and 0.2 μΜ) can be maintained for many 
hours in the oral maintenance therapy of ALL. 
The cell-kinetic studies demonstrated a clear distinction to be 
made between clonal growth inhibition, due to biochemical 
disturbances especially in the S phase of the cell cycle, and 
cytotoxicity, due to arrest of cell cycle progression. The 
differences between the three cell lines with respect to the 
characteristics of purine metabolism and the effects of MTX and 
6MP separately on cell (cycle) kinetics and on PONS demonstra­
ted to be important parameters in order to explain synergism of 
both drugs after sequential or simultaneous administration. In 
KM-3 cells both manners of administration were advantageous for 
synergism. In MOLT-4 cells combinations with low concentrations 
of ¿MP favoured synergism; in RAJI cells synergism was evident 
after sequential treatment with high concentrations of MTX. 
The flow—cytometric studies in MOLT-4 cells after various 
combinations of MTX and 6MP illustrated an augmentation of the 
perturbations in DNA distribution primarily induced by MTX 
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after co—administration of 6MP. Sequential and simultaneous 
administration of 0.02 μΜ MTX and 2 uM 6MP augmented the 
effects on DNA and RNA synthesis, as compared to the effects of 
administration of each agent separately. Moreover, combination 
chemotherapy preferentially favoured 6MP incorporation into 
DNA. These results indicate that administration of MTX and 6MP 
can also be exploited for induction chemotherapy of ALL. 
7.2. INTRODUCTION 
The efficacy of purine and pyrimidine antimetabolite 
combination chemotherapy is well documented in the literature. 
Synergism of sequential antimetabolite therapy with agents 
which enhance each other's mechanism of action has been the 
main subject of such studies. The most frequently used combina­
tion of two antimetabolites has been methotrexate (MTX) and 
5—fluorouraci1 (5FU). Synergism of this combination was demon­
strated in many in vitro and in vivo tumor models, where MTX 
addition preceded addition of 5FU [1-203. The biochemical basis 
for synergism of these agents was an enhanced intracellular 
availability of phosphoribosyl pyrophosphate (PRPP) after pre-
treatment with MTX, which allowed increased intracellular upta­
ke and conversion of 5FU to its active metabolites. However, 
the therapeutic efficacy of sequential MTX-5FU administration 
has not been demonstrated in all clinical studies [13,21-303. 
Other examples of sequential antimetabolite therapy include the 
combination of methyl—mercaptopurineriboside (MeMPR) and 
6-mercaptopurine (6MP) [31-361, MeMPR and 6-thioguanine (6ТБ) 
[37,383, MeMPR and 5FU [12,13,39,403, MTX and cytosine arabino-
side [41-443, and MTX and 6TB [453. Most of these studies 
extensively investigated the biochemical pharmacology of the 
synergistic effect. In contrast, the synergistic effects of MTX 
and 6MP were only investigated in survival studies in mice and 
man [46,473, not further elucidating its biochemical mode of 
action in human malignant lymphoblasts which was referred to 
only recently [483. This is especially remarkable, because MTX 
and 6MP have been used in the maintenance treatment of acute 
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lymphoblastic leukemia -for more than 25 years. 
Ые could demonstrate the biochemical basis -for potential 
synergistic combination therapy with MTX and 6MP in three sub­
classes o-f human malignant lymphoblasts in short—time incuba­
tions with 6MP administered a-fter pretreatment with MTX, using 
a large number o-f biochemical parameters C49,503. In this study 
we present -further evidence -for the potential synergism o-f 
simultaneous and sequential administration o-f MTX and ¿MP, 
using various cell-kinetic parameters and double labeling 
studies o-f incorporation oí C32P3 and CB-14C3 6MP into DNA and 
RNA, a-fter prolonged exposure to MTX and 6MP. 
7.3. MATERIALS AND METHODS 
MTX (Emtrexate PF) was purchased from Pharmachemie (Haar— 
lem. The Netherlands); [B-14C3 6-mercaptopurine (1.7 mCi/mmol) 
and C32P3 phosphoric acid (200 mCi/mmol) from Amersham Inter-
national LtD (Amersham, U.K.); cal f thymus DNA -from Sigma (St. 
Louis, MO); pronase, 4',6-diamidino-2-phenylindole (DAPI), and 
di thiothreitol (DDT) -from Boehnnger Mannheim (Mannheim, 
F.R.G.); Aqua Luma scintillation fluid from Lumac 3M (Schaes-
berg, The Netherlands). The cell lines MOLT-4 (T-), RAJI (B-), 
and KM—3 (поп—В—поп-Т-, common ALL lymphoblasts) have been 
maintained in continuous culture in our laboratory. The absence 
of mycoplasma contamination, and the presence of antigens on 
the cells in culture were tested regularly. The latter by means 
of monoclonal antibodies C51]. 
Logarithmically growing cells were suspended in fresh RPMI 
1640 Dutch Modification medium in a concentration of 0.3 χ 10* 
cells/ml 24 hr before each e::periment. The conditions for cell 
culture, soft agar colony forming activity and DNA-flow cytome­
try were identical to those described earlier by us 152,531. 
Cell doubling times were 20 hr for MOLT-4 cells. 20 hr for RAJI 
cells, and 16 hr for KM-3 cells. Glutamine was added every 24 
hr to a final concentration of 2 mM in order to prevent gluta— 
mine exhaustion of the medium, resulting in a small inhibition 
of purine de novo synthesis (PDNS) [52]. Glutamine addition was 
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not performed in the double labeling experiments. Cell number 
and viability (trypan blue exclusion) was counted in duplicate 
in a Burl·er—Turk chamber. The number of non-viable cells was 
corrected for non—viable untreated cells. Colony forming 
activity was calculated as percentage of plating efficiency of 
untreated cells, and the results were expressed as -log (clonal 
growth), i.e. "log clonal growth inhibition". 
CB— l4Cl 6-mercaptopurine, from a stock solution containing 
60 mg/1 DDT π order to prevent desulfuration of 6MP t543, MTX 
and С 3 2P3 phosphate (further indicated as C 3 2P3) were diluted 
in a small volume of RPMI 1640 DM medium (0.002-0.01 fraction), 
and were added as a single dose at time points indicated below. 
Double labeling incorporation studies with C B - M C ] 6MP and 
C 3 2PD phosphate into newly synthetized DNA and RNA were 
performed as described by us recently C55]. The final results 
of incorporation of CB-l4CD 6MP and C 3 2P3 into DNA and RNA were 
expressed as nmol/mg DNA/24 hr. 
7.4. RESULTS 
Effects of various combinations of MTX and 6MP on cytotoxicity 
and colony forming activity in the three cell linas. 
The effects of separate exposure to MTX and 6MP on cytoto­
xicity and clonal growth in the three cell lines were presented 
in earlier studies [50,553- In the experiments described below, 
MTX was added always at t=0 in final concentrations of 0.02 μΜ 
and 0.2 μΜ, respectively, and remained present in the medium 
for the duration of the experiment. 6MP (in final concentra­
tions of 2 μΜ and 10 μΜ, respectively) was added at t=0, and at 
those points of time, at which MTX caused a maximal increase of 
PRPP levels С491. As shown in earlier studies С491, incubations 
during 20 min with AMP at these points of time resulted in 
maximal incorporation of 6MP, suggesting a potential synergism 
of MTX and 6MP. These points of time were different for the 
three cell lines and dependent on the concentrations of MTX 
used. In this study, we describe the effects of long—duration 
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exposure to 6MP with or without co-addition o-f MTX. 
Tables 1 and 2 demonstrate the e-f-fects o-f the various 
combinations o-f MTX and 6MP (numbers without brackets) on 
clonal growth (expressed as "log clonal growth inhibition") and 
percentages o-f non-viable cells. To conclude presence or 
absence o-f synergism o-f both agents, we used the definition o-f 
Webb [5611: Synergism is present when the inhibition due to the 
combination of MTX and 6MP (numbers without brackets) is 
greater than the multiplication of the effects of each MTX and 
6MP separately (i.e. summation of both effects; numbers between 
brackets). On this basis we applied data reduction of Tables 1 
and 2 by adding the results of the separate effects of MTX and 
6MP on log clonal growth inhibition and multiplying the results 
on the number of viable cells. Although it should be considered 
that synergism of a combination of two inhibitors which 
influence each other's action cannot definitively be proven in 
this way [56], this method is the only available in order to 
approximate synergism of MTX and 6MP. 
The underlined numbers in Tables 1 and 2 indicate the 
conditions at which a given combination of MTX and 6MP shows 
potentiation in comparison to the separate effects of MTX and 
6MP. Significant potentiation is shown under the following 
conditions: 
a) in MOLT—4 cells with respect to clonal growth and non—viable 
cells after prolonged exposure of 0.02 uM and 2 uM 6MP, 
added simultaneously or sequentially (Table In); 
b) in MOLT-4 cells after sequential administration of 0.2 uM 
MTX and both concentrations of 6MP (Tables 2ft and 2B); 
c) in RftJI cells with respect to clonal growth after short 
exposure to sequential 0.02 μΜ MTX and 2 /JM 6MP administra­
tion (Table 1A). and both concentrations of MTX and 10 uM 
6MP (Tables 1A and 2B); 
d) in RAJI cells with respect to non-viable cells after 
prolonged sequential administration of 0.2 μΜ MTX and 2 uM 
and 10 μΜ 6MP (Table 2A/B); 
e) in KM—3 cells only with respect to non-viable cells in all 
combinations of MTX and 6MP. 
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Table 1. Clonal gronth and cell viability after (»posure to various cotbinations o< 
0.02 pH ΠΤΙ and 2 μΠ or 10 /iK 6HP 
CLONAL m m INHIBITION NON-VIABLE CELLS 
Duration of exposure: 12 li 24 lb 40 4B 60 S4 72 2 li 24 36 40 48 60 64 72 
Cell line [ЯТП І6ПР) 
A. O.OIfN 2 μη 
N0LT-4 24 hr у.92 1.02 47 І0 
RAJI 
КП-3 
B. 
0 hr 
12 hr 
0 hr 
li hr 
0 hr 
0.02 /iH 10 μη 
0.90 
(1.00) 
0.95 
(0.68) 
0.13 
(0.03) 
1.07 
(0.77) 
0.98 
(1.13) 
1. 
(1, 
•1, ,11) 
2.22 
(2.21) 
,39 
.70) 
0.82 
(l.ò5l 
1.19 
(МП 
1.30 
(1.74) 
(0.48) 
2.І0 
(1.251 
1.B4 
(2.94) 
3.00 
(3.21) 
0 
!5) 
0 
(31 
16 
(29) 
0 
(6) 
0 
(2) 
22 
( 41 
15 
( 4) 
(34) 
66 
(4?) 
(53) 
il 
(66) 
5 
(9) 
3 
(И) 
Ά 
(26) 
32 
(23) 
KOLT-4 24 hr 0.85 0.96 63 75 
(1.04) (1.24) (65) (86) 
0 hr 
RAJI 12 hr 
0 hr 
KM-3 16 hr 
0 hr 
dean of 2 experiients in duplicate. Clonal Drouth inhibition is expressed as -log clonal pronti) (corrected 
for untreated cells). Non-viable cells are expressed as percentages and corrected for non-viable untreated 
cells. The nuibers between brackets represent a sumation of the results of separate exposure to NTH and 
6NP. The underlined nuibers indicate svnerqisi of coibmation treatient Ì561. The folloitin; coibinations 
of 0.02 μη ПП and 6NP иеге studied: Г Ш - 4 , 6MP: 2 μη (A) and IG μ« (В) at 24 and 0 hr; КАЛ, 6ПР: 2 /iH 
(A) and 10 μη (В) at 12 and 0 hr; KN-3. 6I1P: 2 ¡¡П (A) and 10 ¡ІП (В! at li and 0 hr. 
О.ІО 1.05 1. 
(0.B0) (1.І2) (1. 
2.16 
(1.9В) 
1.4В 2.44 
(1.111 (2.38) 
1.22 
(1.94) 
0.30 1.00 
(0,34) (2.Û5) 
2.60 
12.64) 
2.59 
(2.99) 
2.27 
•,3.86) 
3.15 
(4.64) 
22 
72) 
1 
(111 
9 
(3) 
48 
(47) 
9 
I 9) 
28 
(30! 
29 
( 41 
26 
(13) 
І 
(78) 
BI 
(90) 
36 
(54) 
52 
(il) 
56 
(45) 
54 
(50) 
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Table 2. Clonal gro»th and cell viability after exposure to various coibinations of 
0.2 (id NTI and 2/iH or 10 p« b№ 
CLONAL GRQMTH INHIBITION NON-VIABLE CELLS 
Duration cf exposure: 6 12 30 3¿ 54 60 i 12 30 36 54 60 78 
Cell line [HTU W P J 
A. 0.2/iN ipH 
I10LT-4 12 hr 1.75 H 70 95 
RAJ! 
KN-3 
B. 0.2 
Ρ 
0 hr 
6 hr 
0 hr 
6 hr 
0 hr 
10 μη 
(2.5; 
0.34 1.2! 
Il, 
0.52 
(0.501 
0.11 
(-0.021 
I) (4.03) 
з.:о 
.24) (3.501 (4.701 
0.82 
(1.14) 
0.89 
(1.6В) 
0.75 
(1.22) 
0.8В 
(1.30) 
1.77 
(2.631 
1.75 
(3.331 
1.46 
12.75! 
2.70 
,2.82! 
0 
(0) 
3 
(31 
6 
(441 
2 
(4) 
5 
(В) 
12 
( 5) 
12 
( 51 
(591 
63 
(65) 
19 
(20) 
15 
(20) 
36 
(17) 
26 
(171 
(92) 
89 
(95) 
45 
(2В) 
37 
(281 
І Ш - 4 12 hr 2.5: И 74 97 
О hr 
RAJI 6 hr 
О hr 
КИ-З 6 hr 
0 hr 
See legend to Table 1. II, undefmite. The follomno coibinations of 0,2 /iN HTX and 6HP неге studied: 
I1DLH, 6ИР: 2 μΠ (A) and 10 μ« (В) at 12 and 0 hr; RAJI, бПР: 2 pH (A) and 10/iH (B) at 6 and 0 hr; 
КН-3, 6ПР; 7 μη (Al and 10 fi« (BI at 6 and 0 ΊΓ. 
(3. 
0.48 2. 
,C91 (5.90) 
10 
(1.62) ¡4.651 
0.68 
(0.70) 
-0.02 
(-0.021 
2.40 
il.71) 
2.60 
(2.95) 
0.96 
(1.35) 
0.96 
(1.75) 
2.70 
(3.85) 
3.15 
14.48) 
2.16 
i3.44ì 
2.10 
(3.52) 
it 
(til 
0 
(0) 
0 
(11 
11 
(50) 
в 
(IO) 
25 
(231 
11 
( 7) 
17 
( 5) 
(B2) 
64 
IB4) 
54 
ι53) 
51 
(70) 
58 
(321 
53 
(33) 
(96) 
95 
(981 
71 
(67) 
58 
(82) 
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The data in these tables demonstrate other important 
differences between the cell lines: MGLT-4 cells are the most 
susceptible cells with regard to cytotoxicity (number of 
non-viable cells) with all combinations of MTX and 6MP. KM-3 
cells are the most susceptible cells 41th respect to inhibition 
of clonal growth after simultaneous and sequential exposure to 
0.02 μη MTX and both concentrations of 6MP, and also 
demonstrate significant cytotoxicity. Moreover, although clonal 
growth inhibition of RAJI cells is clear in all combinations, 
these cells are not susceptible to combinations of 0.02 JJM MTX 
and 2 μΜ 6MP, because cytotoxicity is negligible. RAJ1 cells 
require high concentrations of 6MP for significant cytotoxici­
ty. Thus, important differences seem to exist between the cell 
lines with respect to the effects of various combinations of 
MTX and 6MP on clonal growth inhibition or on cytotoxicity. 
Effects of 6MP on changes in DNA distribution 
Flow-cytometric studies were performed in MOLT-4 cells in 
relation to the double labeling studies, described below. 
Changes in DNA distribution in MOLT—4 cells after separate 
exposure to MTX and 6MP were described earlier by us C50,553. 
Exposure of MOLT-4 cells to 0.02 JJM MTX resulted in a decrease 
of cells in G2 + M phase and a delay of cell progression in 
(early) S phase, whereas MOLT-4 cells treated with 0.2 i^M MTX 
showed a decrease of cells in G2 + M phase and a complete 
cessation of cell progression through the cell cycle at the 
Gl/S phase boundary, associated with an increase of cells in Gl 
phase. After separate exposure to 2 діМ 6MP we could demonstrate 
a delay of progression of MOLT-4 cells in S phase associated 
with a decrease in Gl phase and an arrest in 62 phase. 
Treatment with 10 /JM 6MP augmented these effects and added an 
arrest in S phase. 
The changes in DNA distribution due to combinations of MTX and 
6MP are shown in Fig. 1. Exact computer calculations of the 
number of cells in each cell cycle phase were not possible, due 
to the overlap of the phases. The histograms did not show 
important changes with regard to both concentrations of 6MP, 
suggesting that the changes in DNA distribution reflect the 
rapid and distinct effects of MTX. In Fig. 1 we demonstrate 
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72 hr 
72 hr 
60 hr 
60 hr 
Fi]. 1. EHtcts of various coibinatmns of NTI ind 6ИР on DNA distribution of IIDLT-4 
cells, leisured by DNA-flou cytoietry. 
A. 0.0?/il 1TÍ (0 hrl * 2 μ? 6ΠΡ (0 li--., в. 0.02/id НТК (0 hr) + 2 pH 6ИР (24 hr) ; 
С. (!.2 /іГ «TU (0 hr! + 2 ¡¡П ЬНР (0 h- ; D. 0.2 >iN ЯТИ (0 hrl t 2 μη Ь№ ι12 hr). 
Th; histagracs are representative exâiples of 2 individual eiperiients and ire 
СОирагаЬ'.е t ; dose ot caibinations M'.th 10 /il «ПР. I . cell debris. 
combinations with 2 μΜ бМР as an example. 
Simultaneous exposure to 0.02 μΜ MTX and both concentra­
tions o-f ÒMP <Fig. 1A) results in an accumulation o-f cells in 
early S phase and decrease o-f cells in Б2 + M phase a-fter 24 hr 
which is comparable to the e-ffects of 0.02 /JM MTX alone at this 
point of time on cell cycle distribution C50D. After 48 hr of 
incubation cells are blocked in S phase, followed by a complete 
cessation of cell progression through the cell cycle at 72 hr 
and accumulation of cells in Gl phase. 
Exposure to sequential treatment with 0.02 μΜ MTX and both 
concentrations of 6MP (Fig. IB) results in an accumulation of 
cells in S phase after 4Θ hr, which again is comparable to the 
effects of MTX alone at this point of time [50]. However, after 
72 hr still a large number of cells are in S phase, suggesting 
both accumulation and arrest in S phase after sequential 
treatment. Thus, comparison of these data with the effects of 
separate exposure to MTX indicates that addition of 6MP 
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augments the effects of MTX at each point of time, and changes 
a delay of cell cycle progression into a complete cessation of 
cell cycle progression. 
The effects of simultaneous (Fig. 1С) and sequential (Fig. ID) 
exposure of MOLT-4 cells to <J.2 μη MTX and both concentrations 
of 6MP on changes in DNA distribution are similar, and demon­
strate a complete loss of cells in G2 + M phase, associated 
with a complete cessation of cell cycle progression at the 61/S 
phase boundary already after 12 hr, which is comparable to the 
effects of separate treatment with 0.2 JJM MTX C50]. 
Incorporation of C8-14C3 6MP and/or С 3 2P3 phosphate into newly 
synthetized DNA and RNA. 
The extensive double labeling experiments in MOLT-4 cells 
were performed as an example of the effects of various combina­
tions of 0.02 fiM MTX and 6MF on DNA and RNA synthesis. Combina­
tions with 0.2 /iM MTX were also studied, but the data will not 
be presented here because 0.2 uM MTX lowered incorporation of 
phosphate into DNA to almost zero. Therefore, synergism of MTX 
and 6MP could not be measured under these conditions. 
C 3 2P3 was added at t=0 or at t=24, and cells were collected 
after 24 hr in order to measure the effects of exposure to each 
agent separately or to combinations of MTX and 6MP during a 24 
hr period. The following combinations of 0.02 μη MTX and 
tB- 1 4C] 6MP were studied (with reference to Figs. 2 and 3 ) : (A) 
simultaneous addition of MTX and 2 μη 6MP during two 24 hr 
periods; (B) sequential administration of MTX and 2 iiM 6MP 
during the second 24 hr; and (C) sequential administration of 
MTX and 10 μη 6MP during the second 24 hr. 
The effects of 0.02 uM MTX on DNA and RNA synthesis are 
shown in Fig. 2 (black bars). 0.02 μη MTX lowers DNA synthesis 
to 757. of control within the first 24 hr, and to 507. of control 
in the second 24 hr. These data are in agreement with an 
increasing delay of cells in S phase, mentioned before [501, 
because incorporation of deoxyribonucleotide triphosphates into 
DNA is an S phase specific phenomenon. RNA synthesis is lowered 
to 85% of control within the first 24 hr after exposure to 0.02 
μη MTX, and to 917. in the second 24 hr, suggesting a small 
recovery in the latter period. These data are in agreement with 
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the perturbations o-f ribonucleotide levels in MQLT-4 cells in 
earlier studies, indicating a recovery o-f RNA synthesis after 
28 hr of exposure to 0.02 jili MTX, associated with a recovery of 
PONS t49,50a. 
The inhibition of DNA and RNA synthesis due to 4B hr exposure 
to 2 uM 6MP shown in Fig. 2A has been demonstrated recently by 
our group C55]. 
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Simultaneous administration of 0.02 μΗ MTX and 2 μη 6MP results 
in a further inhibition of DNA as well as RNA synthesis Mithin 
both time periods, compared to each agent separately (Fig. 2A) . 
These data confirm the flow-cytometric results in Fig. 1A, 
demonstrating an augmentation of the effects of MTX on the S 
phase of the cell cycle by co-administration of 2 jaM 6MP. 
Although RNA synthesis recovered in the second 24 hr after 
separate exposure to both agents, this is not the case for 
simultaneous administration. 
The inhibitory effects of 0.02 μΜ MTX and 2 /jM 6MP 
separately on DNA synthesis are augmented from 50X to 757. of 
control after sequential treatment (Fig. 2B). Moreover, the 
recovery of RNA synthesis in the second 24 hr after treatment 
with MTX alone is absent after sequential administration of 
both agents. This was confirmed in experiments measuring PRPP 
levels (data not shown) during this treatment: separate 
exposure of MQLT-4 cells to 0.02 μΜ MTX resulted in an increase 
of PRPP levels to 1.32 nmol/lO* viable cells after 24 hr, 
followed by a decrease. However, addition of 2 μΜ 6MP at 24 hr 
further increased PRPP levels with 0.19 nmol after 1 hr and 
with 0.36 nmol after 4 hr, and PRPP levels remained elevated. 
This was in contrast to the decline of PRPP levels after 
separate exposure to MTX, indicating a further and continuous 
inhibition of PDNS after sequential treatment with MTX and 6MP. 
The augmented inhibition of PDNS by this combination of MTX and 
6MP is due to the formation and the additional effects of tIMP 
and Me-tIMP, subsequently lowering the formation of natural 
nucleotides required for RNA synthesis [55J. 
The effects of sequential administration of 0.02 μΜ MTX and 10 
μΜ 6MP on DNA and RNA synthesis do not demonstrate a 
significant augmentation of the effects of each agent separa­
tely (Fig. 2C). This may be due to the pronounced effects of 
IO uM 6MP. 
Fig. 3 demonstrates the incorporation of C8— 14C3 6MP into 
newly synthetized DNA and RNA after separate exposure to ¿MP 
and after the combinations of 0.02 μΜ MTX and 6MP, mentioned 
before. These data indicate that simultaneous or sequential ad­
ministration of 0.02 μΜ MTX and 2 μΜ 6MP, enhances the incorpo­
ration of 6MP into DNA, although DNA synthesis is lowered to a 
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significant amount due to exposure to MTX (Fig. 2). In the case 
of simultaneous administration of both agents (Fig. ЗА), the 
augmentation of 6MP incorporation within the first 24 hr (in­
crease to 1577.) is greater than within the second 24 hr (113%). 
This has to be attributed to our observations that the initial 
concentration of 2 JJM 6MP in the medium rapidly declined to 
undetectable levels after 6 hr of exposure. Moreover, we could 
not detect formation of 6MP—nucleotides after 24 hr of 
incubation with 6MP С553. 
When 6MP was added separately at 24 hr, the incorporation into 
DNA (Fig. 3B, black bar, 2.37. of C 3 2PD, i.e. total nucleotide 
incorporation) was less compared to incorporation in DNA after 
administration of 6MP at 0 hr (Fig. ЗА, black bar, 3.6%). This 
may be due to environmental culture conditions and omission of 
glutamina addition in these experiments, resulting in more 
uptake of natural nucleotides into DNA. Nevertheless, sequen­
tial administration of MTX and 2 pM ¿MP (Fig. 3B) enhanced 6MP 
incorporation into newly synthetized DNA (130% increase). 
Enhanced incorporation of 6MP into RNA after simultaneous admi-
nistration is present within the first 24 hr (127% increase, 
Fig. ЗА), in contrast to the second 24 hr, because 6MP-nucleo-
tides were hardly available within this period for their 
contribution to RNA synthesis, as shown before. After 
sequential combination therapy (Fig. 36) the increase of 6MP 
incorporation into RNA is 123%. 
Sequential administration of 0.02 pM MTX and ΙΟ μΜ 6MP does not 
result an increase of 6MP incorporation in both DNA and RNA, as 
compared to separate exposure to 10 /LIM ¿MP (Fig. 3C). 
The data in Fig. 3 also demonstrate that 6MP is incorporated in 
a significantly higher amount into newly synthetized DNA than 
into newly synthetized PNA after separate exposure to 6MP as 
well as after various combinations of MTX and 6MP. 
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DISCUSSION 
Synergism of purine and pyrimidine antimetabolites has 
been an important subject of discussion in the literature. The 
biochemical basis for synergism of most combinations of 
sequential antimetabolite therapy consists in an inhibition of 
PONS by the pretreatment agent, MTX or Me-MPR, resulting in an 
increase of intracellular PRPP C7,10-12,34,57D. The enhanced 
availability of PRPP can be used for an enhanced intracellular 
uptake and conversion of the second agent (6MP, 6TB or 5FU). 
Dur previous studies demonstrated that pretreatment with MTX, 
followed by short-time (20 min) incubation with 6MP, resulted 
in an enhanced intracellular uptake and conversion of 6MP in 
human malignant lymphoblasts, when 6MP was added at those 
points of time, at which the inhibition of PDNS due to MTX 
pretreatment was maximal [4"?]. The· studies suggested that RAJI 
and KM—3 cells would be more vulnerable for sequential MTX and 
¿MP exposure than MOLT—4 cells, based on intracellular 
incorporation of labeled 6MP in these short-time incubations. 
In this study, however, we compared the effects of sequential 
and simultaneous long duration exposure of these drugs on cell-
kinetic parameters, especially clonal growth inhibition and 
cytotoxicity (number of non-viable cells). In previous studies 
we demonstrated that these two parameters can be significantly 
divergent within one cell line or between cell lines [50,55]. 
For example, 72 hr exposure to 0.υ2 μΜ MTX in MDLT-4 cells did 
not result in clonal growth inhibition (ІЗ ТС of control), 
whereas cytotoxicity was evident v357.) . Comparable divergences 
between clonal growth inhibition and cytotoxicity could be 
demonstrated after exposure to 6MP C55]. This divergence is 
especially true for combinations of MTX and 6MP, and explains 
why the definition of the synergistic action of two agents by 
Webb C56] is less appropriate for two agents which influence 
each other's action. We, therefore, have to unravel the mecha­
nism of combination therapy in each cell line and with each 
concentration of MTX and 6MP, leading to the data in Tables 1 
and 2, by explaining their biochemical and cell-kinetic 
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e-f-fects, as demonstrated by us in earlier studies C49,50,551. 
The active purine salvage pathwa/ in MOLT-4 cells is able 
to convert a considerable amount o-f 2 uli 6MP in a short period 
o-f time, demonstrated by the rapid disappearance o-f detectable 
άΜΡ levels in the medium, leading to undetecable 6MP-nucleotide 
formation after 24 hr. The rapid increase of PRPP levels due to 
inhibition of PONS by tIMP and Me-tIMP contributed to a 
self-enhancement of É>MP conversion. Treatment with 0.02 uM MTX 
resulted in a significant, but slow increase of PRPP 
availability with a maximum at 24-28 hr. During the first 24 hr 
of treatment with 0.02 pM MTX, flow-cytometry studies showed an 
increasing accumulation of MOLT-4 cells in early S phase, which 
is the most susceptible cell cycle phase for treatment with 6MP 
153,541. fill these characteristics of MGLT-4 cells are 
advantageous for a synergistic effect of both simultaneous and 
sequential treatment with low concentrations of both agents. 
Because both agents especially caused cytotoxicity after 
prolonged exposure, cytotoxicity is the most sensitive parame-
ter of synergism (Table 1A). The shift from a delay and accumu-
lation of cells in S phase (after separate exposure to O.02 ¡лП 
MTX) to an arrest of progression through the cell cycle (after 
prolonged exposure to sequential or simultaneous treatment) 
confirmed the cytotoxic power of combination therapy. The 
slowly increasing amount of ιlonal growth inhibition between 4B 
and 72 hr of exposure in Table 1A can be explained by the reco­
very of clonal growth after prolonged exposure to each agent 
separately. Nevertheless, synergism remains present with regard 
to clonal growth inhibition, due to the biochemical 
pharmacology of low concentrations of both agents in MOLT-4 
cells. 
Synergism of simultaneous or sequential exposure of MOLT-4 
cells to 0.02 μΜ MTX and 10 μη 6MP could not be demonstrated on 
the basis of the data presented in Table IB. This has to be 
attributed to the preponderant effects of 10 μΜ 6MP on clonal 
growth and cytotoxicity, which do vanish the synergistic 
effects of 0.02 /iM MTX. 
Synergism of 0.2 μΜ MTX and both concentrations of 6MP could be 
demonstrated in MOLT—4 cells only after prolonged sequential 
exposure (Tables 2A and 2B). The enhancement of 6MP uptake in 
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short-time incubations with 10 μΜ 6MP was demonstrated in our 
earlier studies C49D. However, the absence of synergism after 
simultaneous exposure is affected by three phenomena: 1) the 
early arrest of cell cycle progression at the Gl/S phase 
boundary after treatment with 0.2 μΜ MTX, which prevents rapid 
incorporation of ¿MP into DNA; 2) the significant cytotoxicity 
and clonal growth inhibition bv 0.2 μΜ MTX; and 3) the 
significant early and late cytotoxic effects of 10 uM 6MP. The 
absence of the third phenomenon in the combination of 
sequential treatment with 0.2 μΜ MTX and 2 μΜ 6MP, and the 
maximal inhibition of PONS, resulting in optimal and rapid 
conversion of 2 μΜ ¿>MP, may explain its synergistic effects, 
especially on cytotoxicity. 
In RAJI cells the conversion of 6MP to its active 
metabolites is rapid due to the active purine salvage pathway 
in these cells. This leads to sel f-enhancement of 6MP 
conversion, because the activity of PONS in RAJI cells is 
relatively low. Exposure to 0.02 μΜ MTX resulted in a rapid and 
important inhibition of PONS. These phenomena explain a minor 
synergism of 0.02 μΜ MTX and both concentrations of AMP on 
clonal growth inhibition (Table 1A/B) after relatively short 
periods of incubation, which is mainly due to biochemical 
disturbances (decreased levels of purine nucleotides and dTTP). 
The absence of synergism with regard to cytotoxicity of these 
combinations has to be attributed to the changes in DNA 
distribution after exposure to 0.02 μΜ MTX. RAJI cells did not 
demonstrate an accumulation of cells in early S phase, as was 
the case in MOLT-4 and KM-3 cells, but only a small delay of 
cell progression. The delay of progression through the cell 
cycle did not result in significant cytotoxicity by MTX and 
will not favour the incorporation of 6MP-nucleotides as 
thioguanine deoxyribonucleotides into DNA, which especially 
occurs in early S phase, shown in MOLT-4 and KM-3 cells. 
Simultaneous and sequential administration of 0.2 μΜ MTX and 2 
μΜ 6MP in RAJI cells only resulted in a significant synergism 
with respect to cytotoxicity after prolonged exposure (Table 
2A, 78 hr). We can not give a satisfying explanation for this 
phenomenon from our data. The cell—kinetic studies in RAJI 
cells demonstrate that these cells are mainly affected by 
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combinations of high concentrations of both MTX and 6MP. 
The data in Tables 1 and 2 showed synergism for all 
combinations of MTX and 6MP on the cytotoxicity of KM-3 cells. 
These cells do not possess such an active PDNS and purine 
salvage pathway as compared to MOLT-4 and RAJ I cells, which 
explains the relatively small effects of separate exposure to 
6MP on both clonal growth inhibition and on cytotoxicity. 
However, exposure to 0.02 uM MTX resulted in a severe 
inhibition of PDNS and an arrest of cells in early S phase, 
favouring rapid conversion and incorporation of 6MP into DNA, 
which is almost absent without co-administration of MTX. These 
characteristics explain the Tiost pronounced synergism for both 
combinations of 0.02 μη MTX and 2 μΜ 6MP in KM-3 cells in 
comparison to MOLT—4 and RAJI cells. Clonal growth inhibition 
after this combination treatment is even greater than in MOLT-4 
and RAJI cells. Moreover, cytotoxicity of sequential treatment 
is significantly higher than that of simultaneous treatment, 
whereas the duration of exposure to 6MP is longer in simulta­
neous treatment. These data confirm the important role of PDNS 
inhibition by pretreatment of MTX, especially in KM—3 cells. 
This phenomenon was also evident in our short-time incubations 
with labeled 6MP after pretreatment with MTX C49D. 
The synergistic effects on cytotoxicity by combination 
treatment with 0.2 μΜ MTX in KM-3 cells (Table 2) are striking. 
This concentration of MTX irduced a rapid cessation of progres­
sion through the cell cycle, which could prevent incorporation 
of 6MP into DNA. Nevertheless, table 2 demonstrates that the 
enhancement of 6MP conversion by the severe inhibition of PDNS 
results in adequate incorporation of thioguanine deoxyribonu-
cleotides in order to produce synergistic cytotoxicity. 
The flow-cytometric studies in MOLT-4 cells after 
combination therapy with MTX and 6MP demonstrate important 
differences in comparison with separate exposure to 6MP. 
Cytotoxicity caused by 6MP or 6TG was shown to be the result of 
incorporation of thioguanine deoxynbonucleotides into DNA, 
followed by cell kill in the G2 phase, due to morphological 
chromosomal changes C5B-65D. Our flow-cytometric data confirmed 
these findings, but we also could demonstrate an additional 
cell kill in S phase after exposure to 10 μΜ 6MP C55D. We could 
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not show an arrest o-f MOLT-4 cells in Б2 phase after exposure 
to combination chemotherapy with MTX and 6MP. The 
DNA-histograms in Fig. 1 merely demonstrate an augmentation o-f 
the primary effects of MTX which are present at the moment of 
addition of 6MP, i.e. cell kill in S phase in combinations with 
0.02 μΜ MTX and cell kill due to a block at the Gl/5 phase 
boundary in combinations with 0.2 uM. The absence of a block in 
G2 phase after combinations of MTX and 6MP may be due to the 
rapid decrease of cells in G2 + M phase by MTX. 
The data from our double labeling studies with [ 3 2P] and 
CB- 1 4C] 6MP in MOLT-4 cells further elucidated the mechanism of 
cytotoxicity after sequential or simultaneous administration 
with MTX and 6MP. The most important phenomena are the 
preponderant incorporation of 6MP into newly synthetized DNA in 
comparison to RNA, and the enhancement of òMP incorporation 
into newly synthetized DNA and RNA (Figs. ЗА and 3B). The 
enhancement of 6MP incorporation into DNA of MGLT—4 cells is 
not shown for sequential treatment with 0.02 μΜ MTX and 10 μη 
6MP (Fig. ЗС), which confirmed our cell-kinetic studies (Table 
IB) discussed above. 
We can not compare the results of these extensive studies in 
human lymphoblastic cell lines with other data reported in the 
literature. Comparison with the study of Armstrong et al [453, 
showing an enhancement of 6-thioguanine cytotoxic activity with 
MTX in L.1210 cells was impossible, because these authors 
investigated incubations during 3 hr with 6TG with or without 
MTX pretreatment. They demonstrated a decrease of 6TG 
incorporation into DNA (expressed per pq DNA) and an increase 
of 6TG uptake into RNA (expressed per μg RNA) after 3 hr MTX 
pretreatment. However, the results were not expressed as 
incorporation into newly synthetized DNA or RNA as we did. So, 
we can not compare the data with our data. Moreover, the method 
of DNA, RNA and nucleotide isolation described by these authors 
caused 507. decontamination of DNA in the RNA fraction in our 
hands. We used С3Η]-thymidine labeled DNA in order to verify 
the separation of DNA and RNA. The decontamination could be 
prevented in our assay С553 by ethanol precipitation of labeled 
DNA after addition of carrier DNA. 
The findings in our studies indicate that a large amount 
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of interrelated assays are necessary in order to elucidate the 
complex mechanism of action tf MTX, 6MP and, especially, combi-
nations of both agents. Discrimination between clonal growth 
inhibition, which mainly reflects the biochemical events, and 
number of non-viable cells, reflecting cytotoxicity, is 
necessary in these studies, because the goal of antimetabolite 
therapy in leukemia is kill of malignant cells. This study 
indicates that long-term sequential and simultaneous treatment 
with low concentrations of MTX and 6MP is especially advanta-
geous for common-ALL lymphoblasts and T-lymphoblasts. This is 
already an empirical datum in the oral maintenance treatment of 
ALL in children C47,66]. However, our study also indicates that 
combination therapy with M7X and 6MP, using knowledge of the 
biochemical characteristics of the* target cell and other routes 
and sequence of administration of both drugs, can be exploited 
for induction chemotherapy of ALL. 
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θ. 1. SUMMARY 
Methotrexate (MTX) and 6-mercaptopurine (6MP) have been 
used -for more than 25 years in the maintenance treatment of 
acute lymphoblastic leukemia of childhood. The basis of the 
investigation => presented in this Thesis was the hypothesis of a 
potential syrargism of MTX and 6MF, due to the effects of MTX 
on purine de novo synthesis (PONS) enhancing intracellular 
conversion of 6MP by hypoxanthine-guanine phosphoribosyltrans­
ferase (HGPRT), and its incorporation into DNA and RNA. 
In chapter 1 the historical background for our interest in 
these two antimetabolites of purine and pyrimidine metabolism 
is presented, and a survey of the biochemical pharmacology of 
MTX and 6MP is given. The purpose of our studies is an analysis 
of the effects of MTX and 6MP, administered separately and in 
sequential or simultaneous combination, on purine and pyrimi­
dine metabolism and on cell-kinetic parameters of the three 
subclasses of human malignant lymphoblasts. 
Chapter 2 describes the methodology of the assays, measu­
ring the biochemical effects of MTX απ PONS, by detection of 
phosphoribosyl pyrophosphate (PRPP) and aminoimidazolecarbox— 
amide ribonucleotide (AICAR) levels, and by incorporation of 
labeled glycine into purine metabolites. The concentrations of 
MTX used in our studies (0.02 μΜ and 0.2 ¿iM) can be maintained 
in vivo for many hours during the oral maintenance treatment 
with MTX. The results of exposure of MTX to MOLT—4 human malig-
nant T-lymphoblasts demonstrate a time- and dose-dependent 
inhibition of PONS. The enhanced availability of PRPP can be 
used for increased intracellular uptake of hypoxanthine and its 
analogue 6MP and increased conversion to their nucleotides. 
Leukemic lymphoblasts are shown to be selectively susceptible 
for MTX treatment in comparison to normal bone marrow cells and 
peripheral blood lymphocytes due to the low activity of PONS in 
the latter. 
In chapter 3 the effects of exposure to MTX in MOLT-4 
cells are analyzed on the basis of cell—kinetic parameters 
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(cell growth, cell viability and soft agar colony -forming 
activity), on cell cycle perturbations (DNA flow-cytometry), 
and on purine and ругι midine (deaxy)ribonucleotide levels. 
Correlations are demonstrated between eel1-kinetic parameters, 
cell cycle perturbations and deoxynbonucleotide levels, and 
between the inhibition o-f PONS and ribonucleotide levels. After 
exposure to 0.02 діМ MTX a temporary incomplete inhibition o-f 
PDN5 and thymidylate synthetase (TS) is associated with an 
accumulation o-f MOLT-4 cells in the S phase of the cell cycle, 
and a delay of cell cycle progression through this phase. The 
changes in ribonucleotide levels suggest a temporary incomplete 
inhibition of RNA synthesis. Exposure to 0.2 jiM MTX results in 
a complete inhibition of PONS and TS, associated with a rapid 
cell cycle arrest at the Gl/S phase boundary, inhibition of RNA 
synthesis, and significant cytotoxicity. 
In chapter 4 the effects of MTX on the parameters, descri­
bed in chapter 2, in the three malignant human lymphoblastic 
cell lines MOLT-4 (T-), RAJI (B-) and KM-3 (non-B-non-T, common 
ALL) are presented, and the various effects on these cell lines 
are compared. The activities of the PONS and the purine salvage 
pathway are high in MOLT-4 cells and relatively low in KM-3 
cells; RAJI cells show a low activity of PONS and high activity 
of the purine salvage pathway. These differences explain the 
various degrees of inhibitory effects of 0.02 ¿iM MTX on PONS in 
these cell lines. In MOLT-4 cells an incomplete and transient 
inhibition of PONS is demonstrated, in RAJI cells an incomplete 
and steadily increasing inhibition, and in KM—3 cells complete 
inhibition with 0.02 μΜ MTX. These observations accomplish dif­
ferences in uptake and conversion of labeled 6MP (in short-time 
incubations) after pretreatment with MTX. The enhanced incorpo­
ration of 6MP and conversion to its nucleotides after pretreat— 
ment with MTX is most obvious in KM-3 cells. 0.2 JJM MTX results 
in a complete inhibition of PONS in all cell lines. Differences 
in polyglutamation of MTX between the cell lines are discussed. 
In chapter 5 further analysis and comparison between the 
cell lines is demonstrated of the effects of MTX on the parame­
ters, presented in chapter 3. The data suggest also differences 
in polyglutamation between the cell lines after exposure to 
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0.02 μη MTX. In contrast to MOLT-4 cells, KM-3 cells show an 
increasing complete inhibition o-f TS and PONS, more delay o-f 
cpll progression through the cell cycle at the Gl/S phase boi— 
der and in early S phase, and impairment o-f RNA synthesis, as 
determined by changes in ribonucleotides levels. This concen­
tration o-f MTX was most vulnerable for KM-3 cells. The effects 
in RAJI cells were significantly less except for the inhibition 
of TS. Exposure to 0.2 μΜ MTX results in comparable 
disturbances between the cell lines in purine and pyrimidine 
(deoxy)ribonucleotide levels, whereas the cell-kinetic and 
flow—cytometric parameters in RAJI cells are less affected. 
The cell-kinetic observations after exposure to 2 uM and 
10 μΜ ¿MP in the three cell lines are described in chapter 6. 
These data indicate a clear distinction to be made between 
cytotoxicity (cell kill) of 6MP, measured by number of 
non-viable cells and clonal growth capacity (a reflection of 
biochemical perturbations). KM-3 cells are less vulnerable for 
6MP due to their relatively low activity of purine salvage 
pathway. The effects of 6MP on PONS and on DNA and RNA synthe-
sis are described in detail in MOLT-4 cells as an example. 2 μΜ 
6MP from the medium is completely incorporated within 6 hr, and 
formation of 6MP-nucleotides cannot be demonstrated after 24 hr 
of incubation. A rapid inhibition of PONS is associated with a 
decrease of purine ribonucleotide levels, and a small 
inhibition of RNA synthesis measured by labeled phosphate 
incorporation. RNA synthesis recovers after 24 hr. DNA synthe­
sis is inhibited to 507. of control and DNA—distribution demon­
strates a increasing delay of cells in S phase and arrest in G2 
+ M phase. After exposure to 10 uM these effects are more pro­
nounced and an additional arrest in S phase is observed. 6MP is 
preferentially incorporated into DNA, as compared to RNA. 
Cytotoxicity and clonal growth capacity after sequential 
and simultaneous combinations of various concentrations of MTX 
and 6MP are demonstrated in chapter 7. Again, both cell-kinetic 
parameters have to be distinguished. The differences between 
the three cell lines with respect to the characteristics of 
purine metabolism and the effects of MTX and 6MP separately on 
cell (cycle) kinetics and on PDNS are important parameters in 
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order to explain synergism of both drugs after sequential or 
simultaneous administration. In KM-3 cells synergism is evident 
with both manners of administration. Synergism in MOLT—4 cells 
is present after combinations with low concentrations of 6MP, 
whereas RAJ I cells demonstrate synergism after sequential 
treatment with high concentrations of MTX. The effects of 
various combinations of MTX and 6MP on DNA and RNA synthesis 
are again described in detail in MOLT-4 cells as an example. 
Cell cycle perturbations, primarily induced by MTX, are 
augmented after co-administration of 6MP and the inhibition of 
DNA and RNA synthesis is augmented after combinations of 0.02 
μη MTX and 2 ^ іМ 6MP, as compared to administration of each drug 
separately. Combination chemotherapy preferentially favoured 
6MP incorporation into DNA. 
В.2. PERSPECTIVES 
Early studies demonstrated a synergism of the combination 
of MTX and 6MP on the survival of leukemia. However, studies 
concerning the biochemical and cell-kinetic basis for this 
synergism were not available. In this Thesis an attempt has 
been made to elucidate the biochemical pharmacology of both 
agents separately and the potential synergism of combinations 
of both agents, based on the biochemical characteristics of the 
cell lines used. We studied only one example of each of the 
three immunologically distinctive subclasses of lymphoblasts. 
However, we expect that the outcome of this study is indicative 
for the three subclasses of ALL. This has to be attributed to 
the distinctive characteristics of enzymatic "make-up" of each 
immunological subclass of lymphoblasts. Our studies indicate 
that combination treatment with low concentrations of MTX and 
6MP is especially advantageous for non-B, non-T, common-ALL 
lymphoblasts and T-lymphoblasts. This is in agreement with the 
empirical results of oral maintenance treatment in children 
with ALL. In our studies we used concentrations of MTX which 
can be maintained in vivo for many hours after oral administra­
tion of MTX in a dosage of 30-50 mg per meter square. The bio— 
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availability after oral administration of 6MP is difficult to 
Measure, since it is rapidi ν converted into many metabolites 
With different half-life times. However, the presence of pro­
longed measurable levels of 6MP after cessation of maintenance 
treatment in ALL suggests that the human body still contains a 
large pool of 6MP. The long-term bioavailability of 6MP in vivo 
suggests that results of in vitro studies with low concentra­
tions of MTX and 6MP can be translated to the in vivo situa­
tion. Moreover, our studies suggest that prolonged exposure to 
similar concentrations of MTX and concentrations of 2-10 |iM 6MP 
-which can be maintained during 24 hr infusions with MTX and 
Ы in patients- will be especially advantageous for induction 
chemotherapy of ALL. This is stressed by our findings that the 
synergism of MTX and 6MP on cytotoxicity is preferably present 
in cells with an active PONS and, thus, selective for malignant 
human lymphoblasts and absent in normal bone marrow cells. 
Therefore, further studies using prolonged infusions of MTX and 
6MP in animals are indicated in order to investigate host 
toxicity. 
Although the prognosis of children with standard risk ALL 
has improved significantly and although investigations concer­
ning chemotherapy in ALL are not a priority in national cancer 
funds awarding grants for research at the moment, studies in 
children using new drug schemes of MTX and 6MP are necessary. 
In addition, it should also be considered to investigate syner­
gistic interactions of other antimetabolites in order to 
improve the prognosis of childhood leukemia. 
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SAMENVATTING 
Methotrexaat (MTX) en 6-mercaptopurine (6MP) worden reeds 
meer dan 25 jaar gebruikt in de onderhoudsbehandeling van akute 
lymfatische leukemie (ALL) bij kinderen. De grondslag van de 
onderzoekingen, die in dit proefschrift worden beschreven, werd 
gevormd door de hypothese van een synergisms van MTX en 6MP ten 
gevolge van de effekten van MTX op de purine de novo synthese 
(PDNS) van kwaadaardige lymfobi asten, waardoor de intracellu-
laire omzetting van 6MP door hypoxanthine-guanine fosforibosyl-
transferase (HGPRT) en de inbouw in DNA en RNA wordt bevorderd. 
De achtergrond van onze belangstelling voor deze twee 
antimetabolieten van de purine en pyrimidine stofwisseling 
wordt beschreven in hoofdstuk 1. Een overzicht wordt gegeven 
van de biochemische farmacologie van beide geneesmiddelen. Het 
doel van de studie is een nadere analyse van de effekten van 
MTX en 6MP op het purine en pyrimidine metabolisme en de cel-
kinetische parameters van de drie verschillende subklassen van 
humane maligne lymfobi asten, na inkubaties met ieder geneesmid-
del afzonderlijk en na sequentiële of simultane toediening van 
MTX en 6MP. 
In hoofdstuk 2 worden de methodieken beschreven, waarmee 
de effekten van MTX op de PDN5 werden bepaald: door meting van 
fosforibosyl pyrofosfaat (PRPP), aminoimidazolcarboxamide ribo-
nucleotide (AICAR) koncentraties en door meting van de inbouw 
van gelabeld glycine in purine metaboiieten. De koncentraties 
van MTX, die in onze studies worden gebruikt (te weten 0.02 uM 
en 0.2 /iM), kunnen gedurende vele uren worden gehandhaafd in 
vivo bij orale onderhoudsbehandeling met MTX. Na inkubatie met 
MTX in MOLT-4 humane T-lymfobi asten ontstaat een tijds- en 
koncentratie-afhankelιjke remming van de PDNS. De verhoogde 
koncentraties van PRPP, die daarbij ontstaan, kunnen benut woi— 
den voor een toegenomen intrl cellulaire omzetting van hypoxan-
thine en zijn analoog 6MP in nucleotiden. Leukemische lymfo-
Ыasten blijken gevoeliger voor behandeling met MTX dan normale 
beenmergcellen en perifeer bloed—lymfocyten wegens de lage 
aktiviteit van de PDNS in de laatste. 
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In hoofdstuk 3 Morden de effekten van MTX geanalyseerd op 
cel-kinetische parameters (cel-groei, cel-vitaliteit, kolonie-
groei in "soft" agar), op veranderingen binnen de celcyclus 
(DNA flow-cytometrie), en op purine en pyrimidine (deoxy)ribo— 
nucleotide koncentraties. Er bestaat een duidelijke korrelatie 
tussen de effekten van MTX ар de cel-kinetisehe parameters, de 
veranderingen in de celcyclus en de deoxynbonucleotiden, en 
ook tussen de remming van de PDNS en de veranderingen in 
ribonucleotide spiegels. Na behandeling met 0.02 μΜ MTX 
ontstaat een onvolledige tijdelijke remming van de PDNS en van 
het enzym thymidylaat synthetase (TS), die gepaard gaat met een 
ophoping van MDLT-4 cellen in de S fase van de celcyclus en een 
vertraging van de celcyclus in deze fase. De veranderingen in 
ribonucleotide spiegels doen een onvolledige remming van de RNA 
synthese vermoeden. Na inkubatie met 0.2 μΜ MTX ontstaat een 
volledige remming van de PDNS en van TS, gepaard gaande met een 
snel optredende stilstand in de celcyclus op de grens tussen de 
Gl en de S fase. Tevens vindt een remming van de RNA synthese 
en een signifikante cytotoxieitelt plaats. 
In hoofdstuk 4 worden de effekten vergeleken van MTX tussen 
de drie maligne humane lymfoblastaire cellijnen M0LT-4 (T-), 
RAJI (B-) en KM-3 (non—В —non-T, common-ALL) op basis van de 
parameters beschreven in hoofdstuk 2. De aktiviteiten van de 
PDNS en van de purine "salvage" route blijken hoog in MQLT-4 
cellen en relatief laag in KM—3 cellen te zijn, terwijl RAJI 
cellen een lage aktiviteit van de PDNS en een hoge aktiviteit 
van de purine "salvage" route hebben. Door deze verschillen 
wordt de mate van remming van 0.O2 μη MTX op de PDNS verklaard. 
In MOLT-4 cellen wordt een onvolledige en tijdelijke remming 
van de PDNS waargenomen, in RAJI cellen is een onvolledige, 
doch toenemende remming waarneembaar, en in KM—3 cellen is de 
remming met 0.02 μΜ MTX volledig. Hierdoor is de opname en 
omzetting van 6MP (in kortdurende inkubaties) in de drie 
cellijnen na voorbehandeling met MTX verschillend. De verhoogde 
omzetting van 6MP tot nucleotiden na voorbehandeling met MTX is 
het meest opvallend in KM—3 cellen. Behandeling met 0.2 JJM MTX 
leidt tot een volledige remming van de PDNS in alle cellijnen. 
Tevens worden verschillen tussen de cellijnen wat betreft de 
vorming van polyglutamaten van MTX bediskussiëerd. 
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In hoofdstuk 5 vindt een verdere analyse en vergelijking 
plaats van de e-ffekten van MTX op de drie cellijnen op basis 
van de parameters beschreven in hoofdstuk 3. De resultaten doen 
eveneens verschillen in de vorming van MTX-polyglutamaten vei— 
moeden tussen de cellijnen na behandeling met 0.02 uM MTX. In 
tegenstelling tot M0LT-4 cellen tonen KM-3 cellen een in tijd 
toenemende remming van TS en de PDNS. Er vindt een grotere ver— 
traging van cellen plaats op de grens tussen de Gl en de S fase 
en in de vroege S fase van de cel cyclus. Tevens wordt een rem­
ming van de RNA synthese waargenomen aan de hand van verande­
ringen in de ribonucleotide koncentraties. De koncentratie van 
0.02 jiM MTX blijkt het meest schadelijk voor KM-3 cellen. De 
effekten op RAJI cellen zijn duidelijk minder, behoudens de 
sterke remming van TS. Behandeling met O.2 μϊ\ MTX leidt tot 
vergelijkbare effekten xn de cellijnen wat betreft purine en 
pyrimidine (deoxy)ribonucleotiden. In RAJI cellen blijken de 
cel-kinetische en f 1ow-cytometri sehe parameters minder te zijn 
verstoord dan in M0LT-4 en ИM-3 cellen. 
De cel-kinetische studies aan de drie cellijnen na behan­
deling met 2 uM en 10 μΜ 6MP worden beschreven in hoofdstuk 6. 
De gegevens tonen aan dat er een duidelijk onderscheid gemaakt 
dient te worden tussen cytotoxiciteit (celdood) van 6MP, die 
bepaald wordt door het aantal vitale cellen, en remming van 
kolonie—groei (een afspiegeling van de biochemische veranderin­
gen). 6MP blijkt minder schadelijk te zijn voor KM—3 cellen, 
omdat deze een relatief lage aktiviteit van de purine "salvage" 
route hebben. De effekten van ¿MP op de PDNS en op de DNA en 
RNA synthese worden duidelijk gemaakt met MOLT-4 cellen als 
voorbeeld. 2 uM 6MP wordt geheel uit het medium opgenomen bin-
nen 6 uur en vorming van 6MP-nucleotiden kan niet meer worden 
aangetoond na 24 uur. Een snelle remming van de PDNS na inkuba— 
tie met 2 μΜ ¿>MP gaat gepaard met een daling van ribonucleotide 
spiegels en gelijktijdig een geringe remming van de RNA synthe-
se, gemeten met inbouw van gelabeld fosfaat. De RNA synthese 
herstelt zich na 24 uur. De DNA synthese wordt 50ïi geremd en de 
flow-cytometrie histogrammen tonen een toenemende vertraging 
van de celcyclus in de S fase en een stilstand in de 62 + M 
fase. Na behandeling met ΙΟ μΜ 6MP worden deze effekten nog 
duidelijker en treedt tevens een stilstand in de S fase op. 6MP 
wordt bij voorkeur in DNA ingebouwd en veel minder in RNA. 
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In hoofdstuk 7 zijn de effekten op cytoto>:iciteit en 
kolonie—groei na sequentiële en simultane kombinaties van MTX 
en 6MP in verschillende koncentraties beschreven. Opnieuw moet 
een duidelijk onderscheid gemaakt worden tussen beide 
cel-kinetische parameters. De verschillen tussen de cellijnen, 
wat betreft de purine stofwisseling en de effekten van MTX en 
6MP afzonderlijk op de cel(cvclus;-kinetiek en op de PDNS, zijn 
belangrijke parameters, waarmee het synergisme van beide 
geneesmiddelen na sequentiële of simultane toediening verklaard 
kan worden. In KM—3 cellen is een duidelijk synergisme aantoon-
baar na beide wijzen van toediening. Synergisme in MOLT—4 cel-
len is al aanwezig na kombinaties met lage koncentraties òMP, 
terwijl in RAJI cellen een synergisme pas kan worden gemeten na 
sequentiële behandeling met hoge koncentraties MTX. De effekten 
van verschillende kombinaties van MTX en 6MP op de DNA en RNA 
synthese worden duidelijk gemaakt met MOLT-4 cellen als voor— 
beeld. De veranderingen in de celcyclus verdeling, die voorna-
melijk door MTX zijn teweeggebracht, worden versterkt na 
toevoegen van ¿MP. De remming van de DNA en RNA synthese is, 
vergeleken met de afzonderlijke toediening van beide 
geneesmiddelen, duidelijk toegenomen na toediening van 
kombinaties van 0.02 μΜ MTX en 2 ¿JM 6MP. Tevens blijkt dat 
kombinatie chemotherapie bij voorkeur inbouw van 6MP in DNA 
bevordert. 
VOORUITZICHT 
Studies uit het verleden lieten een synergisme zien van de 
kombinatie van MTX en 6MP wat betreft de overlevingskansen van 
patiënten met leukemie. Onderzoek betreffende de biochemische 
en cel—kinetische achtergrond voor dit synergisme is echter tot 
nu toe m e t bekend. In dit proefschrift is een poging onderno-
men om de biochemische farmacologie van beide geneesmiddelen 
afzonderlijk nader te verklaren, alsmede het synergisme van 
kombinaties van beide, gebaseerd op de biochemische kenmerken 
van de cellijnen. Hoewel wij van ieder van de drie immunologi-
sche subкlassen van lymfobi asten slechts een voorbeeld onder— 
zochten, verwachten wij dat de waargenomen verschillen tussen 
cellijnen ook gelden voor de drie subklassen van ALL. Dit kan 
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worden toegeschreven aan de duidelijke verschillen in enzyma-
tische "make-up" van de verschillende immunologische subklassen 
van lymfobi asten. Onze studies geven aan dat de gekombineerde 
behandeling met lage koncentraties van MTX en 6MP met name zin-
vol zijn bij non-B -non T, common—ALL lym+oblasten en T—lymfo— 
blasten. Dit is een empirisch gegeven in de orale onderhouds— 
behandeling van ALL bij kinderen. In onze studies gebruikten 
wij MTX-koncentraties die in vivo gedurende vele uren bereikt 
Kunnen worden na orale toediening van MTX in een dosis van 
30-50 mg per vierkante meter. De biologische beschikbaarheid 
van 6MP na orale toediening is moeilijk te bepalen, omdat 6MP 
snel wordt omgezet in vele metabolieten met verschillende half-
waarde-tijden. Het feit, dat zeer langdurig spiegels van 6MP 
kunnen worden aangetoond na het staken van de onderhoudsbehan-
deling bij ALL, maakt het waarschijnlijk dat het menselijk 
lichaam een grote pool 6MP tot zijn beschikking heeft. De 
langdurige biologische beschikbaarheid van 6MP doet vermoeden 
dat de resultaten van in vitro studies met lage koncentraties 
van MTX en 6MP vertaald kunnen worden naar de in vivo situatie. 
Tevens tonen onze studies aan dat langdurige toediening van 
0.02-0.2 /JM MTX en 2-10 jiM 6MP -welke bereikt kunnen worden bi j 
24 uurs infusen in patiënten- van speciaal belang kan zijn voor 
induktie-chemotherapie bij ALL. Dit wordt extra benadrukt door 
onze bevinding dat het synergisme van MTX en 6MP op de 
cytotoxiciteit bij voorkeur aanwezig is in cellen met een ak— 
tieve PDNS. Derhalve is dit synergisme selektief voor maligne 
humane lymfobi asten en afwezig in normale beenmerg cellen. De 
toxiciteit van langdurige infusen met MTX en 6MP dient echter 
eerst in dier—experimenteel onderzocht te worden, voordat deze 
bij de patiënt kan worden toegepast. 
Hoewel de prognose voor kinderen met standaard-nsiko ALL 
signifikant gunstiger is geworden en hoewel onderzoek wat 
betreft leukemie geen prioriteit heeft in de nationale organi-
satie voor kankerbestrijding, moeten toch nieuwe wijzen van 
toediening van MTX en 6MP onderzocht warden. Bovendien is het 
wenselijk nader onderzoek te verrichten omtrent synergistisehe 
interakties van andere anti metabo11 eten met het doel om een 
verdere verbetering te verkrijgen van de prognose van leukemie 
bij kinderen. 
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STELLINGEN 
Behorende bij het proefschrift 
NEW ASPECTS OP METHOTREXATE AND 6-HERCAPTOPLtRINE 
Potential ayn*rgiaa and biochemical phamacology 
in human malignant lymphoblasta 
In het openbaar te verdedigen 
op vrijdag 22 mei 19Θ7 
des namiddags te 3.30 uur 
door 
JOS P.M. BÖKKERINK 
STELLINBEN 
I 
Intraveneuze sequentiële toediening van methotrexaat en 
¿i-fliercaptopurine verdient aandacht in de induktie-behandeling 
van akute lymfatische leukemie bij kinderen. (Dit proefschrift) 
II 
De t o x i c i t e i t van ant imetabol ie ten op de cel n œ t n i e t gemeten 
worden aan de hand van de "soft" agar ko lon ie -groe i van c e l l e n , 
maar door middel van de v i t a l i t e i t s b e p a l i n g van maligne c e l l e n . 
(D i t p r o e f s c h r i f t ) 
I I I 
De cytotoxiciteit van methotrexaat wordt bepaald zowel door de 
mate van remming van thymidylaat synthetase als door de Effek-
ten op de purine de novo synthese. (Dit proefschrift) 
IV 
De gemeten geringe biologische beschikbaarheid van oraal 
toegediend —mercaptopunne, waarop door diverse auteurs wordt 
gewezen, is niet het gevolg van de wijze van toediening, maar 
van onvoldoende mogelijkheden om de biologische beschikbaarheid 
te meten. (Dit proefschrift) 
V 
Het feit, dat kinderen met akute lymfatische leukemie een 
gunstige prognose hebben, die 70—307. bedraagt bij de beste 
behandelingsmethode, mag geen reden zijn voor het afwijzen van 
Projekten aangevraagd met het doel deze prognose verder te 
verbeteren. (Dit proefschrift; кommentaar op prioriteiten voor 
subsidie van onderzoek door het K.M.F.) 
VI 
Naast haar rol in de loco-regionale behandeling heeft de 
radiotherapie zich steeds verder in de systemische behandeling 
geprofileerd. 
VII 
De afspraak om het toevoegsel "X" van H i s t i o c y t o s i s - X weg t e 
l a t e n en het z i e k t e b e e l d voortaan "Langerhans* cel H i s t i o c y t o ­
s i s " t e noemen v e r d o e z e l t het gegeven dat men de e t i o l o g i e nog 
steeds m e t kent. ( I n t e r n a t i o n a l e K o n f e r e n t i e over H i s t i o c y t o -
sen, U.S.ft-, 19B5) 
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Vili 
Het probleem van de euthanasie verdient noch een politieke noch 
een juridische besluitvorming. Dit zou immers betekenen dat de 
waarde van de mens beoordeeld wordt naar zijn persoon en niet 
naar zijn wezen. 
IX 
De verhoging van de prognose bij vele kindertumoren sedert de 
komst van cisplatinum staat in schril kontrast met de negatieve 
bijwerkingen van dit middel: de verlaging van het magne­
si um-gehalte en het gehoor van de kinderen. Deze verhogen de 
multidisciplinaire (be)zorg(dheid). 
X 
Om tot een nadere klassi-fikatie van anorexie te komen, kan men 
deze indelen in: 
Stadium 1. Slechte eetlust bij akute infektieziekten. 
Prognose: 100% gunstig, dikwijls zonder behandeling. 
Stadium 2. Anorexie bij cytostatische behandeling. 
Prognose: 1007. bij staken van de behandeling. 
Stadium 3. Slechte eetlust bij de peuter in de opstandigheids-
fase. Prognose: afhankelijk van de pedagogische 
kwaliteiten van de ouders. 
Stadium 4. Anorexia nervosa. Prognose: afhankelijk van de 
metastasen op afstand in het gezin. 
XI 
Nie zijn post verlaat in deze tijd van bezuinigingen in de 
gezondheidszorg loopt de kans dat anderen zijn ontslag-brief 
openmaken. <Vrij naar Bescheurkal ender 13.01.19Θ6) 
XII 
De bevindingen dat kinderen die altijd zijn gevoed met macro­
biotische voeding kleiner zijn dan de "normale" populatie 
nederlandse kinderen, zijn in tegenspraak met de verwachtingen 
die het voorvoegsel "macro" wekken. 
XIII 
Dankzij nieuwe, ultramoderne apparatuur in de geneeskunde is 
het mogelijk geworden voor de ministeries van O&W en WVC steeds 
eenvoudiger de kraan dicht te draaien voor verdere ontwikkeling 
van de geneeskunde op de medische fakulteiten en in de 
akademische ziekenhuizen. 
XIV 
De zwakste schakel in het proces van onderwijsvernieuwing is de 
docent. Maar de zwakste schakel in de opleiding van studenten 
tot goede artsen gelegen is, moet nog worden uitgezocht. 
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XV 
Een oudervereniging van kinderen met kanker is wenselijk zowel 
voor het onderling kontakt, de begeleiding en de inspraak van 
ouders, alsook voor het funktioneren van een kinderoncologisch 
centrum. 
XVI 
De genezingskansen voor kinderen met kanker overtreffen verre 
die van kanker bij volwassenen en hebben vele kinderen een 
volwaardig bestaan gegeven. Toch kampt het Kinderoncologisch 
Centrum Zuid—Oost Nederland met voortdurend personeelstekort en 
betaalt huur voor de ruimten die zij gebruikt. Dit beleid 
betekent dat de kinderoncologie nog niet als volwaardig wordt 
aangezien en nog geen vaste ondergrond heeft gevonden voor haar 
bestaan. 
XVII 
De verhouding tussen draagkracht en draaglast van een gezin met 
een kind dat lijdt aan kanker is te vergelijken met het labiele 
evenwicht van de wip. Wanneer iedereen in de omgeving tracht de 
last iets te helpen dragen, zal de wip niet doorslaan. 
XVIII 
Het belang van een eenmalige spi egelbepaling in het bloed van 
geneesmiddelen of andere stoffen om de "compliance" te meten 
geldt alleen voor al kohol en verdovende middelen. In andere 
gevallen kan men degene die het ingenomen heeft er nooit op 
pakken. 
XIX 
Na het zeil kamp "Zomerzotheid" voor kinderen met kanker waaide 
de wind voor velen uit een gunstige hoek. 
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